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SYNOPSIS 
PERIPHERAL NEUROPATHIES OF CHILDHOOD 
This thesis is divided into six chapters, the first of which is a summary of the literature 
assessing the available data on children presenting in childhood with chronic peripheral 
neuropathies (Table 1.1). Specific clinical, neurophysiological and histopathogical markers 
are noted which may aid in diagnosing children in the setting where DNA testing is not 
available or affordable. These markers can also be used to assist more targeted genetic 
screens, thus allowing more direct investigations and avoiding more costly unnecessarily 
extensive studies. The terminology has become complex and the genetic labels (CMT1-4) 
have reverted to being the preferred terms for most conditions, further divided into multiple 
sub-groups. Tables 1.2-1.4 summarise the key data on the many sub-groups of conditions 
dominated by peripheral neuropathy, combining clinical, neurophysiological, histopathology 
and molecular genetic data for each condition – “endotyping”. The tables illustrate the 
heterogeneity of the various conditions and the frequent occurrence of different genotypes 
producing a given phenotype. The area is complex and such endotyping tables are essential 
for the clinician to attempt to maintain any level of confidence when categorising patients. 
Table 1.4 lists the known gene mutations and / or protein deficiencies with the current insight 
into their roles in nerve function. This data in Table 1.4 facilitates an understanding of how 
nerve damage arises from these mutations and how the same defect can manifest with either 
axonal or demyelinating pathology. Tables 1.2 and 1.4 also demonstrate how the 
categorisation of the previously rigid concepts of “axonal”, “demyelinating” and “mixed” 
categories can become unrealistic with some conditions, e.g. X-linked Charcot Marie Tooth 
(CMTX), and early onset neuronal hereditary motor sensory neuropathy (EOHMSN). 
Chapter 2 examines the role of peripheral nerve biopsy. The chapter describes the 
technique used, the evolution and maturation of nerves in children and the information 
potentially gained from the investigation. A series of tables and images concentrate on 
conditions with particular features, some of which are diagnostic in isolation, others provide 
useful guides to direct further investigations. 
Chapter 3 addresses a very large cohort (n=296) of Australian children presenting 
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with the combined information on clinical, neurophysiological, neuropathological and, in many 
cases, molecular genetic peripheral nerve data is unlikely to be repeated again as the role of 
molecular genetics has resulted in fewer patients proceeding to nerve biopsy. Some of the 
patients who presented early in the study predated storage of DNA. A proportion of those 
from slightly more recently acquired definitive diagnoses with the combined data and 
subsequent molecular genetic analysis – often up to 20 years after data was originally 
collected: hence the importance of storage of DNA. The descriptions from Tables 1.2-1.4 
were used to categorise the patients. Most molecular genetic studies were available for this 
group of patients but despite this a significant proportion of the database with a clear genetic 
aetiology remained without a molecular genetic diagnosis. This was most marked for the 
proportion of patients from the axonal / mixed group (15/37) compared to the demyelinating 
group (34/50). This data was important to illustrate the proportions of the more common 
conditions previously considered predominantly adult onset disorders (CMT1 and CMT2). 
Further, by nature of the large numbers of patients included in the study, otherwise rare 
mutations (e.g. PRPS1 and frabin mutations) were also identified. The data also emphasised 
the importance of EOHMSN in the spectrum of childhood onset hereditary neuropathies, this 
group representing 22% of the axonal degenerative group. 
Chapter 4 reviews in more detail a sub-group of children from the larger cohort, 
described in chapter 3, who presented under one year of age with symptoms of peripheral 
neuropathy (n=50). Similar findings were evident for the discrepancy in making definitive 
diagnoses in the axonal group compared to the demyelinating group. The range in pathology 
and heterogeneity was illustrated by groupings such as the representation of a number of 
infants with CMT1. The findings highlighted the condition severe infantile axonal neuropathy 
with respiratory failure (SIANR) (genetic category- SMARD1) – as an important and severe 
peripheral neuropathy presenting in infancy. 
Chapter 5 reviews a smaller cohort of patients (n=123) managed in a dedicated 
paediatric neuromuscular service in South Africa. All patients with chronic peripheral 
neuropathy were included, although particular attention was placed on those who underwent 
peripheral nerve biopsy (n=15) and / or molecular genetics (n=22). Of the group, the 
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inflammatory demyelinating polyradiculoneuropathy (AIDP). Five patients with HIV disease 
were referred into the neuromuscular service with neuropathies related to the toxic effects of 
antiretroviral agents. It is suspected that the proportion of children with neuropathies related 
to HIV is higher but based on anecdotal experience these patients may remain sub-clinical or 
are managed in other services (infectious diseases). Investigations in these patients were 
useful, with 11 out of the 22 patients who had molecular genetic screens performed gaining a 
definitive diagnosis. Similarly, all the children who underwent peripheral nerve biopsies (n=15) 
had findings which were of diagnostic use. Variations from international figures were striking 
for the smaller number of patients with demyelinating forms of CMT – most markedly in the 
CMT1 group in which no patients of indigenous African ancestry were detected. The CMT1A 
gene does not appear to manifest as commonly in this population group. The study illustrated 
the limitations of incomplete genetic analyses and the need for comprehensive genetic 
screens to be available for the more relevant mutations in childhood, namely duplications and 
deletions at chromosome 17p11.2-12, myelin protein zero, PMP22, connexin32, mitofusin and 
SMARD1 mutations.  
Chapter 6 summarises the key points from the previous chapters in comparison with 
the available literature. The author proposes guidelines for the optimal investigation of 
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CHAPTER 1 
INTRODUCTION AND LITERATURE SUMMARY. 
Peripheral nerve disease was described by Galen (AD 130-200) over a thousand 
years ago.(3) Detailed anatomical illustrations were documented by Andreas Vesalius in his 
major work “De humani corporis fabrica” in 1543.(4) Over the last two centuries an explosion in 
knowledge in the area has occurred, with a further exponential increase in the last 20 years 
mostly related to understandings in the field of molecular genetics.(5) Although some degree of 
diagnostic closure was possible for a number of the hereditary peripheral neuropathies, this 
has not been the end point of knowledge but only the beginning. The diverse clinical 
presentations and molecular genetic heterogeneity of hereditary peripheral neuropathies are 
significant.  
Acquired forms of peripheral neuropathy were described in the 1800’s for diphtheria, 
epidemic polyneuritis, lead and arsenic intoxication, diabetes, alcoholism and beri-beri.(6-10) 
Guillain and colleagues described the currently termed condition acute inflammatory 
polyradiculoneuropathy in 1916.(11) Although the clinical features of the condition were 
originally described by Octave Landry in 1859.(12) Chronic inflammatory polyradiculopathy 
received recognition over the following years.(13-16) Toxic neuropathies and neuropathy 
secondary to malignancy were also investigated further.(17,18) 
Of the neurodegenerative conditions associated with peripheral neuropathy, probably 
the most recognised is that described by Friedreich in 1863. This disorder, now referred to as 
Friedreich ataxia, required a nerve biopsy study to consolidate the diagnosis prior to a 
molecular genetic screen becoming available.(19)  
According to available facilities early descriptions of hereditary peripheral 
neuropathies were based on clinical appearance, with recognition of subtypes evolving 
later.(20-22) Electrophysiological data in the 1960s further enhanced understanding of disease 
processes, followed by more detailed pathological assessments.(23-26) The categorisations of 
the hereditary peripheral neuropathies evolved further. Molecular genetics further sub-divided 
the major groups with to date over 44 mutations identified.(5) However, most patients are 
limited to the original method of assessment – that of clinical assessment. The majority of the 
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histopathology and molecular genetic screens are lacking. It remains important for centres 
with the capacity to perform all these studies to build a knowledge base which can be used to 
guide centres in resource-poor settings.  
Peripheral neuropathies in childhood are underdescribed in the medical literature. 
There are few large studies reviewing the pattern of disease morphology. (2,27-32)  Table 1.1 
summarises some of the larger studies with a breakdown of the types of neuropathy occurring 
in childhood. The peripheral neuropathies which occur in childhood differ from those in adults 
with a far greater number of inherited conditions. Early recognition of peripheral neuropathies 
enables accurate genetic advice and detection of pathology. 
Charcot-Marie-Tooth disease is the commonest neuromuscular disorder based on 
adult prevalence studies or combined studies with paediatric figures integrated, with an 
estimated prevalence of 17-40:100,000.(33,34) CMT1 is the commonest demyelinating disorder, 
representing 70% of all demyelinating CMT. (35-37) Of the available paediatric studies this 
figure is closer to 50%.(29,30)  Most studies are from European and North American centres. In 
our Australian biopsy based study (chapter 3) the patients with CMT1 represented 37% of the 
demyelinating group, with 27% having CMT1A. The CMT1 group constituted 16.7% of the 
total inherited peripheral neuropathy group. This figure is an under representation of the 
prevalence since following identification of the 17p duplication defect in 1991, patients 
underwent molecular genetic assessment primarily and only proceeded to nerve biopsy if the 
result was not diagnostic.(38,39)  
Children present with more autosomal recessive forms related to point mutations. 
Lack of access to centres with the capacity to undertake these complex molecular genetic 
screens requires that clinicians base their diagnoses on a combination of clinical phenotype, 
neurophysiology and histopathology. As stated above, knowledge to interpret this information 
is hard to access. 
As the spectrum of molecular genetic screens has expanded 
(http://neuromuscular.wustl.edu/ and http://194.167.35.195/)(40) it has become evident that the 
heterogeneity in phenotypic presentations is wide with the same mutation resulting in different 
types of neuropathies and even overlapping myopathies and neuropathies. (5,41,42)  The 
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the expanding number of mutations which can result in the same clinical phenotype. 
Following on from this and with the exponential increase in the recognised mutations, the 
terminology has shifted back to use of the term “CMT” for most diagnostic labels instead of 
“HMSN”. CMT1 (HMSN type 1) is currently subdivided into subtypes 1A-F. Rather than 
reducing the need for histopathological analysis of peripheral nerve samples it remains 
necessary to combine the data in order to delineate disease categories with greater accuracy 
and understanding. For example confirming that a patient has a myelin protein zero mutation 
will not clarify to the clinician the type of neuropathy as this mutation is described in numerous 
forms of peripheral neuropathy including hypomyelinating, de- and re- myelinating as well as 
axonal degenerative forms.(43) This scenario requires endotyping, in which a diagnosis is 
established through combining information from various sources including the clinical 
phenotype, the neurophysiology findings, the peripheral nerve histology and if possible the 
molecular genetics.  
The typical clinical phenotype of a patient with peripheral neuropathy consists of 
distal wasting and weakness, especially of the peroneal compartment, usually with some 
distal sensory impairment (to touch, pain and vibration, and occasional ataxia related to 
impaired joint position discrimination), skeletal deformities (pes cavus and hammer toes), 
contractures (scoliosis, claw hand “main en griffe”) and decreased or absent deep tendon 
reflexes. (44) As such many of the peripheral nerve diseases cannot be subdivided based on 
the clinical appearance alone. Specific phenotypes are evident for a few peripheral nerve 
diseases, but with inevitable overlap of other sub-types (Table 1.2).  
Dysfunction in many of the proteins, even when they primarily affect the myelin, lead 
to eventual axonal degeneration(45-47). It is the axonal degeneration which is suggested to lead 
to the clinical deterioration.(46)  
Table 1.2 summarises the primary hereditary motor and sensory disorders including 
their main clinical features, described neurophysiological and histopathological findings and 
the latest associated gene location. Table 1.3 summarises similar features for various 
neurodegenerative disorders with associated peripheral neuropathies. Table 1.4 summarises 
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associated disorders. These tables form the basis for the diagnostic categories used later in 
the text. 
The data was tabulated because the field has become complex; new findings are 
reported separately both in the clinical and genetic texts. As the field expands the information 
and correlation in the terminology have run the risk of pulling apart and functioning separately. 
There are cases of CMT sub-catetgories having conflicting protein mutations associated with 
them and likewise the same mutation labelled for several CMT sub-groups. The tables are an 
attempt to present the information in a comprehensive but accessible manner and to correlate 
the molecular genetic data with the the clinical, neurophysiological and histopathological 
findings. 
In Chapter 3 we present our findings from patients who underwent nerve biopsy 
examination between 1969 and 2007 at The Nerve Research Laboratory, University of 
Sydney. Those who were symptomatic in the infantile period were reported in an earlier 
publication but still included in this study for completeness and are described in detail in 
Chapter 4.(2)   Tables 1.2-1.4 were used as guides to the diagnostic categories subsequently 
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Pure peripheral neuropathy 
Other 
Gamstorp(1968)(27) 43 3 13 4 13 13 - 
Evans (1979)(28) 61 0 25 4 16 12 4 
Hagberg & Lyon 
(1981) “hereditary 
neuropathies”(29)  




120 68 6 16 21 66 11 
Rossi et al (1983) 
pts with HMSN(31) 
24 11 0 0 0 24 0 
Ouvrier and 
Macleod (1988)(32) 
125 125 16 15 27 62 5 
Wilmshurst et al 
(2003)(2) 
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Table 1.2: Hereditary peripheral neuropathies(48) (http://neuromuscular.wustl.edu/ and http://194.167.35.195/) 
 
Disorder(OMIM) Clinical features NCS Biopsy findings Genetic screen 
CMT1 
(Demyelinating)  
    
CMT IA-F(49) 

















Autosomal dominant.  
Onset 1-4th decade. Predominant distal 
weakness, decreased DTR, mild distal 
sensory loss, hypertrophy of nerves 
common  
CMT1A: Commonest form recognised, 
seen in all ages (but more adults) 
CMT1B:  Approx 5% of CMT1 group 
CMT1C: Childhood onset, start with 
abnormal gait, then distal weakness and 
wasting, occasional nerve hypertrophy. 
Rarely early onset hearing loss 
CMT1D: possible cranial nerve 
involvement. Late onset in childhood or 
early adulthood 
CMT1E associated with deafness (29-
45%) 


















Segmental demyelination and 
remyelination with onion bulb 










































Recurrent mononeuropathy simplex or 
multiplex frequently related to trauma.  
Significant slowing of 
motor and sensory 
conduction velocity in 
clinically affected, but 
also in unaffected, 
nerves  
Tomaculous or sausage like 
swellings of myelin sheaths, 
transnodal myelination and 
segmental demyelination. 
Figure 1.1 




Often Miscellaneous group. Incidentally 




Myelin thinning with no evidence of 
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CMT2 (axonal)     
CMT 2 A-L 








A2 (=HMSN VI) 
 
 






2C   (606071) 
 
 
2D   (601472) 
D  (allelic to dSMA) 
2E   (607684) 
E (allelic CMT 1F) 
 
 
2F   (606595) 
2G   (608591) 
 
 
2H   (607731) 
H (allelic CMT4A) -
Autosomal dominant (A,B,D,E,F,G,I)(72). 
Autosomal recessive (BI, B2, H and 
K)(73,74) Clinically similar to CMT type I, 
except for later onset, absence of 
peripheral nerve enlargement and less 
marked weakness. 
 
CMT2A: proximal weakness also present 
in 60%, prominent distal weakness, Optic 
atrophy and central involvement 
reported. Main form related to MFN2 
mutations(75-77)  
CMT2B: severe sensory loss, often 
complications with infections, 
arthropathy, amputations, foot ulcers, 
distal weakness 
CMT2B2: Average onset 34 years (Costa 
Rican family) 
CMT2C: vocal cord, diaphragm and 
respiratory involvement, decreased 
longevity 
CMT2D: upper limb predominance  
 
CMT 2E – 30% associated with 
deafness, early childhood onset with gait 
abnormalities, occasional hyperkeratosis, 
increased sensory involvement  
CMT2F: Trophic changes feet and knees 
CMT2G: Onset 9-76 years, average 20 
years, large Spanish family. But also 
severe form with early onset 
CMT2H: pyramidal involvement, vocal 
cord involvement  
Nerve conduction 
velocities are greater 
than HMSN type I 
(>38m/s), but are 




























/ slow NCS  
Neuronal atrophy and degeneration 
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CMT4C2 in original 
publication(71) 
2I    (607677) 
2J   (607736) 
 
2K   (607831) 
 
2L   (608673) 
 
 
CMT I and J – possible late onset, 
pupillary anomalies, pain, hearing loss, 
dysphagia  
CMT2K: vocal cord paralysis, more 
severe early onset form  
CMT2L: occasional proximal leg 
weakness (like dHMNII), large Chinese 























I MPZ; (97) 






HMSN II with onset 





Autosomal recessive. Weakness within 
first 5 yrs, rapid progression of 
weakness, usually complete paralysis 
below elbows and knees by teens, 
absent DTR, moderate sensory changes 
in most cases. Normal CSF protein. 
Occasional optic atrophy  
Axonal pattern with 
axonal-degenerative 
polyneuropathy.  
Absent SNAPs, No 
response to 
stimulation in the CP 
nerve, UL nerves 
normal or mildly 
slowed. EMG 
denervation 
Neuronal atrophy with degeneration 
of peripheral motor and sensory 
neurons.  Marked reduction in MF 
density, especially of large MF. No 
demyelination or active axonal 
degeneration, occasional cluster 
formations. Increased Schwann cell 





distress type 1 






New term distal 
SMA type 1 
(dSMA1)(107) 
(604320) 
Autosomal recessive. Onset in infancy 
(3-6 months), respiratory failure, 
progressive distal weakness, eventual 












Absent conduction in 
most cases 
Decreased myelinated fibre, no 
onion bulb formations, active axonal 
degeneration or active evidence of 
regeneration. Increased Schwann 










Peripheral Neuropathies of Childhood Jo M Wilmshurst 








Adult onset (after 30 years). Autosomal 
dominant. Slowly progressive proximal 
dominant area of weakness. 
Fasciculations of extremities and truck. 
Raised creatine kinase, hyperlipidaemia, 
diabetes mellitus, eventual loss of 
ambulation, absent DTR, sensory 
disturbances. Most patients described 
from Japan. 
Motor and sensory 
axonal neuropathy. 
SNAP, CMAP, 
MNCV and SNCV 




picture early on. 
 
Reduced anterior horn cells, 
reduced MF density in the posterior 
funiculus, cauda equine, roots, 
posterior tibial nerve. Sural nerve 
does not have onion bulb 
formations.   
3q13(109,110) 




Onset first 2 yrs, overall disability less 
severe than CMT 4. Hypotonia, motor 
delay by 1st yr, poor coordination, ataxia, 
distal weakness (max lower limbs), short 
stature. By second decade proximal 
weakness and hand and feet deformities. 
Nerve hypertrophy. Moderate to severe 
sensory loss. Scoliosis. Common cranial 
nerve involvement, nystagmus, deafness 
and, mild bifacial weakness.    
Raised CSF protein 





Decreased MF density. Thin MF 
Multiple OB formations. 
Increased trans fascicular diameter 
due to OB formations, collagen and 
Schwann cell proliferation. 
Figure 1.2 
















Similar or slightly more severe clinical 
picture to CMT1 form, increased ataxia, 
areflexia, scoliosis. Nerve hypertrophy 




A < 2yrs, (adult 2K) Tunisian and 
Moroccan families. Severe progressive. 
Less severe European phenotypes. 
B1 Ophthalmoplegia, vocal cord 
paralysis, facial, bulbar weakness (all 












Marked reduction of myelinated fibre 
density, with some well myelinated 
fibres, segmental demyelination and 
a few classic onion bulbs. In a few 
subtypes a higher frequency of OB, 
consisting of single or double basal 
laminae 
A demyelinating or axonal. 
Hypomyelination and onion bulbs 
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4C   (601596) 
 
 
4D   (601455) 
 
 
4E   (605253) 
 
 
4F   (145900) 
 
 
4G   (605285) 
 










infrequent). Weakness below 5 yrs, 
proximal and distal weakness, absent 
DTR   
B2 Early onset glaucoma. 1st decade. In 
Tunisia, Japan and Turkey  
C early-onset scoliosis, Algerian pop, 
glaucoma and neutropenia. 1st and 2nd 
decade 
D Closed gypsy pedigree; Onset < 10 
years. Deafness (by 2nd-3rd decade) 
Tongue atrophy (HMSN-Lom)  
E: Congenital hypotonia 
 
 
F Severely affected at birth, or by 7 
years, AMC common, respiratory and 
feeding difficulties, often die young 
G: type Russe. Onset 8-16 years. Origin 
Bulgaria 
H. Increased in Lebanese / Turkish. 
Onset infancy – childhood (1-2 years). 
Delayed motor milestones. Occasional 
scoliosis, Increased distal weakness, 
usually absent DTR. 
J: onset by 5 years. Severe disorder. 
Similarities to motor neurone disease(117) 
 
CCFDN: Congenital cataract, 
microcornea, facial dysmorphism, mental 




































B2:myelin-outfolding, loss of MF 
 
C: Basal membrane onion bulbs 
 
 
D: Hypomyelination, onion bulbs, 
myelin decompaction, axonal 
inclusions, loss MF 
E severe loss of myelinated and 
unmyelinated fibres, OB formations 
and focally folded myelin sheaths  
F cong hypomyelination. Very little 
myelin and virtually absent OBs 
 
G: Hypomyelination, Regenerating 
clusters 
H: Hypomyelination, small onion 




J: Profound axonal loss, thinly 
myelinated fibres, de- and re- 
myelination 





B2 SBF2, MTM13, 
(125,126) 
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X1: X-linked dominant. Onset 1st-2nd 
decade. Progressive wasting and 
weakness of distal limb musculature, 
especially hands, more marked in 





X2: X-linked recessive. Rare infantile 
onset, intellectual disability, females very 
mildly affected 
X3: X-linked recessive. +/- Spasticity. 
Females unaffected 
 
X4: X-linked. Severe neuropathy, 
Females very mildly affected Isolated 
case reports. Onset birth- early 
childhood. Slowly progressive. Many 
develop deafness by 5 years. Mental 
retardation commonly seen Occasional 
also with optic atrophy. (Cowchock 
syndrome) (142) 
X5: X-linked. Mild-moderate neuropathy, 





X1: Median nerve 
motor conduction 
studies < 40m/s (but 
faster than CMT1A) 
Intermediate slowing 












CV mild delay (33-
56m/s). Sensory very 
abnormal 
EMG: Denervation, 
large MUP and 
fasciculation 
X5: Axonal 





X1: Axonal degeneration and 
regeneration with some evidence of 
segmental demyelination. Variable 
findings with some patients having 
cluster formations, but also thin 




X2: Mixed demyelinating / axonal 
 
 
X3: Mixed demyelinating / axonal 
 
 
X4: Axonal neuropathy. Axonal loss 
and “sprouting” with no segmental 






X5: Axonal neuropathy – mild 
demyelinating changes 
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A – autosomal rec 
form (608340) 
 
Patients with this condition have 
neurophysiological results which fall 





DI-CMTA: Italian family: 
 






Recessive CMT with GADP1 mutations: 
(CMT2K&4A) Spanish and Tunisian 
family – severe childhood form reported. 
Also called DI-CMTA autosomal 
recessive form(151) 
CMT with NF-L: (CMT1F & 2E) 
CMTX1  
“Intermediate values” 
30-40m/s – most 
accurate from 
median motor 
nerves. Some forms 













Axonal and demyelinating pathology. 






































    
HMSN V / Spastic 
paraplegia with 
HMSN type V / 
CMT5 
(CMT with 
pyramidal signs)  
(600631) 
Variable inheritance. Spasticity in the 
lower limbs causing difficulty walking and 
toe walking. Autosomal recessive form 
associated with MR. Lower limb marked 
spasticity with little weakness, increased 
DTR, ext plantars, pes cavus, often distal 
amyotrophy. Expanding field with 
multiple subforms n=37(40,163). Not all 
Small / absent 
SNAPs. Motor 
studies axonal type 
 




KIF5A, HSPD1, BSCL2, 
REEP1, ZFYVE27, 
SPG7, SPG20, SPG21, 
ALDH3A2, ALS2, 
L1CAM, PLP1 










Peripheral Neuropathies of Childhood Jo M Wilmshurst 
Thesis presented for the Degree of Doctor of Medicine 
 26 
associated with peripheral neuropathy. 
CMT with pyramidal signs part of HMSN 
V but described without spasticity(164).  
signs: MFN2(164)  
HMSN VI (77) 
(allelic CMT2A) 
Visual impairment due to optic atrophy. 
Dominant and recessive forms. Onset in 
first decade. Distal weakness, often 
proximal involvement too. Less sensory 
involvement. Scoliosis.  
No response or 
motor conduction 
around 45m/s. 
Sensory often cannot 
stimulate 
Demyelinating(165) or axonal(166)forms 
described. Mitochondrial alternations 
described(167).  
MFN2 
HMSN VII HMSN with retinitis pigmentosa. CSF 
protein raised. Usually adult onset 
condition. Rare entity described in a few 





























dHMN type I: Autosomal dominant – 
juvenile onset, distal weakness and 
wasting(170) 
dHMN type II  autosomal dominant adult 
onset, distal weakness and wasting 
juvenile form (allelic CMT2F, CMT2L)  
 
dHMN type III. Autosomal recessive, 
adult onset, slow progressive muscle 
wasting and weakness, no diaphragmatic 
paralysis 
dHMN type IV: Autosomal recessive, 


















Sural nerve mostly normal. Muscle 
mild neurogenic atrophy with small 



















dHMN type I 7q34-
q36(171) 
 
dHMN type II HSPB8 
(HSP22)(163,172,173) 
dHMN type II adult 
juvenile HSPB1(94) 
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SMA (600175)  
 
and weakness and diaphragmatic 
paralysis 
dHMN type V: (allelic CMT2D) 
Autosomal dominant, upper limb 
predominance, occasional pyramidal 
features 
dHMN type V: Silver syndrome: 
Autosomal dominant, prominent hand 
muscle weakness and wasting, and mild 
to severe spasticity of the lower limbs. 
dHMN type VI (allelic SMARD1): 
Autosomal recessive severe infantile 
form with respiratory distress. 
dHMN type VII: Autosomal onset with 
vocal cord paralysis 
dHMN type VIIB: Autosomal onset with 
vocal cord paralysis and facial weakness 
X-linked dHMN: X-linked recessive, 
juvenile onset with distal wasting and 
weakness 
dHMN/ ALS4: Autosomal dominant, early 
onset with pyramidal tract signs 
dHMN-J: Autosomal recessive onset with 
pyramidal features 
Congenital distal SMA: Autosomal 
dominant congenital non-progressive 





























































dHMN type V: Silver 
syndrome BSCL2 (177) 
 
 
dHMN type VI (allelic 
SMARD1): IGHMP2(108)  
 
dHMN type VII:2q14  
(178,179) 



















Autosomal recessive. Increased in 
French Canadian populations. 
Progressive axonal neuropathy. CNS 
malformations – absence / hypoplasia of 
the corpus callosum, early onset, 
developmental delay, areflexia, 
dysmorphology. Later increased motor 
EMG: Denervation 
Axonal neuropathy 
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disability, hallucinatory psychosis. Death 







Autosomal dominant. Episodes of 
paralysis and muscle weakness initiated 
by severe pain. Onset can be from birth 
or later childhood but usually adult onset. 
Outcome usually good but some left with 
residual dysfunction. Episodes often 
triggered by infections, immunizations 
and stress. Some pedigrees dysmorphic 
with hypotelorism(191,192) 
 
Normal or mildly 
prolonged motor 
NCV distal to the 
affected brachial 
plexus(193) 
Axonal degeneration distal to the 








    
HSN (HSAN) 1 
(162400) 
1: Autosomal dominant, Onset 2nd-5th 
decade. Predominant loss of pain and 
temperature sensation, preservation of 
vibration sense, lancinating pain, variable 
distal motor involvement(198,199).  
 
CMT2B: see above – acro-mutilating 
complications 
1B: Autosomal dominant, predominantly 
sensory neuropathy with cough and 
gastroesophageal reflux, rarely foot 
ulcers. More adult onset. Often hearing 
abnormal. 









Primary axonal nerve damage. 
Marked decrease of unmyelinated 
fibres, as well as small and large MF 















HSN (HSAN) 2 
(201300) 
Autosomal recessive. Onset infancy / 
early childhood.- first two decades. 
Mutilating acropathy. Often unrecognised 
fractures. Marked sensory loss affecting 
all cutaneous modalities, most marked 
Normal MCV, 
sensory nerve action 
potentials are absent 
Marked or total loss of MF in sural 
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distally all limbs. Autonomic dysfunction 
less marked. Absent or decreased DTR.  






Autosomal recessive: History of 
neurological abnormality and of difficult 
feeding from birth. Failure to regularly 
produce tears. Absent or reduced DTR. 
Absent corneal reflexes, postural 
hypotension, emotional liability. Relative 
indifference to pain, absence of fungiform 
papillae on tongue, absence of flare with 
intradermal histamine. Normal 
intelligence (207-209)    
Motor CV usually 
slightly below control 
values. Sensory 
conduction normal or 
decreased. 
Sural nerve biopsy decreased in 
myelinated and unmyelinated fibres, 
small myelinated and unmyelinated 
most affected. Active degeneration 
or demyelination is rarely seen.  
IKBAP(210-212) 






Autosomal recessive. Onset from 
infancy, often high fevers sec to truncal 
anhidrosis during hot weather, Painless 
injuries of extremities and oral structures, 
often self-mutilation. Lack of pain 
sensation, both peripheral and visceral, 
inability to distinguish hot and cold. 
Preservation of DTR. Mild mental 
retardation. Hyperactivity and emotional 
lability common (214,215)  





Marked reduction / absence in small 
myelinated and unmyelinated fibres 
in the sural nerve, unmyelinated 
fibres the most affected(217,218) 
NTRK1(219-221) 
HSN (HSAN) 5 
(608654) 
Autosomal recessive. Onset early life. 
Rare disorder. Painless injuries of the 
extremities. Lack of pain and thermal 
sensitivity in the limbs but preservation of 
response to tactile and mechanical 
stimuli. Preservation of muscle strength 
and DTR. Distal anhidrosis. Bone and 
joint fractures. Normal intelligence(222)    
Normal motor and 
sensory NC 
Selective loss of small myelinated 
fibres and moderate loss of thin 
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Figure 1.1: Transverse section of part of a nerve fascicle from a patient    Figure 1.2 Transverse section of part of a nerve fascicle 
with hereditary neuropathy with liability to pressure palsy (light microscopy,  from a patient with CMT3 (LM, toluidine blue,    
toluidine blue, magnification x400). Several fibres are tomaculous (T)    magnification x200). The MF density is reduced;    
and others are thinly myelinated.       most fibres have thin or absent myelin and 
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Figure 1.3 Electron micrograph of a patient with X-linked CMT. There is a reduction in myelinated fibre density, cluster formations and onion bulb formations. 
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Table 1.3 (see also table 2.2 page 57): Neurodegenerative disorders with peripheral neuropathy.  
 




Onset first 7 yrs, usually delay in early 
milestones, progressive weakness, 
affecting LL first but spreading to affect all 
areas. Slurred speech, poor school 
performance – learning difficulties, small 
stature, Gen weakness, distal wasting, 
Absent DTR, impaired sensation 
especially proprioception and vibration, 
plantars often extensor, nystagmus, 
dysarthria, facial weakness. Tightly curled 
hair (“kinky”). Evolves into more 
spinocerebellar degeneration 
Motor NCS normal / 
mildly decreased. 
SNAPS usually 
absent. Suggestive of 
axonal degeneration 
(similar to FA) 
Numerous fusiform and sausage 
shaped axonal swellings with mod 
reduction in density of myelin and 
unmyelinated fibres. Myelin sheaths 
abnormally thin. OB around some 
fibres. Occasional Wallerian 
degeneration. EM axonal spheroids 






Ataxia earliest finding, onset 4-5 yrs. 
Insidious progression. Areflexia LL, 
dysarthria, post column signs LL, muscle 
weakness with or without hypotonia. 
Occasional pes cavus. Extensor plantars 
evolve with time. Nystagmus (20-50%). 
Kyphoscoliosis. Cardiomyopathy.  
Normal or mild 
slowing of motor 
nerve conduction 
velocities, absent or 
very diminished 
SNAP.  
Decreased density and total number of 
MF. Large MF affected.   
FRDA 




Onset 3-13 yrs. Typically retinopathy, 
ophthalmoplegia or abnormal sensory 
conduction. Occasional extensor plantars, 
tremor, dystonic movements. Abnormal 
posterior column function.   
Axonal pattern.(230) Axonal features with large myelinated 
fibre involvement more marked than 













Typically adult onset but childhood forms 
occur with anticipation 
Axonal pattern 
compatible with a 
dying back 
axonopathy and / or a 
neuronopathy  
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Weakness and hypotonia lower limbs, 
progressive neurodeficit. Neuropathy 
subtle – depressed ankle reflexes. 




Reduced MF density, chronic 
demyelination. Onion bulb formations. 
Granular material in the perinuclear 
regions of the Schwann cell visible as 
metachromasia in cresyl violet or 
toluidine blue stains. Electron 
microscopy accumulations of myelin-
like material as well as lipid-containing 









From second year with progressive gait 
difficulty and weakness, dementia, 
blindness and death occurs within a few 
years. 
EMG denervation Globular, ovoid or fusiform swellings 
along course of axons and patchy 














phytanic acid storage disorder 
Often mixed motor 
and sensory 
impairment – severe 
demyelinating – 
mainly with phytanic 
acid disorder 





Multifocal – Leigh’s disease main 
condition(244) 
More axonal picture Demyelination with patchy axonal loss  











Peripheral Neuropathies of Childhood Jo M Wilmshurst 
Thesis presented for the Degree of Doctor of Medicine 
 34 
Table 1.4: Specific protein deficiency or gene mutation(245,246) (Abbreviations in key at end of table) 
Protein / mutation (OMIM) Role Disorders linked to Comment 
DNM2(155,156) 
(602378) 
DNM2 is part of the family of large GTPases and is 
involved in the cellular fusion-fission apparatus. In 
transiently transfected cell lines, DNM2 mutations 
reduced binding of DNM2 to membranes by altering 
the conformation of the beta3/beta4 loop of the 
plecktrin homology domain 
CNM 
DI-CMTB 
DI-CMTB reported in American 
family 
EGR2 (Krox20)(62,114) 
(129010) Acts as a zinc finger transcription factor.  Regulates cellular proliferation  Expression associated with 
myelination in peripheral nerve  Plays role in PNS 
myelin development and maintenance  Activated in 
Schwann cells before onset of myelination  
Disruption blocks Schwann cells at early stage of 
differentiation. Activates transcription of several 
myelin-associated genes  Directly: PMP22, Cx32 & 
PRX  Via EGR2/Sox10 synergy: MPZ; MAG  






FRABIN is a GDP/GTP nucleotide exchange factor 
(GEF), specific to Cdc42, a member of the Rho 
family of Rho GTPases, which play a key role in 
regulating signal-transduction pathways in 
eukaryotes. They are important in mediating actin 
cytoskeleton changes during cell migration, 
morphogenesis, polarization, and division.  




FIG4 gene encodes a PI(3,5)P(2) 5-phosphatase. 
Mutations result in impaired trafficking of intracellular 
organelles due to obstruction by vacuoles. Based on 
plt mice - axonal degeneration in motor and sensory 
neurons, limited segmental demyelination, lack of 
TUNEL staining and lack of accumulation of 
ubiquitinated protein in vacuoles of motor and 




Gigaxonin is composed of an amino-terminal BTB 
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domain followed by six kelch repeats, predicted to 
adopt a beta-propeller shape. .Gigaxonin is a novel 




Mutations in the gene encoding glycyl-tRNA 
synthetase (GARS) impair function of tRNA-charging 








GDAP1 expressed in the peripheral and central 
nervous system with high levels in Schwann cells 
and oligodendrocytes. Levels of GDAP1 increase 
during development. Participation in the 
mitochondrial fission process, mitochondrial swelling, 
aggregates, disruption of cristae in EM. 
CMT4A, CMT 2H, CMT 2K Described in Mediterranean, 




GJB1 encodes the gap junction protein connexin 32 
(Cx32).In myelinating Schwann cells, Cx32 probably 
forms "reflexive" gap junctions (between layers of the 
same cell) in non-compact myelin, found in 
paranodal loops and Schmidt–Lanterman incisures 
Cx32 mutants may disrupt the diffusion of small 
molecules and ions across the peripheral nervous 
system (PNS) myelin sheath. 
DSS, CMTX1  
HSPB1(95,251) 
(602195) 
Neuronal cells transfected with mutated HSPB1 less 
viable - Cotransfection of neurofilament light chain 
(NEFL) and mutant HSPB1 alters neurofilament 
assembly in cells devoid of cytoplasmic intermediate 
filaments. 
CMT2F, dHMNII adult / juvenile  
HSPB8(101,163,169,172,173) 
(608014) 
Greater binding of HSPB8 mutants to the interacting 
partner HSPB1. Expression of mutant HSPB8 in 
cultured cells promotes formation of intracellular 
aggregates. 




IGHMBP2 protein contains adenosine triphosphate 
binding, helices-like motifs and two nucleic acid-
binding domains.  Cellular pathomechanisms leading 
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Component of the elongator complex and /or is a c-
junction N-terminal kinase-associated protein  
HSN 3  
KIF1B(79) 
(605995) 
KIF1B is important for mitochondria transport. KIF1B 
heterozygotes have a defect in transporting synaptic 
vesicle precursors. 
CMT2A1 Described in one Japanese 
family – data not reproduced 
LITAF(60) 
(603795) 
Stimulator of monocytes and macrophages. Causes 
secretion of tumour necrosis factor-α and other 
inflammatory mediators. May play a role in protein 
degradation pathways.  
CMT1C Location: Irish and English 
LMNA(42,84-87)  
(150330) Hypothesised that there are distinct functional domains in Lamin A/C which are essential for the 
maintenance and integrity of different cell lineages. 
There may be unique mutations in LMNA encoding 
Lamin A/C nuclear envelope proteins since 
mutations in LMNA lead to different phenotypes. The 
problem of the specificity of different domains of the 
protein and, conversely, of a possible common 












(608507) MFN2 is a large mitochondrial GTPase. It may function to tether mitochondria before fusion. 
Mitochondria undergo continued cycles of fission and 
fusion of their inner and outer membranes. The 
neuropathy may be due to a defect in mitochondrial 
fusion/fission which interferes with energy production 
and slows axonal transport. Many mutations are de 
novo. Mitochondrial aggregates and swelling onEM. 
CMT2A2  
HMSN V (CMT with pyramidal 
signs) 
CMT with deafness and white 






MPZ found in myelinating Schwann cells only. It is 
the most abundant protein in peripheral nerve myelin 
occupying 50% of total peripheral myelin protein. 
Within myelin it compacts myelin. Associated 
proteins: are PMP-22 & myelin basic protein. It is 
absent from CNS myelin. MPZ is necessary for 
normal myelin structure & function. It regulates 
Schwann cells. It is increased with axonal contact 
CMT 1B:  CMT 1E:   CMT 2I:  
CMT 2J:  CMT 4E, CMT 4B. 
CMT-DI3:   Congenital 
hypomyelinating neuropathy:  
Dejerine-Sottas: Sometimes 
partial steroid responsive:   Adult 
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and reduced by loss of axonal contact: It is turned off 
during Wallerian degeneration  
MTMR2(121,122,253) 
(603557) MTMR2 is widely expressed and encodes a phosphatase (substrates include phosphoinositides). 
It is detected in all cytoplasmic compartments of 
myelin-forming and non-myelin-forming Schwann 
cells, and both sensory and motorneurons. In 
contrast, MTMR2 is detected in the nucleus of 
Schwann cells and motorneurons, but not in the 
nucleus of sensory neurons. As MTMR2 is diffusely 
present also within the nerve, a specific function 
could derive instead from nerve-specific interacting 
proteins. The neurofilament light chain protein (NEF-
L) has been found to interact with MTMR2 in both 
Schwann cells and neurons. 
CMT4B1  
NDRG1(130) 
(605262) NDRG1 is ubiquitously expressed and has been proposed to play a role in growth arrest and cell 
differentiation, possibly as a signalling protein 
shuttling between the cytoplasm and the nucleus. 
There are high levels expressed in the Schwann cell. 
NDRG1 may have a role in the peripheral nervous 
system, possibly in the Schwann-cell signalling 






Required for organization of neurofilaments. 





(162030) Mutations in the gene result in substitution of tryptophan for arginine – separates the effects of 
NGF involved in development central nervous 
system functions(e.g. mental abilities)from those 
involved in peripheral pain pathways 
HSN5  
NTRK1(220) 
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Role in the initiation of myelin spirals, regulation of 
growth and differentiation of Schwann cells and 
control of thickness and stability of myelin 
sheaths.(254)  
CMT1A, CMT1E, DSS, HNPP   
PRPS1(148,149) 
(311850) 
PRPS1 is an isoform of the PRPS gene family. It is 
ubiquitously expressed in human tissues, including 
cochlea. The enzyme mediates the biochemical step 
critical for purine metabolism and nucleotide 
biosynthesis. Decreased enzyme activity in affected 
patients. PRPS1 is the first CMT gene recognised to 




Periaxin proteins are important for normal Schwann 
cell function. 
CMT4F, DSS (CMT3) Lebanese populations 
RAB7(84) 
(602298) Rab GTPases localize to the cytosolic face of specific intracellular organelles, regulating distinct 
steps of membrane traffic. It has a fundamental role 
in growth factor-regulated cell nutrition and 
apoptosis. It is known to be involved in the control of 
retrograde axonal transport of neurotrophin 
receptors. Hypothesised that mutated Rab7 gene 
causes CMT2B disease by alteration of neurotrophin 
receptor trafficking 
CMT2B  
(some clinical overlap with HSN1) 




Implicated in formation of the cytoskeleton, cell 
division and tumour-genesis 
Hereditary neuralgic amyotrophy  
SH3TC2 (KIAA1985)(128) 
(608206)  
KIAA1985 protein may acts as an adapter or docking 
molecule. The translated protein belongs to a so-far-
unrecognized family of putative adapter proteins 
CMT4C Increased in Algerian 
populations 
SLC12A6 (KCC3)(189) 
(604878)  The gene encodes the K+-Cl- transporter KCC3 and 
maps within the ACCPN (peripheral neuropathy 
associated with agenesis of the corpus callosum) 
candidate region. It is suggested to play a critical role 
for SLC12A6 in the development and maintenance of 
the nervous system. 
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Encodes serine palmitoyltransferase, long chain 
base subunit-1. The gene is located within the HSN1 
locus, expressed in dorsal root ganglia (DRG) and 




YARS localizes to axonal termini in differentiating 
primary motor neuron and neuroblastoma cultures. 
This specific distribution is significantly reduced in 
cells expressing mutant YARS proteins. It is the 
second aminoacyl-tRNA synthetase found to be 
involved in CMT, linking protein-synthesizing 
complexes with neurodegeneration. 
DI-CMTC  
Key: 
Proteins / mutations 
DNM2: dynamin 2        MTMR2: myotubularin-related protein 2 
EGR2 (Krox20): Early Growth Response 2 protein    NEFL: Neurofilament light chain  
FGD4: actin-filament binding protein Frabin     NDRG1: N-myc downstream regulated gene 1 
FIG4: poly phosphoinositide phosphate activity     NGFβ: Nerve growth factor β gene 
GARS: glycyl-tRNA synthetase       NTRK1: Neurotrophic tyrosine kinase receptor type 1 
GAN1: gigaxonin        PMP 22: peripheral myelin protein 22 
GJB1: gap junction protein, beta 1, 32kDa (connexin 32)    PRPS1: phosphoribosyl pyrophosphate synthetase 1 
HSPB1: heat shock 27kDa protein 1      PRX: periaxin 
HSPB8: heat shock 27kDa protein 8      RAB7: member RAS oncogene family 
IGHMBP2: immunoglobulin mu binding protein 2     SEPT9:septin9     
IKBKAP: IkB kinase complex-associated protein     SH3TC2: KIAA1985 protein 
LITAF; SIMPLE:  Lipopolysaccharide-induced tumour necrosis factor-α factor  SLC12A6 (KCC3): solute carrier family 12, member 6 
LMNA: Lamin A/C        SPTLC1: serine palmitoyltransferase, long chain base subunit-1 
MFN2: mitofusin 2        YARS: tyrosyl-tRNA synthetase 
MPZ: Myelin protein zero 
Disorders:  
1A -CMD1A :Cardiomyopathy, dilated,      FPLD2:Lipodystrophy, familial partial, type 2 - 
CNM: Myopathy, centronuclear, autosomal dominant     HGPS :Hutchinson-Gilford progeria syndrome - 
DSMAV: Spinal muscular atrophy, distal, type V –    HMN2:Neuropathy, distal hereditary motor, type II - 
EDMD2:Emery-Dreifuss muscular dystrophy, autosomal dominant -   HMN V: Neuropathy, distal hereditary motor type V - 
EDMD3:Emery-Dreifuss Autosomal recessive -      LGMD1B: Muscular dystrophy, limb-girdle, type 1B -  
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CHAPTER 2 
THE ROLE OF NERVE BIOPSY 
 
This article “Nerve Biopsy” (Jo M Wilmshurst, Robert A Ouvrier) was published in 
Neuromuscular Disorders of Infancy, Childhood and Adolescence. A Clinician's Approach. 
Editors H. Royden Jones, Darryl De Vivo, Basil Darras, 2003, 91-109(1) 
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Introduction 
 Chapters 3, 4 and 5 will illustrate the usefulness of peripheral nerve biopsy in the 
clinical context. When electing to undertake this investigation on a child with a peripheral 
neuropathy the following text will aid to clarify the role, optimal methodology and 
interpretations of nerve biopsies.  
Although the rapidly expanding area of molecular genetics has reduced the necessity 
of invasive investigations, peripheral nerve biopsy remains a valuable diagnostic aid when 
used appropriately. In many countries, access to comprehensive molecular genetic studies is 
limited. If centres have the capacity to analyse peripheral nerve biopsies, the results may aid 
diagnostic closure or support motivation for further investigations. There are specific DNA 
tests for many of the demyelinating hereditary motor sensory neuropathies (HMSN) or Charcot 
Marie Tooth (CMT) demyelinating disorders.(255) In contrast many of the axonopathies, remain 
poorly understood and difficult to categorise diagnostically. Nerve biopsy is particularly useful 
in the evaluation of a child with an indeterminate peripheral neuropathy when clinical 
assessment, laboratory investigations, and EMG are unsuccessful in identifying an aetiologic 
mechanism for a neuropathy. The clinician needs to have clear indications and expectations 
for performing the nerve biopsy in a chronically affected sometimes debilitated patient where 
confirmatory data would aid prognostic, genetic and, ideally, therapeutic management.(256). In 
the 1989 study of Argov and colleagues, forty- eight percent of children and adults, aged 12-
78 years, with a peripheral neuropathy were diagnosed without proceeding to nerve biopsy. 
Biopsy contributed to diagnosis in 38% of the remaining patients and management was 
affected by the specific histological findings in half of these. The importance of careful patient 
selection was emphasized.(257) Nerve biopsy also has an important role for excluding a 
number of devastating diseases such as infantile axonal neuropathy and giant axonal 
neuropathy.   
Nerve biopsies need to be analysed in a centre skilled in the appropriate 
histopathological techniques, interpretation of both light and electron microscopic findings, and 
with the ability to perform quantitative analysis where appropriate. Peripheral nerves in the 
paediatric age group differ from those of adults. Between birth and age 5 years, significant 
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including thickness. There is a gradual evolution in these parameters from early infancy until 
the mature adult histological pattern is approached in the pre-school years.(258) 
Although peripheral electrophysiology is useful in identifying neuropathies, the 
findings are not always consistent. A patient with a suspected neuropathy, particularly one 
with a small fibre sensory neuropathy, may have normal conventional nerve conduction 
studies. Likewise, a patient with an axonopathy will sometimes have peripheral 
electrophysiological features suggesting a demyelinating condition.(259) Without proceeding to 
nerve biopsy the exact nature of the neuropathy cannot always be reliably determined. See 
Case 2 below. 
Although there is little in the literature discussing large group studies of nerve biopsies 
in childhood, four hundred and twenty six paediatric biopsies have been performed in children 
aged 1 month to 17 years during the last 37 years at the Nerve Research Laboratory of 
Sydney University. These biopsies confirmed and defined 296 peripheral neuropathies. The 
other 130 biopsies with normal findings were performed in children whose clinical features and 
/or nerve conduction studies suggested the possibility of a neuropathy (such as distal spinal 
muscular atrophy). In recent years, advances in molecular genetics have reduced the need for 
nerve biopsy in the investigation of many inborn errors of metabolism typically associated with 
a demyelinating polyneuropathy. In contrast, many of the paediatric axonal degenerative 
neuropathies remain poorly understood. Therefore peripheral nerve biopsy continues to 
provide an important means to aid these diagnostic efforts. The relative proportion of primary 
axonopathies studied has consequently increased as specific DNA testing is yet to be 
developed for most of these processes.   
 
Nerve biopsy: 
Principles and techniques: 
The sural nerve is the usual source for most biopsy specimens. This primarily sensory 
nerve supplies the sensation to the lateral aspect of the foot. It is made up of both myelinated 
and unmyelinated fibres having both sensory and autonomic origin. Because of this nerve’s 
distal location it is involved early in most generalized neuropathies. Its removal at biopsy 
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usually have a significant sensory loss in its distribution. A general anaesthetic is advisable in 
children although adults usually tolerate the procedure well under a local anaesthetic. In order 
to reduce the number of anaesthetic procedures that a child undergoes, if a muscle biopsy is 
also indicated, as part of the child’s evaluation, it is best performed concomitantly with the 
nerve biopsy. This investigation is often useful in its own right and can complement nerve 
biopsy findings, such as by confirming the presence of a primary neurogenic atrophy 
secondary to chronic denervation.  
Special care needs to be taken in the processing and handling of the nerve. One 
needs to avoid damage to the fascicles by over-zealous contact. Whole or fascicular sections 
are utilized depending on the nerve centre’s experience. When one is specifically screening 
for certain pathologic conditions, such as chronic inflammatory demyelinating 
polyradiculoneuropathy (CIDP), sarcoidosis, and amyloidosis, it is advisable to obtain whole 
nerve sections.(260) The peripheral nerve specimen is placed on a saline-moistened sponge 
that is then placed in an airtight container until arrival in the laboratory. In order to avoid 
artifacts, each biopsied nerve must be processed within 15 minutes of its removal. This 
urgency applies to autopsy samples, because of the rapid propensity to undergo spontaneous 
autolysis. Unless the samples are taken soon after death, there is a significant possibility that 
the findings will be impossible to interpret. Nevertheless, myelinated fibres can be reliably 
assessed up until 24 hours in rats if the cadaver is refrigerated.(261)  
Detailed descriptions of the various techniques used to assess nerve histology are 
published.(260) The following technique is employed at the University of Sydney laboratory.(262) 
It is advisable to store biopsy material in case further histopathological analysis becomes 
necessary. 
Whole sural nerve biopsy is performed usually at the level of the lateral malleolus 
under general anaesthetic. The nerve is divided into three to five portions each 0.5-1cm in 
length. One piece of each nerve is fixed in picric acid, embedded in paraffin, and cut 
transversely and longitudinally into sections of 5µm thickness. Sections are stained with 
haematoxylin and eosin and with congo red.  
A second piece is longitudinally cut into strips of about 1mm diameter which are fixed 
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aqueous osmic acid, transferred to a 2:1 mixture of glycerol and water for 12 hours and 
individually teased out under a dissecting microscope.  
A third piece is fixed in 2.5% phosphate buffered glutaraldehyde overnight at 4oC 
followed by 2% osmium tetroxide for 90 minutes. The tissue is dehydrated in graded 
concentrations of ethanol, passed through acetone, and embedded in Spurr’s resin. 0.25µm 
sections are cut transversely and stained with toluidine blue.  
Portions of nerve are fixed for electron microscopy as indicated. When appropriate, 
pieces of nerve are frozen in liquid nitrogen and cryostat sections cut for immunohistochemical 
staining.  
Light Microscopy Assessment: Certain stains are preferred in order to identify specific 
pathologic processes. One typically utilizes both transverse and longitudinal teased fibre 
sections. 
Transverse sections 
Haematoxylin and eosin (H & E) sections may identify perineurial oedema and signs 
of inflammation (as occurs in CIDP or vasculitis). Cuffing with lymphocytes around endoneurial 
vessels is a significant marker of inflammation that is well demonstrated with H&E sections.  
Congo red stains are used to screen for amyloid infiltration, a test more relevant to 
adults. 
Toluidine blue stains provide data on both demyelinating and axonal disorders. 
Demyelinating disorders are typically associated with reduced myelinated fibre density, 
increased Schwann cell and inflammatory cell numbers, reduced myelin thickness, evidence 
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Figure 2.1: Transverse section of a nerve fascicle from a patient with CMT1A (LM, toluidine 
blue, magnification x400). Many fibres are surrounded by onion bulb formations. Some fibres 
are thinly myelinated and the MF density is reduced. 
Axonopathies are typified by reduced myelinated fibre density, fibres undergoing 
active axonal degeneration and cluster formation when regeneration is occurring (Figure 2.2).  
Figure 2.2: Transverse section of a nerve fascicle from a patient with CMT2 (LM, toluidine 
blue, magnification x200). The MF density is reduced. Remaining fibres are well myelinated.  
Special histochemical stains are used to screen for conditions such as metachromatic 
leukodystrophy, where acid cresyl violet stain confirms the brown metachromatic granules. 
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Teased fibres. 
Teased fibre studies, though time consuming to prepare, provide invaluable nerve 
pathology information. Ideally some 30 –100 fibres need to be separated out to give a 
reasonable selection of the nerve characteristics. This technique allows examination of 
myelinated fibre changes in a longitudinal axis that transverse sections may often not identify. 
It is possible to look for segmental demyelination, widening of the nodal gap with paranodal 
demyelination, segmental remyelination (often appearing as two or more short segments 
between normal length segments), and regenerated fibres where all internodal segments are 
short (0.2-0.6mm) and have disproportionately thick diameters (Figure 2.3). The finding of 
myelin ovoids suggests active axonal degeneration (Figure 2.4). 
 
Figure 2.3: Teased fibre appearance of demyelination from a patient with CMT1 (magnification 
x200). Extensive thinning of myelin and patchy intra and segmental demyelination can be 
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Figure 2.4: Teased fibre appearance of axonal degeneration demonstrating extensive myelin 
ovoids along the course of the fibres (magnification x200).  
Teased fibre sections particularly aid in the differentiation of primary segmental 
demyelination from a secondary demyelinating process due to axonal disease. The finding of 
“clustering” of segmental demyelination along a single diseased axon, where many of the 
remaining axons appear well myelinated, suggests axonal degeneration as the primary 
process, whereas apparently random regions of segmental demyelination throughout many 
fibres are more likely compatible with a primary demyelinating process.(263) 
Electron microscopy 
Electron microscopy (EM) allows estimation of the presence and density of 
unmyelinated fibres. Additionally this is often the only means to confirm the presence of 
conditions such as neuroaxonal dystrophy, where the typical axonal spheroids are often only 
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Figure 2.5: Electron micrograph from a patient with neuroaxonal dystrophy (magnification 
estimated x28000). The plate shows axonal degeneration with the axoplasm containing 
multiple mitochondria and the typical tubulogranular profiles of this condition.  
Electron microscopy is primarily performed, subsequent to LM, in order to assess 
conditions where further information is needed for more precise diagnosis.  
EM provides detailed pictures of the intrinsic nature of the fascicle with basement 
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Figure 2.6: Electron micrograph of a single myelinated fibre, from a patient with Po mutation, 
demonstrating uncompacted myelin round a thinly myelinated fibre. Concentric layers of 
Schwann cell cytoplasm and endoneurial elements, forming an “onion bulb” surround the 
fibre.(Magnification estimated x15000) 
Further, electron microscopy may be the only way to detect evidence of Bands of 
Büngner (early regenerating large myelinated fibres) and Schwann cell subunits (where a 
single Schwann cell profile, or group of profiles, are enclosed by a continuous basal lamina, 
that may or may not include axons). Subtle changes in the myelin folds may suggest early 
demyelination or failure of compaction (Figure 2.6). In contrast early axoplasmal shrinkage, 
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Figure 2.7: Electron micrograph of two nerve fibres, from an infant, undergoing active axonal 
degeneration. The fibres are well myelinated but active breakdown is evident within the 
axoplasm. (Magnification x7000)   
Artifact is a frequent problem with even the most carefully prepared nerves. In such 
circumstances, EM frequently enables the nerve pathologist to differentiate between genuine 
disease pathology and artifactual changes. 
 
Quantitative analysis  
Myelinated fibre morphometric studies are performed utilising photomicrographic 
enlargements of toluidine blue stained sections. Electron micrographs also provide for the 
assessment of unmyelinated nerve fibres. Various computer-assisted methods are available to 
allow for the rapid assessment of larger numbers of fibres. Even the most sensitive programs 
require observer verification. This ensures that the fibre counts only include axons.  
An alternative method utilises visual counts on electron micrographs or magnified LM 
fascicles. At least ten EM plates at a magnification of around x3500 magnitude are taken from 
random sections of the same fascicle. Myelinated fibres (MF) are counted and the density per 
mm2 calculated from this figure and the area. Similarly the fibre diameters are assessed 
through the average of the maximum and minimum diameter or by conversion from the 
circumference of the fibre (D=C/π). From these values the equivalent number per mm2 can be 
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The histographic appearance of certain diseases is typical. For example, in Friedreich 
ataxia, there is a reduction in myelinated fibre density with predominant loss of the large 
MF.(227)  
A similar process is used for unmyelinated fibres (unMF) though as the ratio of 
unmyelinated to myelinated fibres is often as much as 4:1 the numbers are clearly far greater. 
Generally, counting a total number per plate until a value over 80 is reached provides a 
reasonably accurate estimate of unMF density. The diameters are measured by the same 
method as for MF. Other useful measurements from EM include the numbers of Schwann cell 
nuclei, denervated Schwann cell subunits, and collagen pockets, the last two being indicators 
of unmyelinated fibre loss. 
The ratio of axon diameter (d), excluding the myelin, to total MF diameter (D) provides 
an indication of the thickness of myelin around a specific fibre, the “d/D” or “g” ratio, allowing 
confirmation of the presence of excessively thin myelin, (high d/D ratio), as occurs with large 
numbers of regenerated or hypomyelinated fibres, or of excessively thick myelin (low d/D 
ratio), as is seen in the tomaculous neuropathies (particularly hereditary neuropathy with 
liability to pressure palsies). 
 
Other biopsy sites:    
Sural nerve biopsy is clearly relevant for the investigation of generalized sensorimotor 
polyneuropathies but obviously has no value when there is no sensory involvement. With 
certain exceptions, such as in the early stages of an axonal neuropathy, where many large 
diameter fibres are preserved, the lack of sensory nerve involvement may be clinically 
inferred. Supportive findings in the child include the presence of a normal sensory examination 
concomitant with nerve conduction studies (NCS) demonstrating preserved sensory nerve 
action potentials (SNAPs).(260) Thus with each planned biopsy, if such studies are normal, it 
needs to be recognised that the yield from biopsy will be small.  
Occasionally other sites are used when a specific localized neuropathy is suspected 
or if access to the sural nerve is not possible. The superficial radial, the superficial peroneal 
(after the motor component has branched off) or the deep peroneal nerves have been used. 
Similarly the saphenous nerve can be biopsied, although this is a difficult nerve to assess, as 
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If a nerve biopsy of a child with a pure or predominantly motor neuropathy is 
necessary, a motor nerve sample provides more diagnostic information than will a sural nerve 
biopsy. Motor nerves in general are not routinely sampled. However, prognostic information 
was gained from one study in a patient with severe Guillain-Barré syndrome.(264)  Biopsy of the 
terminal branch of the musculocutaneous nerve unequivocally confirmed that the pathological 
process was primary demyelination, not axonal degeneration, and provided more information 
than had previously been reported in such patients from sural nerve biopsies. Other motor 
nerves that may be considered include the lateral terminal branch of the deep peroneal 
nerve(265) and the motor branch of the superficial peroneal nerve (although this is more often 
sampled from autopsy cases).(260)  The nerve to the gracilis muscle has also been used with 
little complication and useful information gained.(266) 
Quantitative peripheral nerve analysis is also possible by performing a skin biopsy.(267) 
It is particularly useful for assessment of small fibre neuropathies.(268) In patients with Fabry’s 
disease, a condition that results in severe distal burning pains with progressive loss of both 
small myelinated and unmyelinated fibres, the study produced convincing evidence that the 
quantification of small myelinated and unmyelinated fibres is as accurately calculated by skin 
biopsy as it was with a sural nerve biopsy.(269) Another advantage is that skin biopsy sampling 
is less invasive, well tolerated, and easily repeated providing quantitative serial measurements 
of disease progression.(267)(269)The application of these techniques may be particularly 
instructive in providing a better understanding of the hereditary sensory neuropathies. 
 
Complications 
In general, about 40 % of adult patients complain of pain or paraesthesiae persisting 
one year after nerve biopsy. The pain is moderate to severe in a quarter of these individuals. 
This discomfort is commonly described as being like a pinprick or a tight sensation during 
standing or walking.(270,271) The outcome is not influenced whether the biopsy is whole nerve or 
fascicular.(272) Prolonged follow up after 2 years suggests that there is a gradual improvement 
in symptoms with time.(273) Most of these studies are derived from the adult age group; there is 
little comparative data from children. However, complaints following biopsy have not usually 
been significant among cases seen in the peripheral neuropathy clinics at The Children’s 
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biopsy of the sural nerve and muscle at the mid-calf level. Subsequently he suffered 
discomfort in that region and this was felt to be secondary to adhesions around the nerve.    
 
Sural nerve morphology varies with age:  
During the first year of life the nerve morphology changes markedly with a more 
gradual evolution over the following years until the adult pattern is approached by 5 years of 
age.(258,274,275) Similarly, nerve conduction parameters do not reach adult values until 3 – 5 
years of age.(276,277)  
Myelination of peripheral nerve commences from 18 weeks gestation. By term, most 
of the fibres that are destined to become myelinated have started the process.(278) The total 
number of MF per sural nerve increases from 4000 at birth to 7-12000 by “adulthood”. 
However, the density of MF per mm2 follows the opposite trend. This is because the sural 
nerve endoneurial area is smaller at birth (0.2-0.5mm2) whilst the adult size increases to 0.6-
1.2 mm2. Densities at birth are as high as 12-20,000 MF/mm2. This rapidly decreases to 
nearer 10,000 MF/mm2 by one year of age.  Adult levels are attained nearer to 10 years of 
age. 
There is relative hypomyelination at birth, with “g”-ratios above 0.8 common.(279) By 5 
years of age the axons reach their adult size whilst final myelin thickness is really only evident 
by 10 years of age. The MF diameter histogram is unimodal at birth and evolves into a 
bimodal appearance towards the end of the first year as large myelinated fibres become 
established. Internode lengths are 200-300 microns at birth and increase to 200-1800 microns 
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 Figure 2.8: Normal MF diameter changes with age (0-10years).4 In early life the myelinated 
fibres are of small diameter (2-5microns) and the histograms are unimodal. By one year of age 
a bimodal trend appears as larger diameter fibres form (8-12 microns).(258) 
 
Biopsy findings in relevant diseases:  
Tables 1.2 (page 19), 1.3 (page 32), 2.1, 2.2 and 2.3 summarise the predominant 
nerve biopsy findings in the various childhood peripheral neuropathies. Tables 1.3 and 2.2 
both describe various neurodegenerative diseases which involve the peripheral nerves, table 
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are possible. Molecular DNA genetic testing easily confirms many of the hereditary 
demyelinating neuropathies. However, a substantial number of the axonal neurodegenerative 
disorders still require a nerve biopsy for diagnosis. The leukocyte (white cell) enzyme screen 
may confirm a leukodystrophy but as with the example of metachromatic leukodystrophy 
(MLD), borderline arylsulphatase A (ASA) levels can be misleading, sometimes leaving biopsy 
as the only firm diagnostic test available.(234) Vasculitis may occur without systemic features. 
Thus, confirmation of this rare immunologically mediated neuropathy with a sural nerve biopsy 
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Table 2.1: Inflammatory and infectious disorders.  
Disease Type of 
neuropathy 
Biopsy findings Comment 
CIDP (281) 
 
Mixed Subperineurial oedema; 
macrophages; density ↓; 
clusters; thin myelin 
Not routinely recommended 
as features can overlap the 
HMSNs and findings are not 
consistent.  
 
Vasculitis (282) Axonal Acute axonal degeneration; 
vasculitis in endoneurium 
and perineurium 
Rare in children – consider 









macrophages and Schwann 
cells filled with organisms 
and debris (foamy cells); 
much of architecture 
preserved.  
 





Axonal Lymphocyte & plasma cell 
infiltration; thick 
pericapillary cuffs without 




(HIV) – CMV 
neuritis (286) 
Axonal Active axonal degeneration 
with some segmental 
demyelination; necrotising 
endoneurial and epineurial 
vasculitis with prominent 
neutrophil infiltrate. On EM 
CMV virions seen in the 
endoneurial cells 
Although neuropathy in HIV 
is rarely reported, it should 
be considered, especially in 
older children. NCS are 
often abnormal even in 
young children with HIV, 
biopsy data however is 
scarce.(287) 
 
Key: CIDP = chronic idiopathic demyelinating polyradiculoneuropathy; SLE = systemic lupus 
erythematosus; RA = rheumatoid arthritis; HIV = human immunodeficiency virus;  
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Table 2.2 (see also Table 1.3 page 32): Neurodegenerative and Metabolic disorders.  
Disease Type of 
neuropathy 
Biopsy findings Comment 
Friedreich’s ataxia10 
Figure 2.9 
Axonal ↓ Density – selective loss 
of large MF; clusters rare 









Axonal Progressive loss of large 





Axonal Giant axons; ↓ density MF; 
axons filled with densely 
packed neurofilaments on 
EM 
Diagnostic picture on 







Axonal Globular, ovoid or fusiform 
swellings along the course 
of axons; axonal 
degeneration. Typical 
neurofilaments  visible on 
EM sections 
Diagnostic picture on 
biopsy – can also be 
diagnosed from other 
biopsy sites e.g. skin, 
conjunctiva.(290) 
Fabry’s disease (269) Axonal Selective loss of small and 
unMF; glycolipid granules 
in perineurial and 
endoneurial cells   
Diagnostic picture on 
biopsy. Various 
mutations of the α-
galactosidase A gene 
are described.(291)  
 
Niemann-Pick 
Disease Type A (292) 
Demyelinating Loss of MF; thin myelin 
sheaths; within Schwann 
cells numerous round or 
fusiform bodies 
Infantile form 
Farber disease (293) Axonal Loss of axons. Round 
membrane-bound clear 
inclusions in Schwann 
cells and histiocytes 
 





Demyelinating Density ↓; inclusions in 
Schwann cells; 
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macrophages possible from white cell 
enzymes, but biopsy 





Demyelinating Density ↓; OB; on acid 
cresyl violet stain 
metachromatic material; 
EM  - macrophages, 




zebra bodies and vacuoles 
Diagnostic picture on 
biopsy. Biopsy is useful 
where white cells 
enzymes cannot 





Demyelinating Demyelinating fibres; 






Demyelinating Demyelinating fibres with 
no Schwann cell inclusions 
Peripheral neuropathy 





Demyelinating ↓ density of MF; 
segmental demyelination; 
clusters; large OB. EM 
lipid inclusions 










Demyelinating Demyelinating and 
remyelinating pattern; 
multiple lipid vacuoles 
especially concentrated in 
Remak cells. 
Mononeuropathy 
occurs in childhood; 
pseudosyringomyelic 
syndrome occurs after 
the second decade. 
Chediak-Higashi 
Syndrome (299) 
Axonal Giant lysosomal inclusions 
in Schwann cells of 
peripheral nerves (and 







↓ MF and unMF. 
Denervated Schwann cell 
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accumulation in the 
nerves.  
Cholestanosis 
Porphyria (304) Axonal Loss of large MF with 









Key: MF = myelinated fibre; EM = electron microscopy; OB = onion bulb formation; MLD = 
metachromatic leukodystrophy 
 
Figure 2.9: Transverse section of a nerve fascicle from a patient with Friedreich’s ataxia (LM, 
toluidine blue, magnification x100). There is marked reduction in MF density, especially of the 
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Figure 2.10: Electron micrograph from a patient with giant axonal neuropathy. Two abnormally 
large fibres are shown (>30 microns diameter), they are surrounded by thin myelin and the 
axons packed with neurofilaments. The fibres are surrounded by rudimentary onion bulbs. 
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Figure 2.11: Electron micrograph of a patient with metachromatic leukodystrophy. Fibre is 
thinly myelinated. Tuff-stone bodies and zebra bodies are present within the Schwann cell 
cytoplasm.(Magnification estimated x20000)    
Figure 2.12: Transverse section of part of a nerve fascicle from a patient with Cockayne 
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Table 2.3: Toxic, nutritional deficiencies and miscellaneous. 
Disease Type of 
neuropathy 
Biopsy findings Comment 
Glue – sniffing 
neuropathy (306) 
 
Axonal Swelling of the axons and 
thinning of the myelin. EM 
axonal swellings densely 
packed whorled masses of 
neurofilaments  
Diagnostic picture on 
biopsy 





Axonal Axonal degeneration  
Ciguatera(309) 
 
Axonal Oedema of the adaxonal 
Schwann cell cytoplasm. 
Poisoning from 
consuming toxins in 
fish from the tropics 
Vitamin B1 deficiency 
(310) 
Axonal Axonal degeneration with 
central peripheral distal 




Axonal Axonal degeneration Cases described of 
infants affected after 





Axonal Loss of large MF and 
axonal degeneration. 
Consider familial 
vitamin E deficiency 




Figure 2.13  
Axonal(313) / 
Demyelinating(314) 
Damage due to 
neurofibromas in the nerve 
sheath(315) with both 
demyelination and 
An association with 
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axonopathy described  
Hereditary amyloid 
neuropathy(317) 
Axonal Loss of MF, especially 
small MF. Positive 
birefrigence of amyloid 
deposit with congo red 
stain 
Very rare in childhood 
Allgrove 
syndrome(318) 












Axonal Moderate loss MF  Characteristic 
adventitious plaque of 
tissue composed of 
hyperplastic, 
interlacing bands of 
Schwann cells and 
MFs overlaying the 
posterior columns of 
the spinal cord. 
Related to mutations 
in the RET proto-
oncogene.(321) 
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Figure 2.13: Transverse section of a nerve fascicle from a patient with neurofibromatosis type 
1 (LM, toluidine blue, magnification x200). The subperineurial space is increased, containing 
neurofibromatous tissue.  
 
Conclusion 
Peripheral nerve biopsy is a valuable investigative modality when appropriately 
utilised and examined by a reliable laboratory. It is an invasive test and therefore must have 
well defined indications. This study should not be performed without good reason. The data 
derived can provide diagnostic information as well as both prognostic advice and patient 
management information. In the setting of a hereditary peripheral neuropathy, a sural nerve 
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Vignettes. 
Case 1:   
 This adopted full term male child was born to a thirteen year old mother in 1981 by 
Caesarean section. Her medical history was unremarkable.  No details of the father were 
known.  He had mild bilateral ptosis in infancy and hypotonia before his first birthday. He could 
sit if placed at six months but did not weight bear on his legs at 14 months. On neurological 
examination at age twenty months, he had mild bilateral ptosis, generalized hypotonia and 
mild weakness.  All muscle stretch reflexes were absent.  
 He eventually walked independently at age three years. By age four years his clinical 
condition had stabilized however he was still not toilet trained. This boy appeared of normal or 
near normal intelligence.  He was able to run a little in a waddling fashion.  Although he 
appeared to feel pain normally, he seemed to have unpleasant sensations when his hands or 
body were rubbed, as with a towel. Both pupils reacted sluggishly to light. He was unable to 
converge and had bilateral ptosis. Mild bilateral facial weakness was present, more marked on 
the right.  There was mild proximal and moderate distal weakness with bilateral foot drop.  He 
could not lift his head from the bed or sit with the arms folded in the supine position.  The 
Gowers' manoeuvre was utilized to arise from the floor.  He had bilateral foot drop and 
bilateral pes planus.  All muscle stretch reflexes were absent.  The peripheral nerves were not 
palpably enlarged. 
 His strength was unchanged at age seven years.  There was distal loss of vibratory 
and proprioceptive sensation. By twelve years, he had difficulty walking because of increasing 
weakness and ataxia. His pupils no longer reacted to light.  
 The following tests were normal: full blood count, serum electrolytes, serum calcium, 
magnesium and phosphorus, fasting blood glucose, serum uric acid, liver function tests, EEG, 
3 day faecal fat estimation, serum lipid electrophoresis, urine metabolic screen, urinary 
excretion of lead and arsenic, free erythrocytic protoporphyrin level, serum phytanic acid, 
white cell aryl sulphatase level, and creatine phosphokinase. DNA testing for mutations of the 
PMP22 and MPZ proteins was negative. Cerebrospinal fluid protein was 20mg/dl. Fasting 
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At age 20 months, sensory nerve action potentials (SNAPs) were absent on testing 
the left median and ulnar nerves.  Motor nerve conduction velocities ranged between 24 to 
19.5 m/s for the right median, left ulnar and left peroneal nerves.  EMG of the left tibialis 
anterior muscle was unremarkable. Repeat nerve conduction studies were unchanged at 2.5 
years.   
 Sural nerve biopsy (at age-20-months) confirmed the diagnosis of hereditary motor 
and sensory neuropathy with focally folded myelin sheaths (CMT 4B) (Figure 4.2).  
Comment: 
 Three other similar, but sporadic, cases are recorded in the Sydney series of 260 
biopsied children. About half of such cases have a mutation of the myotubularin gene. 
Currently, nerve biopsy is the only means to make the diagnosis of individual instances of 
CMT 4B when there is no record of other affected family members and DNA studies are 
negative. 
   
Case 2: 
 After a normal pregnancy, this boy delivered at term weighing 3.3 kg. He was not a 
very active infant. His infantile period was complicated by severe reflux, asthma, recurrent ear 
infections, and tracheomalacia. There was no family history of neuropathy or other 
neurological abnormality. Although he walked at 14 months of age he was clumsy with an 
unusual gait. His feet tended to “flop” down with each step, resulting in frequent falls and 
unsteadiness. Speech dyspraxia was diagnosed at age 20 month. His was of normal 
intelligence. 
 At age three years he presented with a febrile illness. He was hypotonic and had 
absent muscle stretch reflexes. Initially Guillain-Barré syndrome was considered. He also had 
myoclonic jerks. Over the following year, he remained stable but appeared weaker after febrile 
illnesses. He tired after 10 minutes of walking.  
 At the age of four years he remained a small child with a head circumference of 
51.5cm, weighing just 15 kg. His speech was difficult to follow but contained many words and 
some phrases.  He was chronically constipated. His peripheral nerves were not thickened. 
Pupils and optic fundi were normal and there was no nystagmus. Apart from weak ankle dorsi 
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and could not stand on one leg for more than two seconds. Vibration sense was reduced and 
he had a delayed response to pain. Muscle stretch reflexes continued to be absent. 
 Laboratory investigations demonstrated normal full blood count, serum lead, B12, 
folate, iron studies, phytanic acid, plasma lactate, vitamin E, lysosomal enzymes, lipoproteins 
and transferrin isoform pattern. Urinary amino acids, organic acids, mucopolysaccharides and 
oligosaccharides were also normal. CSF protein was 13 mg/dl. Magnetic resonance imaging 
of the brain was normal. Molecular genetic studies were negative for CMT type 1A and HNPP.  
 Nerve conduction studies (at four years of age) showed slow motor conduction 
velocities (median nerve 26 meter / second and ulnar nerve 22 meter / second) and absent 
sensory responses.  
 Sural nerve biopsy at the age of 4½ years showed a severe reduction in myelinated 
fibre density. The unmyelinated fibre density appeared normal. There were no demyelinated 
fibres or onion bulb formations. The teased fibre preparation showed predominantly small, 
thinly myelinated fibres with no segmental demyelination. The changes were consistent with a 
moderately severe axonal neuropathy of childhood.  
Comment:  
            Clinically this boy was considered to have HMSN type III but his motor conduction 
velocities, though slow, were not as delayed as would be expected. The sural nerve biopsy 
confirmed that he had an axonopathy and not a demyelinating condition. Thus, he may well 
have HMSN of axonal type with early onset. (103) From the Sydney series this condition is far 
commoner than recognized or reported in the literature. The nerve conduction velocities are 
sometimes in the demyelinating range in axonal degeneration presumably because of failure 
to develop, or loss of, large diameter fibres. Without proceeding to nerve biopsy in these 
patients the underlying nature of the pathology may be missed. This situation is particularly 
likely to be seen in patients whose neuropathy dates from birth or the first year or two of life.   
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CHAPTER 3 
CHRONIC PERIPHERAL NEUROPATHIES PRESENTING IN CHILDHOOD 
– 37 YEARS OF DATA FROM AN AUSTRALIAN POPULATION   
SUMMARY 
Over a 37 year period (1969-2007) 296 (153 female: 143 male) biopsy-proven 
peripheral neuropathies were identified from a total of 426 (205 female: 221 male) samples 
taken from patients less than 17 years of age. Biopsies came mainly from the two paediatric 
neurology units in Sydney. Samples were sent from a few patients from other centres and the 
clinical decision reasons for the biopsies were not the investigator’s responsibility.  
Of the group 169 had axonopathies, 107 had demyelinating neuropathies, 20 had a 
mixed picture and 130 were normal. Inherited aetiology was probable in 248, 161 of whom 
had primary or “pure” peripheral neuropathy disorders and 87 had peripheral neuropathy 
secondary to generalised (or metabolic) illnesses.  
Within the inherited group 87 were pure axonal disorders and 56 secondary to 
generalised illnesses, whilst 73 were pure demyelinating disorders and 17 secondary to 
generalised illnesses. The remainder were mixed axonal and demyelinating (n=15). Of the 
patients where hereditary motor sensory neuropathies were the primary disorder, of those who 
underwent genetic analysis, confirmation was made in 34 out of 50 patients with 
demyelinating histopathological changes, 14 out of 33 patients with axonal degenerative 
changes and one of four patients with mixed axonal and demyelinating features. Fifteen out of 
25 of the patients with Friedreich’s ataxia and one out of 5 of the patients with spinocerebellar 
disease had genetic confirmation.  
Acquired pathologies were definite or probable in 48 of the total group (axonal n=25, 
demyelinating n=17 and mixed picture n=6).  
This study demonstrated that there is a role for peripheral nerve biopsy if molecular 
biological investigations are unavailable or inconclusive. With some conditions, e.g. HMSN 
with myelin out-folding, giant axonal neuropathy with normal hair, and certain sub-groups of 
metachromatic leukodystrophy, biopsy may be the only tool which clarifies the diagnosis. The 
results confirmed the much higher proportion of inherited as opposed to acquired pathologies 
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INTRODUCTION 
Current research in the field of peripheral neuropathies in childhood is dominated by 
molecular genetics discoveries. This has reduced the input from histopathology. The following 
work is unlikely to be repeated again with such numbers of patients reviewed over many years 
and undergoing extensive complements of diagnostic screens. It is intended that the 
information in the following chapter will provide a comprehensive review of the demographics 
and epidemiology of chronic peripheral neuropathies which occur in childhood. 
 
METHODOLOGY. 
Four hundred and twenty-six patients underwent peripheral nerve biopsy as part of 
their investigation for suspected peripheral neuropathy.  
Samples were from the sural nerve (mid-calf or lateral malleolus) or the superficial 
saphenous nerve. Samples were prepared by the technique as is standard practice in the 
Nerve Research Laboratory at the University of Sydney. This is described in detail in chapter 2 
(The Role of Nerve Biopsy), page 44. 
Data recorded from the light microscopy appearance and, where available, electron 
microscopy appearance of these peripheral nerve biopsies were reviewed and documented 
into a database. The principal investigator (JMW) identified biopsies prepared at the Nerve 
Reseach Laboratory, University of Sydney, which were performed on children under 17 years 
of age between 1969 and 2007. The histopathological appearances were examined by herself 
and assessments made of the pathological findings. She was blinded to the original reports 
but as part of identifying the samples occasional exposure to these results occurred. To 
reduce any possible bias from this, on separate occasions independent analyses were 
undertaken between the principal investigator (JMW) and the other investigators (RAO and 
JP). The latter two were reliably blinded to the pathology reports and the principal 
investigator’s assessments. Based on these two assessments a consensus was reached as to 
the biopsy findings, categorising the results into axonal, demyelinating and mixed features, 
and additional features. Images of the significant pathological findings were taken by the 
principal investigator (JMW) and Dr Min Wang, histopathology specialist, at the Nerve 
Research Laboratory. These images were incorporated into a digital database used at the 
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Additional data including the child’s date of birth, age at time of biopsy, age at time of 
clinical presentation, clinical phenotype, biochemical investigations, molecular genetic results, 
nerve conduction study findings, and muscle biopsy findings were collated by the principal 
investigator to aid categorisation of the cohort. This data was accessed through the patient 
medical records, previous neurophysiological results and direct contact with the referring 
physician. Patients were broadly categorised as having hereditary neuropathies, 
neurodegenerative disorders with associated neuropathies, acquired neuropathies or as 
belonging to a miscellaneous group. Hereditary peripheral neuropathy groupings consisted of 
CMT1-5, CMTX, hypertrophic demyelinating, HMSN VII, atypical demyelinating, EOHMSN, 
SMARD1, atypical chronic axonal, and sporadic sensory neuropathy. These were referred to 
as the “pure” hereditary neuropathies. The neurodegenerative disorders included all 
conditions with evidence of central nervous or systemic metabolic dysfunction. A further group 
separate but linked to this category included hereditary conditions with structural defects such 
as neurofibromatosis and spinal muscular atrophy. The acquired peripheral neuropathies were 
related to post-infectious complications, autoimmune disorders and toxin exposure. Within 
each grouping, further subdivisions were made on the basis of the predominant 
neuropathological pattern, namely demyelinating, axonal degenerative or mixed. 
Demyelinating neuropathy was defined by the presence of a reduction in myelinated fibre 
density, with thinning or hypoplasia of the myelin sheaths, paranodal and/or segmental 
demyelination in teased fibre preparations and onion bulb formations. Axonal degenerative 
neuropathy was defined by reduction in the myelinated fibre density, with active or chronic 
axonal degeneration and cluster formations, with only rare evidence of demyelination. Mixed 
neuropathy had obvious features of both axonal degeneration and demyelination at the light 
microscopic level. Diagnostic labels followed the existing criteria in the literature and paralleled 
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RESULTS. 
A total of 426 peripheral nerve biopsies (205 females: 221 males) were reviewed, 130 
were considered within normal limits These normal studies were from patients with central 
nervous neurodegenerative disorders, hypotonia in infancy and patients with undefined 
conditions undergoing extensive diagnostic “work-ups”. 
Of the remaining 296 (153 female: 143 male) peripheral nerve biopsies, 169 had 
axonal degenerative neuropathies, 107 demyelinating neuropathies and 20 had a mixed 
picture. The groups were further divided into diagnostic categories depending, in addition to 
the peripheral nerve biopsy findings, on the clinical phenotype, neurophysiology and molecular 
genetics findings.  
One hundred and sixty-one patients had a hereditary peripheral neuropathy in 
isolation, 78 had a neurodegenerative or metabolic disorder, 9 had other inherited disorders 
(e.g. neurofibromatosis, SMA) and 48 had acquired disorders (Figure 3.1). Two hundred and 
forty-eight out of the total of 296 had a hereditary nature to their disorders. Diagnostic 
categories and molecular genetic findings are summarised in Table 3.1. Figure 3.2 
summarises the overall patient breakdown from the total number assessed (n=426) to those 
who gain molecular genetic diagnoses. 
All children had accepted clinical features of peripheral neuropathy, namely distal 
wasting (especially of their thenar/hypothenar eminences and extensor digitorum brevis 
muscles), distal weakness and absent or reduced deep tendon reflexes (except the HMSN V 
group).  
Apart from one child with discomfort due to cicatricial traction at the posterior calf 
nerve biopsy site (a site which the study unit does not usually select), side effects in this 
cohort of patients from sural nerve biopsy were not an issue, which is supported by other 
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Genetic confirmation Remaining group
 
Table 3.1: Summary of the motor sensory neuropathies with genetic correlation  
Type Sub-type Genetics Patients  with 
genetic results (n) 
Total 
CMTI 1A Duplication chr 17 20 20 
 1A or B   1 
  Sporadic  1 
  FH +ve  5 
    27 
CMT2  FH +ve / dominant  8 
 2A Mitofusin  3 3 
 2E   1 
    12 
CMT3  P0 mutation 6 6 
  PMP22 mutation 3 3 
  Sporadic  / FH  5 
    14 
CMT4 4B P0 mutation  1 1 
  Sporadic / recessive  4 
 4H Frabin 1 1 
    6 
Remyelinating / 
demyelinating 
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EOHMSN  Mitofusin mutations 5 5 
  Sporadic / recessive  13 
    18 
HNPP  17 p duplication 3 3 
CMTX X1 Connexin 32 mutation 1 1 
 X1 FH  3 
 X1 Sporadic  1 
 X5 PRPS1 mutation 1 1 
 X5 Sporadic  2 
 X type unknown   1 
    9 
HMSN V (CMT5)  Sporadic  2 




   6 
SIANR / SMARD1  IGHMP1 5 5 
  Sporadic / recessive  2 
    7 
Severe relapsing 
axonal 
 Recessive  2 
Atypical chronic 
axonal and sensory 
neuropathy 
 Sporadic / recessive  31 
Distal motor 
neuropathy 
 Sporadic / recessive  1 
HSAN Type 1   1 
 Type 4   2 
 Type 5   1 
 Miscellaneous   2 
    6 
Friedreich’s ataxia  Triplicate repeat 13 13 
  Point mutation 2 2 
  Sporadic / recessive   10 
    25 
Spinocerebellar 
ataxia 
SCA miscellaneous   6 
 SCA7  1 1 
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Figure 3.2: Flow chart of patient breakdown leading to definitive genetic 
confirmation 
 
Total number biopsied 
n=426 (205 female: 221 male) 
↓  
Peripheral neuropathy confirmed 
n=296 (153 female: 143 male) 
↓  




n=48 / 87 
'                           ↓                                (  
Demyelinating          Axonal                      Mixed 
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CHARCOT MARIE TOOTH GROUP (CMT) 
Patients whose biopsies were categorised into the Charcot Marie Tooth group were 
divided into those with demyelinating, axonal and mixed features (Figure 3.3). Separate sub-
sections described these groups in more detail (Figures 3.4-3.7). 
(Hereditary motor sensory neuropathies) 
n= 161 (83 female: 78 male) (Figure 3.3) 
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n=73 (36 female: 37 male) (Figure 3.4) 






























































Genetic confirmation Remaining children
 
Twenty-seven patients (13 male: 14 female) had features consistent with CMT1. 
Genetic studies confirmed type 1A with chromosome 17p duplication in 20 patients, five were 
family history positive, one had a clinical phenotype of type 1A or B and one was sporadic with 
no affected relatives. From the group with genetically confirmed CMT1A (11 female: 9 male), 
13 patients had a positive family history and nine presented under 2 years of age. Clinical 
features included pes cavus (n=10), ataxia (n=5), enlarged nerves (n=7), sensory involvement 
(n=6), cranial nerve involvement (n=4) and nystagmus (n=2). One patient also had 
developmental delay; she had chromosome 17p trisomy and was previously described.(324) 
Sensory nerve conduction studies were abnormal in fourteen of fifteen children tested. Motor 
NCS showed median common peroneal (n=12) and median (n=13) velocities of 16 m/s (range 
5 – 45 m/s). Three patients had no potentials on stimulating their common peroneal nerves 
and one of these patients also had no response to stimulation of their median nerve. The 
patient with 17p trisomy had normal motor and sensory conduction studies. Median biopsy 
age was 8 years (range 1 –16.5 years). Sural nerve biopsies confirmed moderately or 
markedly reduced myelinated fibre density in all patients (n=26). Transverse section analysis 
showed active demyelination (n=17), axonal degeneration (n=1), onion bulb formations 
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in 16 showed segmental demyelination (n=16) (Figure 3.4a) and axonal ovoids (n=2). Electron 
microscopy performed in seven showed onion bulb formations (n=5) and no cluster 
formations. In summary almost half the patients with CMT1 presented by 2 years of age, 
conduction studies were typically delayed in the region of 16 m/s and sural nerve biopsies 
showed consistent demyelinating features. 
Figure 3.4a: Teased fibre analysis (x 200 magnification) of patient with CMT1A demonstrating 
segmental demyelination over numerous fibres. 
Sixteen patients (5 female: 11 male) were labelled remyelinating / demyelinating 
with sporadic or recessive disease. Negative molecular genetic screens were found for 
duplication of chromosome 17p (n=2), MPZ mutation (n=4), PMP22 mutation (n=4), connexin 
32 (n=3), GDAP1 (n=1), MTMR2 (n=1) and mitofusin (n=1). One male patient had a 
polymorphism in the GDAP1 region c.421T>G but since this was not associated with a change 
in amino acids was not considered pathogenic. Four patients had a positive family history. 
Three children presented before one year of age and a further eight by 5 years of age. Clinical 
features included pes cavus (n=13), ataxia (n=3), enlarged nerves (n=7), sensory involvement 
(n=9), cranial nerve involvement (n=1) and nystagmus (n=3). One patient had developmental 
delay. Six children had kyphoscoliosis. Sensory conduction velocities were abnormal in all 
fifteen children tested. Motor conduction velocities showed median ulnar (n=10) and median 
(n=15) velocities of 17 m/s (range 0 – 39 m/s), and common peroneal velocities (n=15) of 0 
m/s (range 0-39m/s) where testing failed to stimulate a potential in most of the nerves tested. 
EMG was performed in seven children, one was normal, one was described as myopathic and 
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(range 0-16 years). Sural nerve biopsies identified markedly or moderately reduced 
myelinated fibre density in 14 of the 16 patients. Light microscopy transverse sections 
detected active demyelination in twelve and secondary axonal degeneration in 2 patients. 
Onion bulb formations were seen in 14 and cluster formation in 2 patients. On teased fibre 
analysis (n=14), demyelination was seen in 12 and axonal changes in 2 patients. On electron 
microscopy (n=12) onion bulbs were seen in 10 patients and no cluster formations. In 
summary over half the patients in this group presented by 5 years of age, a third developed 
kyphoscoliosis and the majority had distal weakness, pes cavus and abnormal reflexes. 
Neurophysiology revealed slower conduction velocities than the CMT 1 group. Sural nerve 
biopsy findings were similar with active demyelination, reduced myelinated fibre density and 
onion bulb formations. These patients are likely to have forms of CMT4 with mutations yet to 
be identified.  
Fourteen patients (8 female: 6 male) had CMT3 (Dejerine Sottas Syndrome). 
Molecular genetic testing confirmed myelin protein zero point mutations in six and PMP22 
point mutation in three. Of the positive group the exact mutations from the myelin protein zero 
mutation patients included one patient with a six base pair insertion (AGTTCT) in exon 3, 
resulting in a 2 amino acid insertion (Phe-Tyr) after aspartate 118, another with a C to G 
substitution at nucleotide 188, leading to a ser 63 cys substitution in the extracellular domain 
(exon 2), the third patient had a homozygous 3 base pair deletion in exon 3, resulting in the 
deletion of the Phe-64 (extracellular), two patients with a C to T substitution leading to arg 69 
cys on exon 2 (extracellular) and one patient with 563_564insC Ala188. From the PMP 22 
point mutation group one patient had a cytosine to adenine base change on exon 1 causing a 
histidine / glycine substitution at position 12 and two patients had cytosine changed to 
thymidine on exon 3, causing a serine/leucine substitution at position 12. Of the five patients 
without molecular genetic confirmation two predated screening, one was mitofusin 2 mutation 
negative, one duplication of chromosome 17 negative and the other negative for mutations in 
connexin 32, myelin protein zero and PMP 22. Of the remaining group clinical features, nerve 
conduction studies and biopsy findings were consistent with the diagnosis of CMT3. Three 
children had clinical symptoms by 1 year of age and a further 7 by 2 years age and the 
remainder sought medical advice by five years of age. Clinical features included pes cavus 
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and globally n=8), enlarged nerves (n=9), sensory involvement (n=10), cranial nerve 
involvement (n=5) and nystagmus (n=8). No patients had cognitive developmental delay. Four 
patients had kyphoscoliosis. Median CSF protein was 0.85g/l (range 0.20 – 1.8g/l). Sensory 
nerve conduction studies were abnormal in all 14 children. Motor conduction studies (n=13) 
failed to stimulate responses in 6 patients and in the remaining patients, four recorded median 
nerve conduction velocities below 10 metres / second, two below 24 metres / second and one 
32 metres / second. These patients with faster conduction from the median nerve recorded 
values of below 10 meters / second over their common peroneal nerves. EMG was performed 
on two patients and detected denervation in both. Sural nerve biopsy was performed between 
7 months and 14 years of age (median 4 years). Markedly or moderately reduced myelinated 
fibre density was evident in all patients. Light microscopy transverse sections detected 
myelinated fibre thinning consistent with demyelination in 14 patients, onion bulb formations in 
14 (Figure 3.4b), and secondary axonal degeneration in one. One patient with a confirmed 
mutation of the myelin protein zero gene had a severe hypomyelinating appearance on the 
sural nerve biopsy but artefact precluded further interpretation. On teased fibre analysis 
(n=11), demyelination was seen in 9 (Figure 3.4c), and there were no patients with axonal 
degenerative changes. On electron microscopy (n=11) 11 patients had onion bulb formations. 
In summary this group presented earlier than the other patients with a more severe 
neuropathy demonstrated both clinically, on NCS and on their sural nerve biopsies. The 
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Figure 3.4b: Light microscopy toluidine blue immunohistochemical transverse section study of 
a patient with CMT3 due to a PMP22 gene mutation (x 400 magnification). Image 
demonstrates multiple onion bulb formations affecting every fibre. 
Figure 3.4c: Teased fibre analysis of a patient with myelin protein zero mutation demonstrating 










Peripheral Neuropathies of Childhood Jo M Wilmshurst 
Thesis presented for the Degree of Doctor of Medicine 
 82 
 
One male patient had HMSN type VII (HMSN with retinitis pigmentosa).  He 
presented before two years of age and had a positive family history with his mother affected. 
He did not have a duplication on chromosome 17p. He had distal weakness, sensory 
impairment, abnormal reflexes, developmental delay and retinitis pigmentosa. His 
neurophysiology revealed a mild motor axonal neuropathy. Sural nerve biopsy performed at 
the age of 12 years revealed a moderately reduced myelinated fibre density with thinning of 
myelin and a few onion bulb formations. Teased fibre analysis revealed segmental 
demyelination. Electron microscopy confirmed demyelinating fibres with a few onion bulb 
formations. Overall his biopsy was felt to be more consistent with a hypertrophic neuropathy 
from a primary demyelinating process. This is a rare form of HMSN and reported cases are 
usually in adults.(168) 
Three children (3 male) had hereditary neuropathy with liability to pressure 
palsies (HNPP). Molecular genetics confirmed a deletion in the chromosome 17p region in all. 
All biopsies were performed at the age of 16 years, one child presented in his first decade and 
the other two in their second decade. None of the children had a positive family history. 
Patients presented with focal weakness, with variable improvement, in addition they had distal 
weakness (n=2), sensory changes (n=2), pes cavus (n=1) and abnormal reflexes (n=2). A 
typical presentation from one of the patients consisted of an 8 month history of weakness of 
his left upper limb not related to trauma and with a normal MRI of the region. Limited recovery 
occurred. Nerve conduction studies revealed abnormal sensory conduction in a patchy 
distribution (related to the focal areas of weakness) and mildly delayed motor conduction 
velocities also with a patchy distribution consistent with a mononeuritis multiplex picture. EMG 
was normal in one and showed denervation in the other two. Sural nerve biopsy detected 
markedly or moderately reduced myelinated fibre density on light microscopy transverse 
section; tomaculous fibres were evident in all, as well as additional thinly myelinated fibres. 
Axonal degeneration was also evident in one patient. Teased fibre analysis (n=3) detected 
axonal changes in one patient and demyelinating features in the other two. EM was not 
performed. In summary these children presented in their second decade and were more likely 
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more subtle than in the other groups. NCS were usually within the axonal range. However 
nerve biopsy detected features secondary to the tomaculous nerve pathology.  
Six patients (4 female: 2 male) had CMT4. Molecular genetics confirmed a myelin 
protein zero mutation in one patient and a frabin mutation in another (CMT4H).(247) The 
remainder were negative for a chromosome 17p duplication (n=3), or for point mutations of the 
MPZ (n=2), mitofusin2 (n=2), and MTMR2 (n=1) genes. The phenotype of five patients was 
suggestive of CMT 4B, including the patient with a myelin protein zero mutation.This patient 
with a MPZ mutation (exon 2, Thr65Ala, ACC>GCC) had a positive family history. Two 
children presented by one year of age, 3 by two years and one by five years of age. Clinical 
features consisted of distal contractures (n=3), nystagmus (n=1), ataxia (n=3), hypotonia 
(n=2), kyphoscoliosis (n=3), nerve enlargement (n=1), weakness (distal n=4, generalised 
n=2), areflexia (n=6), sensory abnormalities (n=4), pes cavus (n=2) and cranial nerve 
involvement (n=1). Nerve conduction studies were abnormal in all five children tested and 
motor conduction velocities were markedly slowed either less than 10 meters / second or 
between 10-24 meters / second. Sural nerve biopsy was performed between 2 and 6 years 
(median 4½ years). Examination of transverse sections under light microscopy detected 
marked to moderate reduction in myelinated fibre density and myelin out-folding in all, and thin 
myelin consistent with de- or hypo-myelination (n=3) (Figures 3.4d and e). One patient had 
some thickened myelinated fibres. Four patients had onion bulb formations. Teased fibre 
analysis (n=6) detected demyelinating features (n=5) and axonal degenerative features (n=2). 
In summary six patients presented typically by two years of age with clinical features of a 
severe neuropathy; nerve biopsy was beneficial towards confirming the diagnosis as the 
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Figure 3.4d: Transverse section light microscopy toluidine blue immunohistochemical stain of 
a patient with CMT4B, demonstrating reduced myelinated fibre density, onion bulb formations 
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Figure 3.4e: Transverse section light microscopy toluidine blue immunohistochemical stain of 
a patient with CMT4H due to frabin mutation, demonstrating reduced myelinated fibre density, 
onion bulb formations and myelin-outfolding (Magnification x 100). 
 
Six patients (5 female: 1male) could not be categorised into any of the recognised 
hereditary demyelinating neuropathy groups, these were labelled atypical demyelinating.  
These were patients, who despite strong evidence of demyelination on their nerve biopsies, 
had clinical or neurophysiological features which did not allow categorisation into any of the 
above groupings. Molecular genetic screening was negative for mutations in GDAP1 (n=1), 
MPZ (n=2), PMP22 (n=1). All presented by five years of age and three by one year. Two of 
the patients were sisters, and one of these sisters went on to have an affected child, 
suggesting autosomal dominant inheritance. Molecular genetic screening in this family proved 
negative for chromosome 17p duplication, MPZ and PMP22 mutations. Exclusion criteria were 
related to a combination of atypical clinical features (n=4), neurophysiological results not in the 
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 AXONAL NEUROPATHIES 
n=81 (47 female:  34 male) (Figure 3.5) 
Figure 3.5: Axonal neuropathies 













































































































Genetic confirmation Remaining group
 
Eight patients (five female: three male) complied with a diagnosis of CMT2 (sub-type 
undetermined). Molecular genetic studies were performed on 6 with absence of 
spinocerebellar ataxia (SCA) mutations in one, absence of SCA and Friedreich’s ataxia (FA) 
mutations in two, absence of 17p duplication in two and one with an inconclusive result as 
only one allele was seen. This patient and one other were also connexin 32 negative. One 
patient was also MPZ mutation negative. Five out of the eight children had a positive family 
history. One child presented less than two years of age, and four were symptomatic by 5 
years of age. Clinical features included pes cavus (n=5), absent or reduced deep tendon 
reflexes (n=8), ataxia (n=2), distal weakness (n=5), generalised weakness and hypotonia 
(n=1), sensory involvement (n=3), cranial nerve involvement (n=1) and nystagmus (n=1). One 
patient had mental retardation. Two patients had kyphoscoliosis. Sensory conduction 
velocities were abnormal in six out of seven children tested. Motor conduction velocities were 
normal in two patients and marginally slowed in the remainder. EMG, performed in three 
children, was normal in one and revealed denervation in two. Biopsy was performed between 
2 years and 9 months and 16 years (median 13 years). Sural nerve biopsies revealed 
markedly or moderately reduced myelinated fibre density in 7 of the 8 patients. Light 
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cluster formations in four. On teased fibre analysis (n=7), demyelination was seen in 3 and 
axonal changes in 4 patients. On electron microscopy (n=1) no cluster formations or active 
axonal degeneration were detected. In summary children with CMT2 presented nearer to 5 
years or older, clinical signs were less severe and nerve conduction studies were either 
normal or consistent with an axonal picture. Nerve biopsy confirmed axonal degeneration with 
most information gained from the light microscopy and teased fibre analysis.  
Three patients were categorised as CMT2A (2 female: 1 male) (defined as an 
autosomal dominant axonal disorder usually associated with mitofusin2 mutations). One 
female patient had a phenotype compatible with CMT2A but was found to have a homozygous 
(i.e recessive) mitofusin2 mutation at c.647T>C. She presented at less than 5 years with 
localised weakness with a mildly progressive phenotype. There were no other clinically 
affected family members. Her peripheral nerve biopsy detected axonal degeneration with a 
moderate reduction in myelinated fibre density and thin myelinated fibres on teased fibre 
analysis. Nerve conduction studies recorded abnormal sensory studies, normal motor 
conduction and denervation on EMG. She could also be classified as a mild form of severe 
early onset axonal neuropathy (SEOAN) or early onset HMSN of neuronal type 
(EOHMSN).(104) Another female patient was confirmed to have a mitofusin2 mutation 
c.640G>A(Asp214Asn). She subsequently had an affected son suggesting dominant 
inheritance. She had presented by 2 years of age ataxic with distal weakness and 
contractures. Both the mother and her son had intermediate nerve conduction velocities, the 
fastest being 33 m/sec. She was not clinically severe enough to be labelled EOHMSN. She 
had mixed pathology and was labelled CMT2A. One male patient presented after five years of 
age with features consistent with CMT2C (as defined by an axonal neuropathy with vocal 
cord, diaphragmatic and respiratory involvement, as well as decreased longevity). However 
his genetic screening confirmed a mitofusin2 mutation, c.892G>A(Gly298Arg), categorising 
him as CMT2A. He had no affected relatives. He had distal weakness with contracture 
formation, kyphoscoliosis, and reduced deep tendon reflexes. In his second decade he 
developed tongue fasciculations and died of respiratory failure aged 16 years. Sensory 
conduction studies were abnormal, but the motor conduction velocities were within normal 
limits. Sural nerve biopsy, at the age of 16 years, showed, on light microscopy, active axonal 
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formations. Teased fibre analysis showed axonal and demyelinating changes. Electron 
microscopy confirmed the above findings. 
One male patient was categorised as CMT2E based on his clinical, 
neurophysiological and histopathogy findings. CMT2E was as defined by typically early 
childhood onset with gait abnormalities, occasional hyperkeratosis, and prominent sensory 
involvement with intermediate to slow NCS and on histopathology giant fibres similar to those 
seen in giant axonal neuropathy. This boy had symptoms from 3 years resulting in peripheral 
nerve biopsy aged 11 years. There was no family history. He was otherwise well with no 
evidence of toxin ingestion or metabolic derangements. His onset at 3 years was with foot 
deformities which progressed until he lost ambulation. He had several dramatic deteriorations 
from which he did not recover resulting in increased disability. His cranial nerves were normal. 
His feet were cold and ulcerated. His upper limbs had mild sensory reduction distally. He had 
no organomegaly. His cognition was normal. His peripheral nerve biopsy had a moderate 
reduction in his myelinated fibre density involving all fibres; he had giant axons - some with 
thin sheaths and others with no myelin. There were several onion bulb formations. He did not 
have teased fibre analysis. He was initially considered to have either giant axonal neuropathy 
or toxin exposure with glue sniffing most likely, but his clinical presentation did not correlate 
with these diagnoses. Although it was not possible to perform NEFL screening on this patient 
his phenotype correlated with CMT2E.  
Eighteen patients (11 female: 7 male) had early onset HMSN of neuronal type 
(EOHMSN) as defined by a severe early-onset axonal neuropathy (SEOAN).(2,104,105) 
Molecular genetic screens confirmed mitofusin2 mutations in five; namely c.310C>T n=2; 
c.640G>A + c.1168T>C n=1; c.292A>G (Lys98Glu i.e.K98E) n=1, c1085C>T + 817-2A>G 
n=1. Of the remainder, 4 underwent additional screens and were negative for duplications on 
chromosome 17p (n=2), MPZ mutation n=1, mitofusin2 n=3, Lamin A/C (n=2) and FA/SCA 
(n=1). Family history following an autosomal recessive pattern of inheritance was positive in 
three. All children presented by 5 years of age, one before one year of age and a further nine 
by two years of age. Clinical features included pes cavus (n=5), distal contractures (n=14), 
hypotonia (n=9), kyphoscoliosis (n=2), reduced or absent deep tendon reflexes (n=17), 
weakness (distal n=16; generalised n=2), enlarged nerves (n=1), sensory involvement (n=10), 
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Neurophysiological examination revealed that sensory conduction studies were abnormal in 
13 out of 14 patients tested. Motor conduction studies detected median motor conduction 
velocities between 32-49 m/s (median 45 m/s) (the median nerves of two patients could not be 
stimulated), ulnar motor conduction velocities between 32-49 m/s (median 45 m/s) (the ulnar 
nerves of three patients could not be stimulated) and common peroneal motor velocities 
(n=11) which were normal in one, marginally slow in another and could not be stimulated in 9 
patients. EMG (n=7) revealed denervation. Sural nerve biopsy was performed between 2 and 
17 years of age (median 8 years). Light microscopic examination of transverse sections 
revealed axonal degeneration (n=4), thinning of the myelin (n=4), markedly or moderately 
reduced myelin fibre density (n=18), onion bulb formations (n=5) and cluster formations (n=5). 
Teased fibre analysis (n=15) revealed demyelinating features (n=6) and axonal ovoid 
formations (n=8). Electron microscopy (n=9) detected cluster formations (n=3) and onion bulb 
formations (n=1) The patients with mitofusin2 mutations were found to have unusual cluster 
formations in some fibres with surrounding basement membrane appearances reminiscent of 
onion bulb formations i.e. a combination of features typically categorised axonal and 
demyelinating (Figures 3.5a-c). Many of the mitochondria were smaller than normal and had a 
rounded appearance, they tended to aggregate at the peripheries of the axons, the inner and 
outer mitochondrial membranes appeared irregular and the cristae were often disrupted  
Excessive numbers of Schwann cell nuclei were evident in some patients. A number of these 
patients and their findings have already been reported.(105) In summary all patients presented 
by five years of age, symptomatology was severe and progressive with debilitating distal 
contractures and weakness. Nerve conduction studies tended to present the severe end of the 
disease spectrum with frequent failure to stimulate the common peroneal nerves and 
conduction velocities slower than commonly seen with axonal neuropathies, reflecting the loss 
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Figure 3.5a: Transverse section: light microscopy toluidine blue stain of a patient with 
EOHMSN due to mitofusin2 mutation (Magnification x 200). The section demonstrates 
reduced myelinated fibre density, especially of large diameter fibres, cluster formation (C) and 
onion bulb (OB) formation. Other sections demonstrated a degree of sub-perineurial oedema. 
The teased fibre preparations showed several fibres with segmental demyelination. This 
patient was considered to have mixed pathology with axonal degenerative and demyelinating 
changes, with the latter predominating. She was initially labelled CIDP but the diagnosis was 
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Figure 3.5b: Electron microscopy section of a patient with MFN2 mutation demonstrating 
reduced myelinated fibre density and an onion bulb formation (courtesy of Professor Vallat) 
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Figure 3.5c.ii: 
Figures 3.5c i and ii. Electron micrograph from one of the patients with confirmed MFN2 
mutation demonstrating abnormal aggregates of mitochondria. Note the abnormal inner and 
outer mitochondrial membranes, disrupted cristae in some and the accumulation of the 
abnormal mitochondria at the peripheries of the axon (courtesy of Professor Vallat) 
 
Seven infants (5 male: 2 female) had severe infantile axonal neuropathy with 
respiratory failure (SIANR) or spinal muscular atrophy with respiratory distress 
(SMARD1).(2,106,108) They all had intrauterine growth retardation and presented at or shortly 
after birth with contractures, hypotonia, distal weakness and areflexia. Diaphragmatic 
weakness resulted in respiratory failure and eventual death in all. Two had a positive family 
history with previous siblings who had died.  Nerve conduction velocities were either 
profoundly slowed or unrecordable. Nerve biopsy showed a marked reduction in MF density, 
apparent failure of regeneration and very little active degeneration, suggesting that the infants 
did not have the ability to recover from the resulting fibre loss. Five of the infants were 
screened and were confirmed to have mutations of the IGHMBP2 gene which as 
demonstrated can be associated with a generalised polyneuropathy (SIANR).(106)  
Two sisters had severe relapsing axonal neuropathy. One patient presented at 8 
months with acute onset ataxia and weakness.(2) After an almost complete recovery she 
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Nerve conduction velocities were in the so-called “demyelinating range” (median nerve motor 
conduction velocity 15 meters/second; common peroneal nerve motor conduction velocity 8 
meters/second) and there was denervation on EMG. Nerve biopsy confirmed axonal 
degeneration, occasional thin myelin sheaths, reduction in myelinated fibre density and an 
increased number of macrophages.  
One patient presented in infancy with hypotonia, macrocephaly, poor head control and 
reduced spontaneous movements especially distally. He improved with time and had normal 
cognition. There was a strong family history on the maternal side. His mother had pes cavus 
and his maternal grandfather was clinically affected with a peripheral neuropathy as were two 
of his maternal uncles. Molecular genetic screens were negative for connexin 32, MPZ 
mutations and for mutations in the CMTX2 region. Nerve conduction studies were in the 
demyelinating range but compatible with axonal loss and his EMG confirmed active 
reinnervation. His CSF protein was mildly raised. His sural nerve biopsy confirmed an 
adequate myelinated fibre density and myelin thickness with no cluster or onion bulb 
formations – there was one fibre undergoing active axonal degeneration. Combining his 
features he was suspected to have CMTX2 or X4 but, in view of the lack of molecular genetic 
confirmation, he was categorised “CMTX type unknown”. 
Three patients (2 female: 1 male) had HMSN with optic atrophy and deafness 
(Rosenberg-Chutorian syndrome or ARTS syndrome newly classified as CMTX5). The boy 
presented by 2 years of age and the girls by five years of age. The boy had a positive family 
history with two affected brothers. Molecular genetic screening confirmed PRPS1 mutation in 
one of the latter.(325) Screening for Friedreich’s ataxia disease was negative in another. Clinical 
features included in addition to the deafness and optic atrophy, nystagmus (n=1), 
kyphoscoliosis (n=1), generalised weakness (n=1), pes cavus (n=1), sensory alterations (n=1), 
hyporeflexia or areflexia (n=3) and developmental delay (n=1). Neurophysiological studies 
revealed abnormal sensory conduction in 2 out of 3 patients, whilst motor conduction was 
normal (n=1) or moderately delayed (range 25-40 m/s). EMG (n=1) was neuropathic. Sural 
nerve biopsy was performed between 2 and 6 years of age (median 3 years). Features 
included thinning of the myelin (n=1), markedly or moderately reduced MF density (n=3), 
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one. The features were felt to be consistent with an axonal neuropathy. This condition is now 
categorised as CMTX5(148,149). 
Thirty-one children (18 female: 13 male) who did not conform with the recognised 
axonal neuropathy groups were labelled “atypical” chronic axonal and sporadic sensory 
neuropathy.(326) A number of them may well comply with the categories for autosomal 
recessive CMT2, but could not be defined further. Three children presented by 2 years of age 
and eight children presented before 5 years of age. Three had a family history of peripheral 
neuropathy. One patient presented with an aggressive progressive axonopathy from 2½ years 
of age with associated respiratory failure and eventual death despite medical and supportive 
interventions. Genetic and metabolic screens were negative; her phenotype was similar to a 
juvenile form of SMARD1.(327) The older sister of this patient also developed a neurological 
disorder. However her onset of symptoms was later, from 7 years of age, and she had a 
milder course, with no respiratory compromise and she was deaf (she has not undergone a 
nerve biopsy to date). Two patients presented before one year of age with static sensory 
neuropathies with large myelinated fibre loss and associated scoliosis.(326) Molecular genetics 
studies in the first patient were negative for SCA types 1, 2, 3, 6 and 7. Two patients were 
negative for FA and two for SCA 1,2,3,6 and 7. Molecular genetics studies were negative in 
eight other patients for chromosome 17p duplication (n=4), GDAP1(n=1), MPZ (n=2), 
connexin32 (n=3), lamin A/C (n=1) and mitofusin2 (n=1) mutations. All patients, except those 
with the sensory neuropathy, had neurophysiological and histopathological changes 
compatible with axonal disease but lacked specific features. Without extensive molecular 
genetic testing these patients could not be categorised beyond having an axonal neuropathy, 
of possible autosomal recessive origin.  
Of nine patients (3 female: 6 male) with a clinical and neurophysiological diagnosis of 
distal hereditary motor neuropathy only one male patient from the group had an abnormal 
sural nerve biopsy. This patient presented after five years of age and did not have a family 
history of neuropathy. He had distal weakness but retained deep tendon reflexes and no 
contractures. Neurophysiological studies confirmed normal sensory conduction and normal 
motor conduction but detected a prolonged distal latency from the right common peroneal 
study. His EMG was neuropathic. Sural nerve biopsy confirmed axonal degeneration and a 
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spinal CMT had normal sural nerve biopsies but an axonal peripheral neuropathy was 
confirmed in one. A condition described as a pure motor neuropathy, would not be expected to 
have sensory involvement however as illustrated in Table 1.2 there are several sub-forms of 
dHMN with sensory involvement described. This is presumed secondary and follows a similar 
pathogenesis to that reported in anterior horn cell conditions such as SMA and ALS.(183,328) 
This condition remains in the section for motor and sensory neuropathies as the clinician 
tends to work backward to the diagnosis i.e. starting with a clinical phenotype and a series of 
results – from these a diagnostic label is desired. Awareness that sensory involvement can 










Peripheral Neuropathies of Childhood Jo M Wilmshurst 
Thesis presented for the Degree of Doctor of Medicine 
 96 
HEREDITARY SENSORY AUTONOMIC NEUROPATHY (n=6) (Figure 3.6) 





































One male patient had HSAN type 1; he had a positive family history following an 
autosomal dominant pattern. He became symptomatic after five years of age with areflexia, 
altered sensibility, especially to pain, and pes cavus. Neurophysiological studies detected 
abnormal sensory conduction and normal motor studies. On sural nerve biopsy, he had 
markedly reduced myelinated fibre density and axonal degenerative changes. 
The remaining patients were described and published in detail in the infantile series in 
chapter 4.(2) Two female patients had HSAN type 4, they had a marked decrease of 
unmyelinated fibres and small myelinated fibres on nerve biopsy. One patient had HSAN type 
5, she had a selective loss of small myelinated fibres.(329) Two patients could not be 
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MIXED PICTURE 
(Axonal and demyelinating features) n= 7 (Figure 3.7) 













CMT X HMSN V
Genetic confirmation Remaining cases
 
Five patients (5 male) had CMT X. Molecular genetics testing confirmed connexin 32 
in one patient (CMTX1), was negative in another and GDAP1 testing was negative in another. 
There was a positive family history in four. All patients presented after five years of age. 
Clinical features consisted of distal contractures (n=4), kyphoscoliosis (n=1), nystagmus (n=1), 
weakness (distal n=4, generalised n=1), nerve hypertrophy (n=1), abnormal reflexes (n=3), 
sensory changes (n=3), and pes cavus (n=5). Neurophysiological studies confirmed abnormal 
sensory conduction in four out of the five patients. Motor conduction velocities were slowed 
with median values of median 32 m/s (range 17-45m/s), ulnar 32 m/s (range 32-45 m/s) and 
common peroneal 45 m/s. EMG was not performed. Sural nerve biopsy performed between 
13 and 17 years of age (median 13 years) detected markedly or moderately reduced 
myelinated fibre density in all patients. On light microscopic study of transverse sections, 
demyelination (n=3), axonal degeneration (n=1), onion bulb formations (n=4) and cluster 
formations (n=3) were seen. Teased fibre analysis (n=3) revealed demyelination in three 
patients. Electron microscopy (n=4) detected onion bulb formations (n=2) and cluster 
formation (n=1). The biopsy findings were consistent with a mixed picture of axonal and 
demyelinating degeneration. In summary this group of boys presented in later childhood with a 
mixed axonal and demyelinating peripheral neuropathy.       
Two patients (1 female: 1 male) had HMSN type V (HMSN with pyramidal signs or 
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was no family history of neuropathies. Clinical findings including distal contractures (n=2), 
ataxia (n=1), distal weakness (n=2), sensory changes (n=1), increased deep tendon reflexes 
(n=1), and pes cavus (n=2). Both had long tract signs with exclusion of central pathology in 
addition to their clinical features of peripheral neuropathy. Neurophysiology revealed abnormal 
sensory conduction in one out of the two patients. Motor conduction was consistent with an 
axonal pattern in both. EMG was not performed. Sural nerve biopsies were performed at 6½ 
and 8½ years. Light microscopic examination of the transverse sections revealed moderately 
reduced myelinated fibre density in one and normal myelinated fibre density in the other 
patient with demyelination (n=1). Teased fibre analysis (n=2) detected axonal degeneration 
(n=1) and demyelination (n=1). EM was not performed. Based on the combined 
neurophysiological and histopathological results the features were felt to be consistent with a 
mild mixed axonal and demyelinating peripheral neuropathy. In summary these two patients 
presented at around five years of age with a progressive peripheral neuropathy of mixed type 










Peripheral Neuropathies of Childhood Jo M Wilmshurst 
Thesis presented for the Degree of Doctor of Medicine 
 99 
Summary of the Genetic data 
Of the above patients (n=161) with hereditary peripheral neuropathies where the 
neuropathy was the primary disease, more than half had undergone genetic analyses (n=87). 
Autosomal dominant patterns of inheritance were evident in 53 patients of the total group and 
recessive or sporadic inheritance in the remaining 108. In most cases molecular genetic 
screens were directed by the clinical phenotype, neurophysiological results and 
histopathological findings. Forty-nine patients attained molecular genetic confirmation, 28 of 
whom had autosomal dominant patterns of inheritance and 21 followed autosomal recessive 
inheritance. The positive results were disproportionately skewed to the patients with 
demyelinating disease. 


















Demyelinating group: 34/50 patients who underwent genetic screens attained a 
definitive genetic diagnosis. These included duplication chromosome 17p11.2 (n=20 CMT1A 
patients), deletion in the chromosome 17p11.2 region (n=3 HNPP patients), PMP22 point 
mutations (n=3 CMT3 patients), frabin mutation (n=1 CMT4H patient) and MPZ mutation (n=7, 
CMT3 n=6 and CMT4B n=1). Apart from MPZ mutations, which were expressed in patients 
with both CMT3 and CMT4, the individual mutations were associated with specific diseases. 
There was an extremely high confirmation rate for particular diseases, especially CMT1 
(genetic confirmation in 20/21 screened) and CMT3 (genetic confirmation in 9/12 screened). 
Negative findings were most marked in the atypical demyelinating (n=3/6) and demyelinating / 
remyelinating sporadic groups (n=6/16) suggesting either incomplete genetic analysis or that 
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attain a genetic confirmation with the rarer mutations associated such as frabin mutation. 
Three out of the five screened did not gain molecular genetic diagnoses.      
Axonal group: 14/33 patients who underwent screening attained a genetic 
confirmation. This consisted of mitofusin2 mutations (n=8; CMT2A n=3 and EOHMSN n=5), 
PRPS1 mutation (n=1, CMTX5) and SMARD1 mutations (n=5 all SIANR). Of this axonal 
degenerative group a further 4 patients were screened and found to be negative for mitofusin2 
mutations. Although the patients with axonal disease are most behind in gaining genetic 
confirmations the identification of mitofusin2 mutations has started to reduce this disparity. 
Further the phenotypic variation in the range of diseases is evident here with the MFN2 
mutation being associated with both CMT2A and EOHMSN (SEOAN). Limited screening was 
evident in many of these patients suggesting suboptimal genetic analyses had occurred. Of 
the patients with atypical axonal disease who could not be categorised, only 7/31 had 
undergone various genetic analyses (with negative results). Similarly 6/12 of the patients with 
CMT2 were screened without gaining a genetic diagnosis. By far the highest efficacy in 
detection of a genetic screen was evident from the mitofusin2 screens with seven negative 
results (EOHMSN n=4, atypical axonal n=1, CMT4B n=1, CMT3 n=1, demyelinating / 
remyelinating sporadic n=1) compared with the 8 diagnostic confirmatory results. Of note 
three of these negative screens were in patients with demyelinating disease. As MFN2 
mutations are not reported in this group the negative results were not surprising. The patients 
in whom it would be of most use to screen for MFN2 mutations would be those with CMT2 and 
EOHMSN. Of the total group of EOHMSN patients (n=18), five attained genetic confirmation 
(mitofusin2 mutations), a further three underwent various genetic screens which failed to lead 
to a genetic diagnosis. Of this last three one was negative for mitofusin2 mutations i.e. of the 
six patients with EOHMSN who were screened for mitofusin2 mutations five were confirmed to 
have MFN2 mutations. 
Mixed group: 1/4 patient attained genetic confirmation; the patient with connexion 32 
mutation who had CMTX1. 
Overall genetic confirmation was possible in 49 out of the 87 patients who underwent 
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Key: Different shading identifies mutations occurring in more than one form of CMT e.g. 
MFN2 mutations occurring in patients with CMT2A (n=3) and EOHMSN (n=5); MPZ occurring 
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PERIPHERAL NEUROPATHIES ASSOCIATED WITH INHERITED DISORDERS 
(n=87) 
NEURODEGENERATIVE AND METABOLIC DISORDERS (n=78) (figure 3.10) 
Figure 3.10: Neurodegenerative and metabolic 











































































































































































Genetic confirmation Remaining cases
 
Twenty-five patients (12 female: 13 male) had Friedreich’s ataxia (FA) (Figure 2.9, 
page 59). Molecular genetics performed many years after the biopsies were performed in 
seventeen of this group confirmed expansions in 13 and identified point mutations in 2. The 
remainder were diagnosed based on clinical, neurophysiological and nerve biopsy findings. 
One pair of siblings was in the group and seven patients had a positive family history of FA. 
Six patients presented by two years of age and a further 9 by 5 years of age. Clinical features 
included sensory alteration (n=20), ataxia (n=21), abnormal deep tendon reflexes (n=25), 
kyphoscoliosis (n=11), weakness (distal n=12; generalised n=1), optic atrophy (n=14), pes 
cavus (n=17), nystagmus (n=6) and learning difficulties (n=3). Neurophysiology was abnormal 
in all 23 patients tested. Motor studies detected mildly delayed conduction velocities or normal 
(n=5) studies. Sural nerve biopsies were performed between 4 and 16 years of age (median 
10.5 years of age). Light microscopic examination of transverse sections revealed selective 
reduction in the large myelinated fibres, thinning of the myelin (n=3), axonal degeneration 
(n=7), onion bulb formation (n=2) and cluster formations (n=6). Teased fibre analysis (n=24) 
identified thinning of the myelin (n=8) and axonal ovoids (n=8). Electron microscopy (n=8) 
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summary 25 patients presented with FA. Nerve biopsy prior to molecular genetic advances 
was the main diagnostic aid used. Since identification of the molecular genetic mutation, 
biopsy remains useful when the molecular genetics fail to identify triplicate repeat mutations or 
a point mutation.  
One patient had molecular genetic confirmation of SCA 7.(233) She presented by 2 
years of age with ataxia, hypotonia, generalised weakness, abnormal reflexes, abnormal eye 
movements with limited abduction, a pigmentary retinopathy and pale discs, and motor 
developmental delay. She had a progressive disorder. Her father subsequently became 
symptomatic with a milder form of the disease reflecting the anticipation which had occurred. 
Neurophysiological studies recorded abnormal sensory conduction studies, with normal to 
mild slowing in motor conduction in the upper limbs and more marked slowing in the lower 
limbs (in the region of 25-39 metres / second). Sural nerve biopsy was performed when she 
was 33 months old. This detected thinning of the myelin, axonal degeneration, marked 
reduction in myelinated fibre density and cluster formations. Teased fibre analysis identified 
thinning of the myelin and electron microscopy identified cluster formations.  
Five children (4 female: 1 male) had forms of spinocerebellar degeneration with 
associated peripheral neuropathy which could not be classified. Molecular genetics failed to 
detect expansions in the FA or SCA regions in one and SCA regions in the others. Three 
patients presented by 2 years of age and a further 2 by five years of age. No patients had a 
positive family history. Clinical features, neurophysiological studies and sural nerve biopsy 
findings were consistent with undefined spinocerebellar degenerative syndromes. 
Neurophysiological studies recorded abnormal sensory conductions in two of the five children. 
Motor studies recorded conduction velocities in the axonal range in all five. Their peripheral 
nerve biopsies detected on light microscopy, axonal degeneration (n=2), moderate or 
borderline myelinated fibre densities (n=5), cluster formations (n=2). Teased fibre analysis 
(n=4) detected segmental demyelination (n=1) and ovoid formations (n=1). Electron 
microscopy examination (n=4) revealed cluster formations (n=2) and onion bulb formations 
(n=2). Overall three of the children were considered to have axonal pathology and two mixed 
pathology. The nerve biopsy was useful to assist exclusion of FA and mitochondrial disease.   
Five children (4 female: 1 male) had metachromatic leukodystrophy (MLD) (Figure 
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was positive in one. Clinical features were consistent with the typical phenotypes of the 
disorder including long tract signs (n=3), nystagmus (n=1), ataxia (n=1), hypotonia (n=1), 
weakness (distal n=2; generalised n=3), abnormal reflexes (n=5), pes cavus (n=2), sensory 
changes (n=1), cranial nerve disorders (n=1), and cognitive decline (n=3). Neurophysiology 
revealed abnormal sensory conduction studies in all four patients tested. Median and ulnar 
motor conduction studies were delayed in the region between 17-32 m/s and common 
peroneal further slowed between 10-24m/s. Sural nerve biopsies were performed between 2 
and 11 years of age (median 3 years). Transverse sections studied by light microscopy 
demonstrated thinning of the myelin (n=4), axonal degeneration (n=3), abnormal staining on 
cresyl violet immunohistochemistry (n=5), markedly reduced myelinated fibre density (n=5), 
onion bulb formations (n=2) and cluster formations (n=1). Teased fibre analysis (n=5) detected 
demyelination (n=4). Electron microscopy (n=5) detected accumulations of myelin-like material 
as well as onion bulb formations, zebra and “tuff-stone” bodies and prismatic inclusions. In 
summary, five children had biopsy-proven metachromatic leukodystrophy. These biopsies 
were performed prior to aryl-sulphatase A levels and gene testing being available. There are 
still situations where biopsy can assist in the diagnosis of MLD – when gene testing is not 
available and where there are very low parental levels of aryl sulphatase, in cases with a pure 
neuropathic syndrome and in the AB variant where the sulphatase levels are normal.  
One boy had Cockayne syndrome (Figure 2.12, page 61). He presented with short 
stature, developmental delay, ataxia, deafness, sensory alteration, and abnormal deep tendon 
reflexes. Nerve conduction studies recorded slow motor and sensory conduction velocities in 
the demyelinating range. Biopsy performed when 14 years of age confirmed features of 
demyelination, marked reduction in myelinated fibre density with onion bulb formations and 
occasional cluster formations. Teased fibre analysis detected segmental demyelination.  
Three female children presented with unclassifiable leukodystrophies. Two 
presented in infancy with developmental delay and are described in detail in the infantile 
series publication (chapter 4).(2) The third girl presented after 2 years of age with 
developmental delay, generalised weakness, abnormal reflexes and cranial nerve 
involvement. She had a positive family history. Sural nerve biopsy at 43/4 years revealed 
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Twenty-three patients (8 female: 15 male) had undiagnosed neurodegenerative 
conditions associated with demyelinating (n=5), axonal (n=16) and mixed (n=2) peripheral 
neuropathies. Nine presented in infancy (chapter 4).(2) Two had demyelination and seven had 
axonal degeneration on sural nerve biopsy. Thirteen patients presented between 1 and 2 
years of age. In summary this study reflected large numbers of children with 
neurodegenerative disorders who, despite positive findings, did not have a definitive 
diagnosis. A proportion of these may have been diagnosed if put through all the biochemical 
screens now available. 
One patient had a clinical phenotype for juvenile motor neurone disease. She 
presented with short stature, microcephaly, expressive language delay, bulbar dysfunction 
and symmetrical distal weakness. Her feet had evidence of old injuries and she had globally 
reduced muscle bulk. She fell often, had difficulty walking with rapid deterioration and eventual 
loss of ambulation. Her intellect was retained. Screens for spinal muscular atrophy, white cell 
lysosomal enzymes and blood lactate were all within normal limits. Her neurophysiological 
studies confirmed a median nerve compound motor action potential (CMAP) amplitude of 2.8 
micoVolts (reduced), conduction velocity 57 metres /seconds (normal), ulnar nerve CMAP of 
2.7 microVolts (reduced), conduction velocity 59 metres / second, common peroneal nerve 
CMAP of 6.8microVolts (normal), conduction velocity 28 metres / second (slowed) and 
posterior tibial nerve CMAP of 3.4 microVolts (reduced), conduction velocity 38 metres / 
second (delayed). Her sensory studies were within normal limits. Her EMG detected large 
polyphasic units. Her sural nerve biopsy performed aged 7 years detected very thinly 
myelinated fibres, moderate reduction in the myelinated fibre density and occasional very 
thinly myelinated fibres surrounded by onion bulb formations. The teased fibre sections 
revealed no ovoid formations but there was one area of segmental demyelination. The 
appearance was consistent with a demyelinating disorder. 
Two children from the series with Leigh syndrome underwent peripheral nerve 
biopsy. One biopsy was normal. One female who presented in infancy had an abnormal nerve 
biopsy which was more suggestive of an axonopathy with reduced MF density than the 
recognised demyelination which occurs with Leigh disease.(2)  
Three patients had giant axonal neuropathy (1 female: 2 male) (Figure 2.10, page 
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had a similar picture to this boy but presented slightly older. She had motor delay, “woolly” 
hair, nystagmus, generalised weakness, areflexia, ataxia and absent vibration and 
proprioceptive sensibility. The characteristic giant axons with thin myelin sheaths which 
confirmed the diagnosis were evident on her nerve biopsy. The other boy had a positive family 
history and presented by 2 years of age with developmental delay, generalised weakness and 
abnormal reflexes as well as the typical “woolly” hair. Nerve conductions studies failed to 
stimulate any sensory responses but the motor responses were only marginally slowed. 
Peripheral nerve biopsy confirmed thin myelinated fibres of abnormally large size with cluster 
and onion bulb formations. The large myelinated fibres were packed with abnormal 
neurofilaments most evident on electron microscopy. 
Three children had neuroaxonal dystrophy (NAD) (2 female: 1 male). All presented 
by 2 years of age and the female patient was related to one of the male patients. The children 
presented with gait difficulty and weakness. They initially developed hypotonia but later 
spasticity was evident. In this group the deep tendon reflexes were depressed. The children 
evolved progressive cognitive neuroregression and blindess related to optic atrophy. 
Neurophysiology confirmed normal sensory conduction (n=2) and normal motor conduction in 
two patients but mild slowing in the other. EMG detected denervation in all. Sural nerve 
biopsies performed at the age of 2½ (n=2) and 3 years of age, detected axonal degeneration 
and abnormal neurofilaments with cluster formations (n=1) and markedly reduced MF density 
in one, borderline reduction in one and normal density in the other. EM detected cluster 
formations (n=1) and abnormal axonal spheroids consisting of storage neurofilamentous 
material in all (Figure 2.5, page 48). The biopsies were diagnostic of NAD with an axonal 
picture. 
One boy presented by two years of age with infantile neuronal ceroid 
lipofuscinosis (INCL), confirmed on rectal biopsy. Clinical features included neuroregression, 
ataxia, abnormal deep tendon reflexes, cranial nerve involvement, central disease and 
developmental delay. His neurophysiology studies were normal. His sural nerve biopsy 
performed aged 6 years revealed normal myelinated fibre density and ovoid formations on 
teased fibre analysis. The changes were consistent with a mild axonal peripheral neuropathy. 
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Four children with peroxisomal disorders underwent peripheral nerve biopsies. No 
neuropathy was found in two. The other two male infants, who presented at birth, were first 
cousins (their mothers were sisters).(2) Their nerve biopsies confirmed a demyelinating 
disorder in one and axonal degeneration in the other with glycogen accumulation in the 
Schwann cells.  
Four boys had different metabolic disorders associated with peripheral neuropathy; 
namely Allgrove syndrome (Tripe A, alacramia, achalasia, adrenal insufficiency) (biopsy: 
axonal degenerative), arginase deficiency (biopsy: mixed picture), orotic aciduria (biopsy: 
mixed picture) and triosephosphate isomerase deficiency (TPI) (biopsy: axonal 
degeneration).(330) 
 
OTHER HEREDITARY DISORDERS WITH ASSOCIATED PERIPHERAL NEUROPATHIES 
(n=9) 
Two patients (1 female: 1 male) had neurofibromatosis type 1 (NF1). One 
presented by 5 years and the other after 5, neither had a positive family history. Both complied 
with international inclusion criteria for NF1.(331) Clinical features included limb deformities 
(n=1), kyphoscoliosis (n=1), distal weakness (n=2), pes cavus (n=1) and developmental delay 
(n=1). Neurophysiology was abnormal in one and motor studies were not performed in the 
other. EMG (n=1) demonstrated a neuropathic process. Sural nerve biopsy performed aged 
11 and 12 years, demonstrated borderline to moderately reduced MF density, with axonal 
degeneration (n=1) and abnormal loosely packed tissue in the subperineurial region 
composed of interlacing bundles of collagen, containing fibroblasts, Schwann cells and a few 
mast cells (Figure 2.13, page 64). Features were felt to be consistent with an axonal 
peripheral neuropathy and were typical of neurofibromatous neuropathy, a recognised entity. 
Sixteen patients, who had nerve biopsies, were subsequently found to have spinal 
muscular atrophy. Of this group five (1 female: 4 male) had features of axonal degeneration 
on sural nerve biopsy. These five infants presented at birth with severe weakness.(2) Two had 
contractures and these bore similarities to the cases described by Korinthenberg et al 
1997.(328)    
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One patient (female) had a connective tissue disorder consistent with Ehlers Danlos 
syndrome. She had a positive family history with onset by 2 years of age. Clinical features 
included limb deformities, hypotonia, kyphoscoliosis, generalised weakness and 
developmental delay. Her neurophysiological tests were normal. Nerve biopsy performed at 
the age of five years detected features consistent with demyelination on teased fibre analysis. 
She was felt to have a demyelinating peripheral neuropathy as part of her Ehlers Danlos 
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ACQUIRED DISORDERS n=48 (figure 3.11) 




























































Twenty-one (15 female: 6 male) had chronic inflammatory demyelinating 
polyradiculoneuropathy.  Fifteen of the group were described in a previous publication.(332) 
The inclusion criteria consisted of patients with a clinical history of progressive weakness and 
hyporeflexia, or multiple relapses, over a period of at least 2 months. Patients had generalised 
slowing of motor nerve conduction velocity to less than 60% of normal values, the presence of 
dispersion of the compound muscle action potential and / or conduction block, prolonged distal 
latencies and absent or prolonged F-wave latencies. Pathologic criteria included an abnormal 
percentage of teased fibres affected by segmental demyelination or electron microscopic 
evidence of demyelination and electron-microscopic or immunohistochemical evidence of 
inflammatory cell infiltrates.(333,334) No patients had a positive family history. One patient 
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(n=4), weakness (distal n=15; generalised n=6), nerve hypertrophy (n=2), reduced or absent 
deep tendon reflexes (n=18), sensory impairment (n=9) and cranial nerve involvement (n=6). 
CSF protein levels were between 0.045-9mmol/l (median 1.135mmol/l). Neurophysiological 
sensory studies (n=19) were abnormal in 18. Median motor nerve conduction velocities 
ranged between 5 –45 metres / second (median 17 metres / second); ulnar: 17-49 metres / 
second (median 32 metres /second) and common peroneal 17-49metres /second (median 32 
metres / second). The median and common peroneal nerves of one patient and the common 
peroneal nerves of two other patients could not be stimulated. EMG was neuropathic in 4 and 
normal in one. Nerve biopsies detected on transverse section thinning of myelin (n=12), 
axonal degeneration (n=10), infiltration with macrophages and inflammatory cells (n=8), 
reduction in the myelinated fibre density (marked (n=4), moderate (n=8) and borderline (n=4)), 
onion bulb formations (n=6) and cluster formation (n=3). Teased fibre analysis (n=20) 
revealed demyelinating changes (n=19) and axonal degeneration (n=11) (Figure 3.11a). EM 
(n=8) detected onion bulb formation (n=1), cluster formations (n=1) and macrophage and 
inflammatory cell infiltration (n=3). Overall the biopsies were felt to be of mixed pathology in 
five, axonal in three and demyelinating in the remaining 13. Of the neurophysiology in 
comparison the mixed pathologies all had conduction velocities in the range 25-39metres / 
second range, whilst the demyelinating neuropathies typically had velocities in the 10-24 
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Figure 3.11a: Teased fibre analysis of a patient with CIDP demonstrating ovoid formations 
(OF), segmental demyelination (SD) and thinly myelinated (TM) fibres (Magnification x200).  
Two patients (1 female: 1 male) had sub-acute inflammatory demyelinating 
polyradiculoneuropathy. The male patient presented aged 3 years and died 6 weeks into his 
illness with respiratory compromise. Clinical features included ataxia (n=1), hypotonia (n=2), 
distal weakness (n=2), reduced reflexes (n=2), sensory impairment (n=1), cranial nerve 
involvement (n=2). CSF protein was 0.2 and 3.6g/l (range 0.2-1.8g/l). Neurophysiology 
revealed abnormal sensory studies in the one patient tested and median nerve conduction 
velocities of 10 metres / second. Sural nerve biopsies were performed at the age of three and 
13 years. Light microscopic examination of transverse sections revealed macrophage 
infiltration and moderate reduction in the myelinated fibre density. Teased fibre analysis (n=1) 
revealed demyelination. EM (n=1) demonstrated macrophage infiltration. The changes were 
felt to be demyelinating in nature. 
Two patients (2 female) had acute inflammatory demyelinating 
polyradiculoneuropathy. There was no family history. Clinical features included hypotonia 
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protein was 0.41 and 1.04g/l. Neurophysiology revealed abnormal sensory conduction studies 
(n=2), median nerve potentials could not be evoked in one, and were < 10 metres / second in 
the other, and common peroneal conduction velocities were >40 metres / second. Nerve 
biopsy performed at the age of eight years for both girls revealed moderate reduction in the 
myelinated fibre density, with myelin thinning (n=1) and macrophage infiltration (n=2). Teased 
fibre analysis (n=1) detected demyelination. EM detected macrophage infiltration. The findings 
were in keeping with a demyelinating disorder.   
 Nine patients (5 female: 4 male) had progressive mononeuropathy. The left sciatic 
nerve was clinically involved in five, the right sciatic nerve in one and two patients had 
mononeuritis multiplex secondary to vasculitis. The nineth patient was a three month old infant 
with distal weakness thought to be related to a vasculitic process. There was no family history 
for any of the patients. Of the five with left sciatic nerve involvement one patient was 
confirmed to have a perineurioma and another had localised hypertrophy of the sciatic nerve. 
One patient with the right foot drop presented with a livedo reticularis rash at the age of 14 
years and a history of right retinal artery occlusion one year previously. He was thought to 
have a vasculitic neuropathy. One female patient presented with distal wasting and weakness 
with reduced reflexes. Her neurophysiology studies and nerve biopsy findings of an axonal 
polyneuropathy with cellular infiltrates around the blood vessel (figure 3.11b), were suggestive 
of an immunological disorder. Clinical features of the group included localised weakness 
(n=8), reduced reflexes (n=5), sensory impairment (n=3) and pes cavus (n=1). The patient 
with mononeuritis multiplex had learning difficulties.  Neurophysiological sensory studies were 
abnormal in 5 out of seven patients tested. Motor studies revealed a range of changes over 
the affected common peroneal nerve with a median conduction velocity of 40m/s (range 32-43 
m/s) (n=4), absent stimulation response of the common peroneal in two patients, and a normal 
result in two patients. Nerve biopsy was performed in eight of the patients between 8 and 15 
years (median 11 years) from the left sciatic nerve (n=2), common peroneal nerve (n=1) and 
sural nerve (n=5). Sural nerve biopsy was taken from the infant aged 3 months. Light 
microscopic examination of transverse sections revealed axonal degeneration (n=6), thinly 
myelinated fibres (n=4), reduced MF density in seven out of the nine biopsies (marked n=3, 
moderate n=3; mild n=1), cluster formations (n=7) and onion bulb formations (n=1). The 
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the girl at 8 years of age. The biopsy from the boy revealed macrophage and inflammatory 
infiltrates around the blood vessels. The biopsy from the girl revealed inflammatory 
lymphocytic infiltrates around one endoneurial vessel on TS and normal density of MF (Figure 
3.11b), with axonal degeneration on the teased fibre analysis demonstrated by ovoid 
formation on one fibre. The infant had evidence of a medium sized recanalising vessel with 
lymphocytic infiltrates and minute blood vessels scattered around it consistent wi  th a past 
healed vasculitic process (Figure 3.11c). The patient with a perineuroma (Figure 3.11d) had 
severe reduction in myelinated fibre density, with remaining fibres surrounded by “pseudo-
onion bulb” formations, consisting of arrays of cells with the morphology of perineurial cells 
occasionally surrounding two or three central MF and some unmyelinated fibres. The 
immunohistochemical staining with vimentin and epithelial membrane antigen supported the 
diagnosis of a perineurioma, a benign but rare tumour.Teased fibre analysis (n=8) revealed 
thinning of the myelin (n=4) and ovoid formations (n=3). The changes were felt to be 
consistent with an axonal degenerative peripheral neuropathy. The peripheral nerve biopsies 
were an aid to diagnostic direction for most patients either confirming vasculitis (n=3), or 
identifying a hypertrophic process predominantly affecting the sciatic nerve (n=6). 
 
Figure 3.11b: Transervse section of the sural nerve biopsy from the eight year old girl with a 
vasculitic neuropathy (magnification x60, haematoxylin and eosin stain). Demonstrating 
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Figure 3.11c: Transverse section from the 3 month old infant with a vasculitic process, 
(toluidine blue stain, magnification x200). The infant had evidence of a medium sized 
recanalising vessel with lymphocytic infiltrates and minute blood vessels scattered around it 
consistent wi  th a past healed vasculitis.  
  
Figure 3.11d Transverse section light microscopy (toluidine blue stain, magnification x400) of 
patient with perineurioma demonstrating atypical onion bulb formations and reduced 
myelinated fibre density from the sciatic nerve sample.  
Two patients (male) had peripheral neuropathies in relation to leprosy. Nerve 
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Six patients (4 female: 2 male) presented with toxin exposure related to glue sniffing 
(n=1), farm pesticides (n=1), ciguatera poisoning (n=1), chemotherapy for a medulloblastoma 
(n=1) and unidentified agents (n=2). All patients were over five years at the time of 
presentation and none had a positive family history. Clinical features were consistent with a 
chronic peripheral neuropathy. Two patients had central involvement. Sensory studies (n=6) 
were abnormal in all six patients. Motor studies were within the axonal range. Sural nerve 
biopsies were performed between 9 and 16 years of age (median 12 years). Transverse 
section light microscopy detected axonal degeneration (n=5), myelin thinning and fibre 
diameter expansion (“giant axons”) (n=1), with reduction in the MF density (markedly n=2, 
moderately n=3) and onion bulb formations (n=1). Teased fibre analysis (n=6) detected myelin 
thinning (n=2), axonal ovoid formations (n=3). EM (n=4) detected expanded MF diameters 
(n=1) with myelin thinning. The picture was consistent with an axonal peripheral neuropathy in 
all patients screened. The patients with “giant axons” identified on biopsy had further 
diagnostic clarity where toxin exposure with glue sniffing was suspected. 
Two patients (1 female: 1 male) had spinal defects (spina bifida and spinal 
dysraphism). They did not have a family history and one presented with clinical neuropathy 
features by two years of age whilst the other was older. Neurophysiology was normal in one 
child but consistent with an axonal peripheral neuropathy in the other with mild to moderate 
slowing of the conduction velocities and a neuropathic EMG. Nerve biopsy performed at the 
ages of 13 and 14 years revealed moderate reduction of MF density (n=1), fibre myelin 
thinning in teased fibre preparations (n=1) and cluster formations on EM (n=1). The patients 
were both considered to have axonal peripheral neuropathies.  
Four male infants had arthrogryposis multiplex congenita. All presented from 
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DISCUSSION. 
Over a 37 year period 296 patients were identified with peripheral neuropathies 
confirmed by nerve biopsy. This group with chronic peripheral neuropathies was dominated by 
hereditary pathologies both in the “pure” hereditary motor sensory neuropathy group, but also 
those associated with central / neurodegenerative disorders. The original group consisted of 
426 nerve biopsies, of these 130 were normal. These patients with normal nerve biopsies 
were dominated by infants and children with neurodegenerative disorders and infants with 
severe hypotonia. Many samples were performed prior to specific molecular genetic and 
neurometabolic screens becoming accessible. 
Charcot-Marie-Tooth disease is the commonest neuromuscular disorder. This data is 
based on adult prevalence studies or combined studies with paediatric figures integrated.(33) 
CMT1 is the commonest demyelinating disorder occurring in 1:2500 of the population and 
representing 70% of all demyelinating CMT. (35-37) Of the available paediatric studies this figure 
is closer to 50%.(29,30)  Most studies are from European and North American centres. In our 
Australian based study the patients with CMT1 represented 37% of the demyelinating group, 
with 27% having CMT1A. The CMT1 group were 16.7% of the total inherited peripheral 
neuropathy group. This figure is an under representation of the prevalence since the 
availability of 17p duplication genetic screening is one of the few tests readily available to 
most centres following confirmation of the defect in 1991.(38,39) Hence many patients 
presenting with demyelinating disease since 1991 would have undergone genetic screens first 
and only proceeded to biopsy if results were negative or the screening was unavailable. The 
cohort described in this study at the time of their biopsy predated the discovery of the mutation 
and were gene tested at a later stage. Despite this, our number of patients with CMT1 was 
high confirming that this condition does indeed occur in childhood. There is literature to 
suggest that anticipation could occur in some patients with CMT1A whereby the severity of the 
disorder is more marked in subsequent generations.(335) The cause for this is not known but 
would explain in some of the familial cases the increased incidence at younger ages with each 
generation. 
From the demyelinating group despite the extensive range of sub-divisions for 
CMT1 (A-F) most patients (n=20) were part of the 1A group, one was suspected to have A or 
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CMT1 (she was negative for chromosome 17 duplication and MPZ mutation). Beyond this, five 
patients had a dominant pattern of inheritance and a phenotype compatible (based on clinical, 
neurophysiological and histopathological data) with CMT1. But despite the key pointers 
highlighted in Table 1.2 they could not be categorised further.  
Fourteen patients complied with the phenotype for CMT3; 9 of them had genetic 
confirmation. The detection rate of point mutations in this group was very high. Despite 
extensive screening of three of the remaining five patients without genetic delineation, none 
have to date been found to have other mutations described in the DSS category, namely 
periaxin, and EGR2. This may reflect that these three patients did not have ancestries from 
the populations who typically carry those other mutations, such as periaxin mutation in the 
Lebanese population.(58,111-114,336) 
Six patients had CMT4; this is a relatively new term. It has defined a number of 
previously unidentified phenotypes and assisted to clarify some of the confusion surrounding 
the hypomyelinating syndromes.(337) From our cohort the patients who were labelled with 
autosomal recessive demyelinating and remyelinating / demyelinating neuropathies were 
reanalysed for features of CMT4. Typically patients are of infantile onset with delayed motor 
milestones and eventual loss of ambulation is not unusual.(115) Extensive peripheral nerve 
involvement occurs and additional vocal cord paresis, bulbar, facial, diaphragmatic weakness 
and sensorineural deafness are often described. This group was already separated from the 
CMT3 category predominantly based on their histopathological data (including myelin-
outfolding CMT4B, CMT4F and CMT4H). With the combined information and definitive genetic 
screens in two of the patients (MPZ mutation and frabin mutation), all patients were 
categorised (CMT4B n=5 and CMT4H n=1).(115,116) Rare forms would be CMT4H related to 
frabin mutations which was identified in one patient from the cohort. Phenotypically this patient 
had no features to differentiate her from a severe demyelinating neuropathy, her peripheral 
nerve biopsy demonstrated the typical myelin-outfolding but without the molecular genetic 
diagnosis she could not be categorised further. Of the remaining group in whom myelin-
outfolding was common, mutations in the MTMR2 region would be expected. However only 
one patient was screened and the results are outstanding. 
One patient was labelled HMSNVII – his phenotype complied with the original 
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Of the 73 patients with demyelinating peripheral neuropathy, 34 (47%) attained a 
molecular genetic diagnosis. But when the group who underwent genetic screening were 
assessed the figure increased to 78%. Twenty-two patients (30%) could not be categorised. 
Many of these patients without categories predated the current molecular screens and did not 
have DNA material available for analysis. 
The patients allocated to the remyelinating / demyelinating group (n=16) did not 
belong in any clear category falling between features of CMT1 and CMT4. Their nerve 
conduction velocities were too slow for CMT1, but they lacked key pointers to sub-divide them 
further. They appeared to have sporadic or recessive patterns of inheritance; most were of 
onset in the first decade and the incidence of scoliosis was high (a third). They may eventually 
be delineated into CMT4 sub-groups once their mutations are identified. Since only six of this 
group had undergone extensive but negative genetic sceening this group may still attain 
diagnostic closure. 
Similarly the six patients in the atypical demyelinating group fitted no known category 
due to combinations of atypical clinical features, neurophysiology and histopathology. Three of 
them had undergone genetic screening without identifying a mutation.  
Eighty-one of the patients had axonal neuropathies. Twelve were in the category 
autosomal dominant CMT2. Of this group it was possible to sub-categorise 4 patients based 
on clinical phenotype and molecular genetics (CMT2A n=3, CMT2E n=1). The finding of 
CMT2A (due to MFN2 mutations) in three of the patients could represent a proportion of a 
larger cohort, yet to be defined, the mitofusin2 mutation is considered the commonest to occur 
and its identification should allow categorisation of many of the patients with hereditary axonal 
forms of CMT.(75,77,252) The patient with CMT2E was initially labelled with either “toxin 
exposure” or giant axonal neuropathy based on his biopsy appearance of giant axonal fibres. 
However he presented early, with no history of toxin exposure and was cognitively intact. The 
combination of his phenotype including his sensory complications complied with the diagnosis 
CMT2E.(65,78) 
Eighteen patients (22%) of the axonal group complied with the category for EOHMSN 
or SEOAN. This entity was the commonest single group of the axonal neuropathy patients. 
This disease is a severe and clearly common form of CMT which occurs in early childhood 
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date reinforces the relevance of this severe form and the need to investigate these children 
thoroughly.(104) Of the eight children with the condition screened for the mitofusin2 mutation 
only one has not had the mutation identified. Affected patients are at risk of significant 
disability with contracture formation, scoliosis, loss of ambulation and occasional optic 
atrophy.(102,103) EOHMSN does not appear to have been categorised as an entity in itself in 
many reviews of sub-forms of CMT, but the size of this cohort should confirm the need to 
recognise it as a specific sub-category of severe childhood onset axonal CMT. It has been 
suggested that EOHMSN should be recognised under the term SEOAN (severe early onset 
axonal neuropathy) and that the condition should be placed in a CMT2B sub-category for 
autosomal recessive disease (personal communication Professor S Scherer). 
Seven patients (8.5% of axonal group) had SIANR (genetic mutation SMARD1). The 
mutation was identified in all those who underwent genetic screening (n=5).This condition is 
probably more frequent than previously recognised with many more patients now being 
reported.(106-108) The range in recognised phenotypes of the condition has also widened.(338) It 
was originally reported as a peripheral neuropathy involving motor and sensory nerves with 
secondary anterior and posterior horn cell fall-out.(106) When the genetic marker was identified 
the condition was described as a primary condition of the anterior horn cells.(108) It is evident 
that both anterior and posterior horns are affected, with heterogeneity in the regions maximally 
affected in patients with the SMARD1 mutation.(339) Diverse ethnicities are affected by this 
devastating condition; prenatal diagnosis is possible and there is ethical debate about the 
level of appropriate intervention.(340-348) 
Two female siblings presented with a severe relapsing axonal neuropathy. Both died 
without a definitive diagnosis. The hereditary nature was assumed as both siblings were 
affected and the parents were normal (presumed autosomal recessive). The older sibling was 
originally considered to have CIDP but this was thought less likely when the second sibling 
became affected. Severe cases of axonal “CIDP” are described with debate about the term 
itself and the inclusion criteria.(349) No children with hereditary forms of CIDP were identified in 
published reports. Of the few with a hereditary nature, all were linked to other conditions.(350-
352) One patient reported had a similar phenotype with young onset and relapsing pattern 
resulting in death from respiratory failure.(353) Although reported as CIDP following publication 
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Anlar). The patient was considered to have demyelinating pathology but with macrophage 
infiltration. 
Thirty-one patients were labelled “atypical axonal and sporadic sensory neuropathy”. 
This interesting mix of patients all had different phenotypes – some may conform to the 
autosomal recessive CMT2 categories.  
Nine patients underwent peripheral nerve biopsies to screen for neuropathies 
associated with distal hereditary motor neuropathy: of this group only one was affected. This 
condition is proposed to be an exlusive motor neuropathy, and has been referred to as a 
neuronopathy based on the concept that the primary disease is in cell body of the anterior 
horn cells and not the axons. However reports of minor sensory abnormalities identified in 
neurophysiological and neuropathological studies, as occurred in one patient from this study, 
have contended this concept. (169,184)   
Nine patients were categorised in the CMTX group – one patient had a connexin 32 
mutation (CMTX1).(116,141) Another patient presented very young with a strong family history – 
his phenotype was more in keeping with CMTX2 or X4 but his genetic screens were 
negative.(354) Three patients complied with the category for CMTX5 with optic atrophy and 
deafness. Two of the group were female, they presenting later than the affected male patient. 
Genetic screening in the one male patient confirmed a PRPS1 mutation.(143,148,149) These last 
four patients were described in the section for axonal disease. The fact that they complied with 
CMTX illustrated the overlap and inevitable difficulties in trying to place the patients into fixed 
“axonal”, “demyelinating” and “mixed” categories. The patients with EOHMSN typically have 
primarily an axonal disorder but manifest on histology with additional features of demyelination 
with onion bulb formations.(105) Secondary demyelination may occur as a consequence of 
axonal disease(355) and axonal degeneration is common as part of severe demyelinating 
disease. This axonal damage is thought to be the determinant of the severity of the clinical 
course in patients with CMT1.(46)  
The HSAN group was relatively small. Clinical features often directed the disease 
categorisation but the biopsy was helpful to further define the condition. One of the group had 
clinical features but normal NCS. His biopsy confirmed axonal neuropathy. This highlighted an 
important scenario occasionally seen where there is clinical suspicion of neuropathy which is 
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disorder affects the small MF and unmyelinated MF which are not the determinants of the 
NCV in conventional surface electrode studies. (256)   
Two patients had CMT5 – this is a complex group and important to recognise. Many 
patients are labelled with forms of cerebral palsy before the progressive nature of their 
disorder is recognised.(356,357) 
Of the eighty-eight patients with hereditary axonal and mixed disease 15 (17%) 
gained molecular genetic diagnoses. However of the group only 37 patients underwent 
genetic screening and 38% of them attained a genetic diagnosis. Thirty-three (37%) of the 
group could not be categorised.  
Genetic correlation: The one hundred and sixty-one patients described with 
hereditary peripheral neuropathies as their primary disorder most typically followed a 
recessive or sporadic pattern of inheritance (n=108), with dominant inheritance less common 
(n=53). Forty-nine patients attained definitive molecular genetic diagnoses, twenty-eight of 
whom had autosomal dominant patterns of inheritance and 21 autosomal recessive. The 
disparity in these figures, where a larger number of patients had autosomal dominant patterns 
of inheritance was due to the diagnoses of patients with CMT1A (n=20). Screening for patients 
with autosomal recessive disorders tends to be more specialized as mutations are more likely 
point mutations. 
Seventy-eight patients underwent peripheral nerve biopsy as part of their 
neurodegenerative screens. Many of them preceded genetic screens being available (e.g. 
Friedreich’s ataxia). Some had conditions for which peripheral nerve biopsy remains useful 
either diagnostically or to direct screens e.g. neuroaxonal dystrophy, giant axonal neuropathy, 
some forms of metachromatic leukodystrophy.(290) In patients undergoing extensive 
neurometabolic screens the nerve biopsy data may direct investigations more effectively.  
Neuronal ceroid lipofuscinosis is rarely described with an associated peripheral 
neuropathy.(358-361) Sural nerve biopsy is not routinely performed and most reported cases are 
based on nerve conduction study findings.(359) The involvement however is logical with 
inclusions in Schwann cells and the neuraxis reported.(362) Of the published reports the 
heterogeneity of the disease manifestations within the same family is noted whereby not all 
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Two patients with neurofibromatosis type 1 (NF) had biopsy-confirmed peripheral 
nerve disease. Localised nerve involvement is well described but a more generalised 
involvement occasionally occurs although there is debate as to whether two pathological 
entities may have arisen co-incidentally.(313-316) Most reports are based on NF type 2 
patients.(314,363,364) The role of reduced merlin gene dosage is believed to be relevant in the 
manifestation of peripheral neuropathy in NF type 2.(365) Although reports of NF type 1 
associated sensorimotor neuropathy are less frequent, there is a suggestion that this 
complication is more common than is realised and may be sub-clinical in most patients. As 
such, peripheral neuropathy in patients with NF1 should be monitored for since the 
complications can be severe.(315,364) Based on histological confirmation, supported in our 
series, there is direct involvement of the peripheral nerves in NF1. (315,364) 
Five out of the sixteen patients with spinal muscular atrophy (SMA) had evidence of 
peripheral neuropathy on sural nerve biopsy. Studies have suggested that this is related to the 
more severe type 1 phenotype and reflects immobility.(328,366-369), However SMA is a 
multisystem disease with studies suggesting fatty acid metabolism and mitochondrial 
dysfunction.(370-373)  Most reports suggest the neuropathy is secondary but full understanding of 
the disease mechanism is still not complete(374) and direct pathological involvement of the 
peripheral nerves is likely.(328,369) 
Forty-eight patients had acquired pathologies, some were screened for CIDP and 
the biopsy assisted in differentiating them from the CMT group.(352,375) Some of these patients 
have already been reported in a separate paper. (332) At times, however, the biopsy 
appearance led to treatment for CIDP before a diagnosis of a hereditary polyneuropathy was 
established. This occurred with one of the patients with MFN2 mutation.(352,375)  
Nine patients had mononeuropathy predominantly involving the sciatic nerve (n=6). 
This is a relatively rare entity.(376) Vasculitic processes are the major cause described, 
especially related to systemic lupus erythematosis, followed by vascular insults and isolated 
lesions in the nerve itself such as perineuriomas.(377,378)  Nerve biopsy has been promoted as a 
useful diagnostic aid in this clinical setting.(379) 
The need for “endotyping”: Modern technology has advanced such that there are 
over 44 gene locations mapped for various peripheral neuropathies.(5) However this 
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always be concluded from the molecular genetic result in isolation. It is often necessary to 
combine the information on the clinical phenotype, neurophysiological and histopathological 
results with the molecular genetics findings in the patients presenting in childhood to gain an 
understanding of the underlying process. This study has attempted to use this system to 
advance understanding of the numerous forms of peripheral neuropathy presenting in 
childhood and to define the prevalence of these in a large population.  
Even this may be an over simplification as the role of the various gene products 
continues to expand with different disease manifestations seen with the same protein 
deficiency. This is illustrated in Table 1.4. Myelin protein zero mutations can result in 
demyelinating and axonal disorders.(58,59,97,98,112,131,159) Some patients present in infancy, 
others in middle age.(380) Some mutations are specifically associated with Holmes-Adie 
pupils(381,382). Some appear to cause remittent neuropathy.(383) The action of myelin protein 
zero in the compaction of the myelin as part of Schwann cell function and regeneration 
explains some of this process.(112,384) The same apparent condition (phenotype) can result 
from different mutations.(111,112,114,336,385)  
Many centres worldwide managing children with clinically diagnosed peripheral 
neuropathies cannot perform molecular genetic analysis or are limited to the most standard 
duplication or deletion screen of chromosome 17p. Similarly the technique of performing nerve 
conduction studies in children is specialised and requires skilled operators and specialists 
trained to interpret the values normally recorded in childhood. Peripheral nerve biopsy 
analysis should only be analysed in centres confident with the technique and analysis. Thus 
three out of the four main requirements used for “endotyping” these patients are lacking in 
most parts of the world. One could debate whether it matters if the management is the same 
for all patients. However in reality there are factors which differ from type to type including 
prognosis, levels of intervention (surgery, splints, frequency of physiotherapy etc), and 
especially genetic advice. Accordingly this data should be used as a guide to key markers 
which may aid diagnosis, subsequent therapy and genetic advice. Vitamin C therapy for 
patients with CMT1A may become a recommended intervention in the near future – thus 
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Many of the patients studied had samples taken prior to molecular genetics being 
available and as such did not have DNA analysis. Some patients attained a genetic diagnosis 
some 30 years after initially being studied. 
Even in the context of a facility with the ability to screen patients for many of the 
recently identified gene loci a significant proportion of the database with clear genetic 
aetiology remained without a molecular genetic diagnosis. This was most marked for the 
axonal / mixed group (15/37) compared to the demyelinating group (34/50). This is the case in 
all centres. 
Allocating specific sub-categories was possible for many of the patients but a 
proportion remained in various miscellaneous categories (remyelinating / demyelinating, 
atypical axonal, atypical demyelinating) even with the capabilities available to a centre 
specialising in paediatric neuromuscular disorders with access to DNA research laboratories. 
Particular mutations have had a significant impact on categorising many of the paediatric 
onset conditions. Mitofusin2 mutations are found predominantly in axonal disorders and to 
date have been identified in 8 patients of the group. It is expected to delineate a large 
proportion of the patients with axonal disease, especially those with EOHMSN.(104) 
Of the miscellaneous groups, many of those patients are likely to be part of the CMT2 
recessive and the CMT4 categories with mutations yet to be identified. Rare protein mutations 
are often located to specific gene pools. 
By nature of its invasiveness as an investigation peripheral nerve biopsy is often left 
at the end of a list of other studies. The expanding field of molecular genetics has further 
lessened the need for biopsy, which was often used to confirm a diagnosis of CMT1. However 
there are many conditions which may remain dependent on biopsy to confirm the diagnosis. 
This includes not just the group with characteristic disease-specific findings evident on biopsy 
alone but also the group whereby the nerve conduction studies may suggest a demyelinating 
process but the biopsy identifies an axonopathy, for example the EOHMSN group.(105) Patients 
with intermediate NCS are often diagnostic dilemmas and nerve biopsy can help define the 
most likely genetic categories to look for. For example mitofusin2 mutations have striking 
mitochondrial abnormalities as well as additional features to the axonal degeneration, such as 
onion bulb formations.(105) Patients with CMT2E may have giant axonal fibres. The patient 
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compatible with gaint axonal neuropathy or toxin (glue sniffing) exposure – ideally he should 
have NEFL screen but his DNA was not available at this time.(65,78)  This case illustrated the 
usefulness of the nerve biopsy. Patients with giant axonal neuropathy are reported without the 
“woolly” hair. In centres where DNA analysis is not available, these biopsy findings can assist 
diagnostic dilemmas.(389,390)  Similarly identifying a patient with myelin-outfolding will direct 
investigations towards forms of CMT4 (B,F and H).(115)  
The degree of nerve involvement will also correlate with disease severity as can be 
seen in patients with Friedreich’s ataxia.(226) 
Conclusion: This study highlights the extensive range of peripheral neuropathies 
found in childhood emphasising the high level of inherited disorders as opposed to acquired 
disorders. 
Many conditions were identified in patients of a far younger age than normally expected to be 
susceptible to specific peripheral neuropathies. 
Nerve biopsy should remain as an essential part of the diagnostic screen for affected 
patients who lack clear delineation despite genetic screening or where there is lack of access 
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CHAPTER 4 
PERIPHERAL NEUROPATHIES OF INFANCY. 
 
Published in Developmental Medicine and Child Neurology(2) 
Wilmshurst JM, Pollard JD, Nicholson G, Antony J and Ouvrier R. Peripheral neuropathies 
presenting under one year of age. Dev Med Child Neurol 2003;45:408-414 
(Publishers granted permission for inclusion in thesis) 
 
SUMMARY 
Over a 30 year period 260 New South Wales patients aged less than 17 years, who 
had peripheral neuropathies confirmed by nerve biopsy, were studied. Of these, 50 infants 
presented with symptoms or signs of neuropathy less than one year of age. The group 
included 24 demyelinating and 21 axonal cases (22 male: 23 female). A further 5 patients had 
spinal muscular atrophy with associated secondary sensory axonopathy (4 male: 1 female). 
Nineteen infants had hereditary motor sensory neuropathy, of whom 13 had myelin protein 
mutations confirmed by molecular genetic studies. Peripheral neuropathy is not an unusual 
diagnosis in infancy. Awareness of this association will aid early diagnosis and prognosis as 
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INTRODUCTION. 
There are few studies specifically describing peripheral neuropathies presenting 
clinically in infancy. The majority of these concentrate on the hereditary types. (29,31,391) The 
European multicentre study identified 287 children with “pure” peripheral neuropathy.(29) Of 
these, 20 presented less than 1 year of age. The majority were congenital and the authors 
emphasised that CMT1 (HMSN I) could occur in this age group. At the time of the study 
molecular genetic analysis was not available and biopsies were not performed in all. 
In a further study reviewing genetic neuropathies in Swedish children (0-15 years) 
over an eight year period, 103 children were identified.(30) The study divided the group into 
motor / sensory neuropathies (n=63), sensory neuropathies (n=3) and central nervous system 
(CNS) disorders with peripheral neuropathy (n=37). Those with infantile onset were not 
separately analysed.  
The following study describes a large series of children with biopsy-confirmed 
peripheral neuropathy who presented with symptoms in infancy. 
 
METHOD. 
From 1969 to 1999, 362 children (0-17 years of age) had sural nerve biopsies 
analysed at the Nerve Research Laboratory University of Sydney. Two hundred and sixty of 
these had a peripheral neuropathy. Fifty children were symptomatic in infancy (less than one 
year of age). Frequent clinical features were hypotonia, weakness, sensory alteration, 
areflexia, ataxia, contractures and wasting. The diagnostic categories were allocated through 
a combination of recognised clinical features, neurophysiology results and biopsy findings. (44) 
As sural nerve biopsy was often one of the last studies to be performed, many patients were 
older than one year at the time of sampling. Median age at nerve biopsy was 2 years (inter-
quartile ranges 1-3.8 years; total range 8 days to 8 years). Since 1993, many of the patients 
have had DNA studies for clinically appropriate diagnostic entities. In all 17 have had such 
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RESULTS. 
Of the 50 children, there were 24 with demyelinating neuropathies, 21 with axonal 
neuropathies (22 male: 23 female) and 5 cases of spinal muscular atrophy with sensory 
axonal degeneration (4 male: 1 female). The group diagnoses are summarised in Table 1.No 
patients had known complications during or following peripheral nerve biopsy.  
 
 
Table 4.1: Summary of infantile-onset peripheral neuropathy diagnostic categories 
24 demyelinating disorder:- 
 CMTI      7 
 Hypertrophic sporadic / recessive  2 
 CMT3      7 
 CMT4B      2 
 HMSN Miscellaneous    1 
 Peroxisomal disorder    1 
 Leukodystrophy-unclassified   2 
 Neurodegenerative disease   2 
21 axonal disorders:- 
 HSAN IV     2 
 HSAN V     1 
 HSAN Miscellaneous    1 
 Sporadic sensory neuropathy   1 
 Chronic axonal - miscellaneous   1 
 Early onset HMSN of axonal type  1 
 Severe infantile axonal neuropathy  3 
+ respiratory failure  
 Severe relapsing axonal neuropathy  1 
 Peroxisomal disorder    1 
Giant axonal neuropathy   1 
Leigh Disease     1 
Neurodegenerative disease   3 
Arthrogryposis multiplex    4 
Secondary axonopathy: 
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Hereditary motor sensory neuropathies of demyelinating and remyelinating type. 
Charcot Marie Tooth (CMT) (n=19) 
Of seven patients with dominantly inherited CMT1, five had chromosome 17p11.2-12 
duplications (CMT1A), one had partial trisomy of chromosome 17p and one had a positive 
family history (her father was affected). The patient with partial trisomy of chromosome 17p 
had the typical phenotype of seizures, global delay and dysmorphism in addition to the 
neuropathy.(324)  
Two patients had remyelinating / demyelinating neuropathies. Clinically they 
presented with a combination of early contractures, hypotonia and areflexia with subsequent 
delay in walking. One of the two had a positive family history with her mother clinically 
affected, but she was negative for the chromosome 17p11.2-12 duplication, myelin protein 
zero mutation, PMP22 mutation and ERG2 mutation. The apparently autosomal dominant 
pattern of inheritance was compatible with CMT1 but the negative Chr17dup and MPZ screen 
precluded type 1A and 1B. The other case was sporadic.  
Nerve conduction velocities were abnormal in all those tested (n=8/9) with common 
peroneal MCV ranging from 0-22 metres/second (mean value 10 metres/sec) and median 
MCV ranging from 6-31 metres /second (mean 18 metres/second). The patient with trisomy 
did not have nerve conduction studies. Of the four EMG studies three were normal (from the 
CMT1 group) and one showed evidence of denervation. 
Nerve biopsies confirmed prominent demyelination with onion bulbs in many 
myelinated fibres. Density was significantly reduced in six of the nine patients. The extent of 
demyelination on teased fibres varied from 20-70%. One patient had secondary axonal 
changes in 5% of teased fibres. The severity of biopsy changes did not correlate reliably with 
nerve conduction studies or clinical disability.              
Seven patients had CMT3. Four had myelin protein zero mutations, two had PMP22 
point mutations and one did not have molecular genetic studies. The patients with myelin 
protein zero mutations had a six base pair insertion (AGTTCT) in exon 3, resulting in a two 
amino acid insertion (phenylalanine to tyrosine) after aspartate 118 in one case, a cytosine to 
guanine substitution at nucleotide 188, leading to a serine 63 cystine substitution in the 
extracellular domain (exon2) in another and the remaining two patients had a cytosine to 










Peripheral Neuropathies of Childhood Jo M Wilmshurst 
Thesis presented for the Degree of Doctor of Medicine 
 130 
patients with PMP22 point mutations one had a cytosine to adenosine base change on exon 1 
causing a histidine/glycine substitution at position 22, the other had a cytosine to thymine 
change on exon 3, causing a serine/leucine substitution at position 22. Five of the seven 
presented between 6 and 10 months of age with motor delay and hypotonia. One patient in 
this group, with a myelin protein zero mutation, died at 11 months being severely weak, with 
bulbar and respiratory dysfunction.(392) His features were similar to the cases described by 
Felice et al.(393) Of the remaining two patients one presented at birth and the other at 6 weeks 
of age with hypotonia. Motor conduction velocities were profoundly slowed, mostly below 10 
metres/second. Nerve biopsies revealed significant reduction in the density of myelinated 
fibres with hypomyelination and / or demyelination and extensive onion bulbs formations 
(Figure 4.1). 
Figure 4.1: Sural nerve section electron micrography plate (magnification x20 000) from a 
patient with myelin protein zero mutation CMT3, showing a thinly myelinated fibre surrounded 
by an onion bulb formation and a Schwann cell nucleus. 
Two patients who were hypotonic at birth, had HMSN with excessive myelin outfolding 
(CMT4B) (394) on sural biopsy (Figure 4.2). One had bilateral ptosis, motor delay, areflexia and 
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time of these patients’ presentations. One of these patients has subsequently been confirmed 
to have a myelin protein zero mutation (AGC > GCC on exon 2 causing a Thr 65 Ala 
substitution). 
 
Figure 4.2: Transverse section from the sural nerve of a patient with CMT with myelin-
outfolding, showing a reduction in myelinated fibre density and myelin outfolding in many of 
the fibres. (Light microscopy, toluidine blue stain, magnification x100) 
One patient did not have the criteria for any of the recognised demyelinating CMT 
subtypes (miscellaneous CMT) She presented at 10 months of age with motor delay, distal 
weakness, clumsiness with a family history of an affected sister (who was negative for 
chromosome 17 duplication, myelin protein zero mutation, PMP22 mutation and ERG2 
mutation). On NCS her motor conduction velocities were below 10 metres/second and 
sensory potentials were abnormal. Her nerve biopsy at the age of 4 years, confirmed 
demyelination with onion bulbs and 40% reduction in fibre density. Studies for myelin protein 
zero mutation was negative. She ultimately went on to have an affected child.  
Of the total CMT group thirteen had diagnostic molecular genetic results with the 
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Hereditary sensory autonomic neuropathy. (HSAN) (n=4) Two patients had HSAN 
type 4. They presented at 3 and 4 months of age with insensitivity to pain, autonomic 
dysfunction and failure to thrive. Sensory potentials studies, performed in one patient at 8 
months of age, revealed normal median and ulnar responses, whilst the sural action potential, 
was reduced at 2 microvolts. Motor conduction studies (median, ulnar, peroneal and tibial) 
were normal in both. There was a marked decrease of unmyelinated fibres and small 
myelinated fibres on nerve biopsy. One patient had HSAN type 5. She presented aged 7 
months with no response to pain, ulcers distally of the limbs and a fractured tibia. Her motor 
and sensory nerve conduction studies were normal. On nerve biopsy a selective loss of small 
myelinated fibres was found.(329) . One patient could not be categorised (miscellaneous 
HSAN). He presented with a history of insensitivity to pain from birth, associated with tongue 
biting. At 11 months it was also evident that he had language and social delay. He had steady 
clinical improvement but was lost to follow up early in his course. Axonal degeneration was 
found on nerve biopsy and nerve conduction studies were normal.  
Sporadic sensory neuropathy / Chronic axonal miscellaneous (n=2) (326) Two 
patients had sporadic atypical sensory neuropathies with large diameter myelinated fibre loss 
and without significant disturbance of pain or temperature sensibility or of strength. One 
presented with motor delay, possibly related to impaired proprioception and the other also had 
motor delay associated with ataxia and scoliosis. Neither patient has progressed (aged 10 and 
15 years) and the scoliosis in the second has improved. Sensory action potentials were 
abnormal in both and motor studies were slightly slowed in the first patient. Nerve biopsies 
identified axonal degeneration in both, with marked reduction in myelinated fibre density. 
Molecular genetics studies in the first patient were negative for SCA (spinocerebellar atrophy) 
types 1, 2, 3, 6 and 7.  
Early onset HMSN of neuronal type (Severe early onset axonal neuropathy). 
(n=1) (103) This patient presented at 11 months, with motor and speech delay. Her biopsy at 2 
years of age showed reduced MF density and axonal degeneration. Denervation was evident 
on EMG but nerve conduction studies were normal. 
Severe infantile axonal neuropathy with respiratory failure (SIANR). (n=3)(106) 
Three patients all of whom had intrauterine growth retardation presented at or shortly after 
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resulted in respiratory dysfunction and eventual death in all. Nerve conduction studies were 
either profoundly slowed or unrecordable. Nerve biopsy showed marked reduction in MF 
density, apparent failure of regeneration and very little active degeneration, suggesting that 
the infants were affected by a previous intrauterine insult and did not have the ability to 
recover from the resulting fibre loss. One of the three infants was tested for a mutation of the 
IGHMBP2 gene and was found to have the mutation responsible for a form of spinal muscular 
atrophy with diaphragmatic involvement (SMARD1) (108) which we have shown to be 
sometimes associated with a generalised polyneuropathy (SIANR).(106) 
Severe relapsing axonal neuropathy (n=1) One patient presented at 8 months with 
acute-onset ataxia and weakness. After an almost complete recovery she relapsed at 21 
months and died. Her sister was similarly affected. Nerve conduction velocities were in the so-
called “demyelinating range” (median nerve motor conduction velocity 15 meters/second; 
common peroneal nerve motor conduction velocity 8 meters/second) and there was 
denervation on EMG. Nerve biopsy confirmed axonal degeneration, occasional thin myelin 
sheaths, reduction in myelinated fibre density and an increased number of macrophages.  
Peroxisomal disorders (n=2) Two infants who presented at birth were first cousins 
(their mothers were sisters). One was generally weak, with nystagmus and areflexia and later 
developed pes cavus. His mother was mildly affected. His very long chain fatty acids were 
abnormal (C26:C22 ratio 0.075 (normal<0.035) C24:C22 ratio 1.2 (normal 0.55-1.15)) and his 
phytanic acid level was 0.1 mmol/l (normal range <0.5 mmol/l). His nerve conduction 
velocities, both sensory and motor, were slow (median nerve MCV 22 metres / second and 
common peroneal nerve MCV 10 metres / second). Nerve biopsy at the age of 2 years 
showed demyelination, thin myelin sheaths, reduction in myelinated fibre density by 
approximately 40%, onion bulb formation and increased macrophages. The other patient, who 
was floppy at birth, was subsequently found to have mental retardation and motor delay with 
areflexia. He had abnormally elevated phytanic acid levels. His nerve conduction velocities 
were slow (delayed sensory conduction; median nerve MCV 19 metres / second; posterior 
tibial nerve MCV 18 metres / second). Nerve biopsy showed a mixed picture. On transverse 
section, there was demyelination and reduced myelinated fibre density but myelin ovoids on 
teased fibre studies. On electron microscopy there was demyelination with glycogen 
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Giant axonal neuropathy (n=1) This patient presented in infancy with motor delay, 
“woolly” hair, dry skin, pes cavus, and subsequently developed nystagmus, generalised 
weakness, areflexia, ataxia and absent vibration and proprioception sensitivity. Nerve 
conduction studies were mildly abnormal with borderline motor and sensory changes. The 
characteristic giant axons with thin myelin sheaths confirmed the diagnosis when a nerve 
biopsy was performed at 4 years. On teased fibre analysis there was a variation in myelin 
thickness and segmental demyelination. 
Leigh disease (n=1) This infant presented at 3 months of age with developmental 
delay, seizures, generalised weakness, abnormal reflexes and cranial nerve palsies. Sensory 
studies were normal and motor nerve conduction studies were marginally slow (median nerve 
MCV 35 metres / second; ulnar nerve MCV 28 meters/second; common peroneal nerve MCV 
31metres / second). EMG suggested denervation. Nerve biopsy at 1 year of age was more 
suggestive of an axonopathy with reduced myelinated fibre density than the recognised 
demyelination which occurs with Leigh disease.  
Leukodystrophy – unclassifiable (n=2) Two infants presented with developmental 
delay from birth. The first had failure to thrive, seizures, hypotonia and microcephaly. Nerve 
conduction studies were slow (median nerve MCV 17 metres / second; ulnar nerve MCV 20 
metres / second; common peroneal nerve MCV 15 metres / second) and sensory potentials 
could not be elicited. Demyelination and sudanophillic deposits suggestive of leukodystrophy 
were seen on nerve biopsy. The second was floppy from birth with developmental delay, 
ataxia, ophthalmoplegia and Hirschsprung disease. Conduction studies were also slow 
(median nerve MCV 25.5 metres / second; absent sensory action potential amplitudes). 
Lysosomal enzyme analysis for metachromatic and Krabbe leukodystrophies were negative in 
this patient. There was a markedly reduced density of myelinated fibre, with demyelination and 
onion bulb formations. The clinical and histological features of this patient were similar to a 
recently described case with a SOX10 mutation (395) or POLIP syndrome (polyneuropathy, 
ophthalmoplegia, leukoencephalopathy, intestinal pseudo-obstruction)(396) . The mutation 
analysis was not available for this patient. 
Neurodegenerative disorders (n=5) Five patients had undiagnosed 
neurodegenerative conditions. Two had demyelination and three had axonal degeneration on 
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developmental delay and infantile spasms. Nerve conduction studies were normal apart from 
marginal slowing of the median motor nerve conduction velocity (43 metres / second). Nerve 
biopsy at 7 years of age identified demyelination on transverse section and onion bulb 
formations and clusters on electron microscopy. His muscle biopsy was normal. The second 
patient had a similar picture but was felt to have an underlying disorder of mitochondrial 
function. This patient’s nerve conduction studies were also slow (median nerve MCV 30 
metres / second; common peroneal nerve 28 metres / second) with normal sensory studies 
and EMG. Demyelination was most evident on teased fibre analysis on nerve biopsy at one 
year of age. The patients with axonal pathology on biopsy included a boy who presented at 3 
months of age with developmental delay, regression and hypotonia. He was diagnosed at a 
time when white cell enzyme studies were not available. Hence, although his clinical picture 
appeared consistent with Krabbe disease, there were several discrepancies, in particular an 
axonopathy on sural nerve biopsy. The other two patients presented at birth. One was 
hypotonic, irritable, had recurrent vomiting, respiratory dysfunction, motor delay and apparent 
absence of peripheral sensation evident by three months. The other patient was floppy with 
developmental delay, dystonia, bulbar dysfunction, failure to thrive and optic atrophy evident 
by four months. Again these patients were managed very early in the study before detailed 
molecular and mitochondrial studies were available.    
Arthrogryposis multiplex congenita (n=4) All four of these male infants had nerve 
biopsy features of axonal pathology. One, who had biopsy findings of a marked decrease in 
MF density with cluster formations, was static clinically. The other three had progressive 
conditions with central nervous system involvement. 
Spinal muscular atrophy (n=5) Sixteen patients, who had nerve biopsies, were 
subsequently found to have spinal muscular atrophy. Of this group five had features of axonal 
degeneration on sural nerve biopsy. These five infants presented at birth with severe 
weakness. Two had contractures and these bear similarities to the cases described by 
Korinthenberg et al.(328) Nerve conduction studies were performed in one, confirming abnormal 
sensory action potentials with median nerve motor conduction between 10-24 metres / second 
and absent common peroneal nerve conduction velocity. Denervation was found in the two 
who underwent electromyography. All had biopsies performed under 4 months of age and all 
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was evident in 4 out of 5. DNA analysis, performed in one patient, confirmed a deletion of the 
SMN gene on chromosome 5. Most of these patients presented prior to the time genetic 
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DISCUSSION 
Peripheral neuropathy in infancy is an uncommon entity. In this series a similar 
incidence of axonal and demyelinating pathologies occurred. Inherited rather than acquired 
causes predominated.  
Charcot Marie Tooth type 1 (CMT1), more commonly recognised in the older 
population, may also have its onset in infancy. (29,31) Seven infants from our series were 
affected, six of whom had confirmation on molecular genetic testing.  
Seven of our patients had clinical features of CMT3 with six of them confirmed to have 
myelin protein zero (PO) or PMP22 point mutations. It is striking how high the genetic yield is 
for these patients with early infantile presentation. A review of hereditary demyelinating 
neuropathy in infancy described nine patients with clinical features consistent with CMT3. (391) 
There was molecular genetic confirmation in six. In the present study peripheral nerve biopsy 
identified 2 of the nineteen infants as having HMSN with myelin out-folding (CMT 4B). In 
approximately half of such patients mutations of the myotubularin gene have recently been 
identified (123), while other scattered cases have been associated with MPZ mutations. In the 
remainder this diagnosis can only be made on nerve biopsy. One of our patients was found to 
have an MPZ mutation. The other has not yet been tested.  
Respiratory dysfunction secondary to phrenic nerve involvement is described in a 
number of neuropathies including CMT3 (392,393), HMSN with myelin out-folding (CMT4B) (391) 
and severe infantile axonal neuropathy with respiratory failure (106) or SMA with respiratory 
distress.(108)  Biopsy may be the only way to differentiate these neuropathies if all molecular 
genetic studies are negative. 
Four of the infants with arthrogryposis multiplex congenita (AMC) had axonal 
degenerative features on nerve biopsy. Most cases of AMC do not have associated 
neuropathies but small groups have been described who have nerve pathology attributed to 
in-utero insults.(397)  
Axonal degeneration involving sensory nerves is described in spinal muscular 
atrophy.(398) Theories as to why there is sensory involvement in a motor condition include SMA 
being a more generalised condition than previously accepted or the loss and degeneration of 
sensory fibres occurring secondary to immobility.(398) Sensory nerve changes were detected in 
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myelinated fibre loss were seen on biopsy. These patients bear similarities with the described 
condition SMA with congenital contractures.(328) Sensory nerve axonal degeneration was 
described in patients with the most severe form of SMA (type 1) and not type 2 or 3.(370) 
Our patients with pure demyelination and / or hypomyelination were more likely to 
conclude with a definitive diagnosis, often confirmed through molecular genetics. When 
investigating these patients nerve biopsy is rarely indicated unless the molecular genetic, 
metabolic and neurodegenerative screens are negative. However the classification and 
inheritance of axonal neuropathies in infancy and childhood remain less well delineated.  
 Recommended investigations for peripheral neuropathy with onset in infancy or 
childhood have become more sophisticated and extensive with time (256). Compared to earlier 
practices peripheral nerve biopsy (as an invasive procedure) needs to be performed less often 
with the availability of molecular genetics. Patients in our series with undiagnosable 
neurodegenerative disorders would almost certainly be diagnosed today, especially with 
increased recognition of mitochondrial disorders, availability of white cell enzyme screens and 
fibroblast cultures.  
An approach to the infant with suspected peripheral neuropathy would be based 
initially on clinical and electrophysiological evidence (Algorithm 4.1). A combination of 
hypotonia, areflexia, distal contractures and muscle weakness more marked distally, 
especially with inappropriate response to pain, would be suggestive of peripheral neuropathy. 
A positive family history should be sought. Peripheral electrophysiology must be performed in 
a centre skilled in infantile studies and in the interpretation of the results. Performing motor / 
sensory studies in infants can be distressing. In our laboratory, they are performed with nitrous 
oxide inhalation for analgesia. Placement of electrodes should be accurate and is often 
problematic in unco-operative patients. The interpretation must be made with caution as the 
normal ranges vary significantly until five years of age when the nerve conduction velocity 
approaches adult levels.(276) In some infants with axonal degeneration and a paucity of large 
diameter fibres, nerve conduction velocity may be in the so-called “demyelinating range” 
leading to fruitless exploration for myelin protein mutations. Further, axonal pathology does 
not always result in measurable abnormality in nerve conduction e.g. in small fibre 
neuropathies such as HSAN types 4 and 5. Thus if the clinician has sufficient clinical evidence 
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Once peripheral neuropathy is confirmed an underlying cause can be sought. Patients should 
be divided into those with and without central involvement for the infantile range. The group 
without central pathology will be dominated by the hereditary motor sensory neuropathies. A 
smaller number, not seen in our study may have acquired causes (Guillain-Barré syndrome, 
toxic, infectious (diphtheria) and nutritional deficiency states (vitamin B12, thiamine and vitamin 
E). Molecular genetic studies usually identify a diagnosis for the demyelinating CMT patients. 
The axonal pathologies are less likely at the present time to have diagnoses which can be 
confirmed by molecular genetic studies, resulting in more nerve biopsies either to confirm the 
diagnosis of a polyneuropathy in the situation of normal NCS or to delineate the nature of 
nerve pathology (such as with toxin induced neuropathy, giant axonal neuropathy and some 
neurodegenerative disorders; infantile neuroaxonal dystrophy). 
Patients with central involvement should be further subdivided into those with 
predominantly white and grey matter disease. White matter disorders will be dominated by the 
leukodystrophies, especially metachromatic leukodystrophy. Lysosomal enzyme studies 
generally confirm the diagnosis. Proceeding to nerve biopsy may only be necessary in 
patients with pseudodeficiency of arylsulphatase. Grey matter diseases include mitochondrial 
disorders (Leigh disease), neuroaxonal dystrophy and giant axonal neuropathy. Extensive 
screening investigations fail to achieve a clear diagnosis in some infants. Proceeding to nerve 
biopsy in these cases may provide the answer (e.g. giant axonal neuropathy without curly hair 
and neuroaxonal dystrophy). A number of patients with neurodegenerative conditions of 
unknown cause are found in most units. For the patients with additional central disease there 
is the potential for more information and the clinician should consider the role of skin, muscle 
and nerve biopsy in such patients already committed to a general anaesthetic to ensure the 
maximum information is collected. Storing histopathological material in these patients is 
essential as science advances and new diagnostic tests become available.  
The role of muscle biopsy of patients with peripheral neuropathy is debatable. 
Generally the additional information for the pure peripheral neuropathies of axonal type is 
limited. Most of these patients will have a denervation pattern of grouped fibre atrophy. It is 
possible that the tempo of the disease progression could be more easily predictable on the 
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With the rapid progression of molecular genetics and available enzyme studies the 
need for peripheral nerve biopsy has steadily decreased. There are patients however, who will 
remain undiagnosed without this investigation. In the correct context peripheral nerve biopsy 
still has a role in both diagnosis and prognosis. That role includes:-  
i. The confirmation of small fibre neuropathies such as HSAN types 4 and 5, where 
conventional nerve conduction studies are normal. 
ii. The delineation of specific diagnostic pathologies in conditions where DNA analysis is 
unavailable or unhelpful such as certain autosomal recessive forms of CMT, some 
cases of CMT with myelin outfolding, giant axonal neuropathy with normal hair and 
neuroaxonal dystrophy. 
iii. The proof that the degenerative process is in fact demyelinative or axonal when nerve 
conduction studies are misleading, as occurs more frequently in infants than in older 











Peripheral Neuropathies of Childhood Jo M Wilmshurst 
Thesis presented for the Degree of Doctor of Medicine 
 141 
Algorithm 4.1: An approach through nerve conduction studies to Charcot Marie Tooth diseases (Hereditary Motor and Sensory Neuropathies). 
Median motor NCV           Median motor NCV                     Median motor NCV 
         ≤ 12 m/sec      >12 m/sec & < 60%lower limit of normal for age*           ≥ 60%lower limit of normal for age 
    å       æ            å            æ            å    æ 
17p duplication         17p duplication 17p duplication      17p duplication   å            Axonal  
      negative                                positive        positive                            negative     å                forms 
  å         æ          â     å             å       æ    å                     of CMT 
P0 mutation    PMP22 mutation    â         å          Mitofusin 2 mutation Mitofusin 2 mutation 
    present            present                           CMT1A                             negative                      present 
        â          â                      å  æ   æ 
CMT1B    CMT1A     Connexin 32       Connexin 32  EOHMSN 
or CMT3        or CMT3         negative                                positive 
       å       â       æ                     â 
               P0          PMP22           P0 and PMP22               X-linked 
          mutation            mutation               mutations         CMT 
          present    present                  absent    
                  å         â                   â        æ  
          CMT1B    CMT1A      Autosomal       Autosomal  
                                  dominant       recessive  
                                   kindred                kindred  
                                                â         å         æ  
                                 CMT1C CMT4B (HMSN     Other recessive 
                                    with myelin       demyelinating 
                                         outfolding)        CMT  
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CHAPTER 5 
Review of Patients managed at Red Cross Children’s Hospital 
Neuromuscular service with Peripheral Neuropathies 
SUMMARY 
There is paucity of data relating to the occurrence of peripheral neuropathy in children 
from South Africa. Over a nine year period 123 children were managed in a dedicated 
paediatric neuromuscular service. Forty-four of them had hereditary causes and seventy-nine 
had neuropathies related to acquired causes. Most of the children with acquired causes had 
acute inflammatory demyelinating polyradiculoneuropathy (n=54) with a high incidence 
following Campylobacter or Mycoplasma infections. Five children from the group were 
referred with peripheral neuropathy related to the toxic side-effects of antiretroviral therapy for 
human immunodeficiency virus infection. Of the children with hereditary causes very few had 
CMT1A (n=4), whilst the majority had axonal forms of neuropathy (n=36), mostly from the 
CMT2 group (n=10). Sural nerve biopsies were performed on 15 children and were of use in 
all, either confirming the diagnosis or reinforcing the category suspected from the clinical and 
neurophysiological findings. Molecular genetic screens were performed in 22 of the children 
and resulted in a diagnostic label in 11. In two patients there were conflicting results where 
the molecular genetic results did not correlate with the patient’s phenotype. The study 
confirmed that peripheral neuropathies do occur in the paediatric South African population; 
the predominance of acquired causes illustrated the multitude of infectious triggers prevalent 
in the country. The hereditary causes reflected the common groups of CMT but differed in the 











Peripheral Neuropathies of Childhood Jo M Wilmshurst 
Thesis presented for the Degree of Doctor of Medicine 
 143 
INTRODUCTION 
 The previous chapters illustrate the range of peripheral neuropathy prevalent in a 
setting where extensive investigations are possible (chapters 1, 3 and 4). Chapter 2 
summarised the optimal method to obtain successful results when performing a nerve biopsy. 
The following chapter aims to use the preceding information to support analysing a cohort of 
patients from a relatively resource-limited setting and in different ethnicities from the Austalian 
patients discussed in chapters three and four. In addition inclusion of all patients in this study 
with chronic peripheral neuropathy, whether they have undergone a nerve biopsy or not, may 
give more comparable results of the demographics of childhood neuropathies which occur in 
this setting. 
There is no data to clarify the prevalence of peripheral neuropathy, especially chronic 
cases in the South African context. There is a need to identify primarily which neuropathies 
are commonly managed, and to establish whether a comparable range of hereditary 
conditions occur or, if as occurs with other conditions in South Africa, the acquired conditions 
dominate. This reflects the poor socioeconomic setting where many children have limited 
access to health facilities, poor nutrition, and frequent infections (e.g. tuberculosis, human 
immunodeficiency virus and streptococcal infections). 
Similarly there are few studies from other parts of Sub-Saharan Africa addressing 
peripheral neuropathies and none dedicated to hereditary neuropathies in children. A study 
from Libya reviewed their cohort of patients with neuromuscular disorders and identified that 
the largest group had forms of CMT followed by AIDP.(399) They estimated a population CMT 
prevalence of 7.9 per 100,000, with CMT1 at 6.4 and CMT2 at 1.5. This study combined 
paediatric and adult data. A study from Senegal in adults between 20-40 years described 
“tropical neuropathies” as responsible for half their cases, followed by toxic neuropathies 
(ethanol and isoniazide), then CMT and finally diabetes.(400) Another study from the same 
group quoted that 8.16% of their neurology referrals were related to peripheral neuropathies. 
The age range screened was 3-80 years, so a proportion of the group were children.(401) 
Molecular genetic analyses for peripheral neuropathies are limited in South Africa 
(SA) to screening for CMT1A and hereditary neuropathy with liability to pressure palsies 
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capacity to send samples abroad but those from the government sector cannot undertake this 
activity because of the cost implications. Fewer and fewer centres internationally are offering 
support to resource-limited centres for molecular genetic screens which are viewed as a 
routine service overseas. Countries such as South Africa are at risk of falling behind in the 
diagnostic wave of genetic screens identified over the last 10 years alone. There are 
treatment and management implications necessitating the correct identification of the specific 
mutations which patients carry. 
Neurophysiological studies are limited to a few centres that may not be skilled in 
performing and interpreting studies on children – this challenges the interpretation of such 
results. 
Pathological samples are rarely assessed further reflecting the limited resources for 
analysis and interpretations. 
The Red Cross Children’s Hospital, located in Cape Town, South Africa, is the tertiary 
paediatric referral hospital for the Western Cape Province (population 5.26 million total; 1.5 
million children 0-14 years of age).(402) It is the paediatric teaching hospital of the University of 
Cape Town. The hospital functions as a national referral centre for complex paediatric 
neurological disorders (population 48 million total; 15.7 million children 0-14 years of age)(402) 
and receives referrals from other countries in Sub-Saharan Africa. The neuromuscular service 
is supported by competent histopathology and neurophysiology departments. Molecular 
genetic screens remain limited to CMT1A and HNPP within SA but the service has been 
supported over the years by other international centres allowing government patients a wider 
access than would otherwise have been available elsewhere in the country for some of the 
essential screens. The principal investigator (JMW) operates the neuromuscular service 
through a weekly clinic. Since the author commenced as head of the paediatric neurology 
service at the Red Cross Children’s Hospital in 2000, all patients have been assessed and 
followed up by her. The clinic staff include a paediatric neurology consultant, a 
physiotherapist and a neurology trainee (senior registrar). 
Based on patient data collated over the last 9 years (2000-2009), this study plans to 
review the types of peripheral neuropathies managed in our service, to summarise the forms 










Peripheral Neuropathies of Childhood Jo M Wilmshurst 
Thesis presented for the Degree of Doctor of Medicine 
 145 




As part of standard practice a database of all patients managed through the 
neurology service has been recorded since 2000 by the author (n=3581). This data has 
provided essential information mainly related to service needs and administrative statistical 
data to ensure services are not cut. Patients are aware that a short summary of their clinical 
diagnoses is recorded and this database is invaluable in emergency settings when medical 
folders are unavailable. Use of this database for the purposes of this study was passed by the 
ethics committee of the University of Cape Town. From this database, patients with 
neuromuscular disorders were selected. From this group, a subgroup of patients with chronic 
peripheral neuropathies was selected. This group was defined by patients with chronic 
symptomatology requiring regular outpatient follow-up. Patients with acute neuromuscular 
disorders were not included. These included patients with typical forms of acute inflammatory 
polyradiculoneuropathy who may have required only one outpatient assessment before 
deemed fully recovered.    
Demographic data were recorded including sex, ancestry (indigenous African, European 
and *mixed), age, clinical features (degree of disability), interventions, neurophysiological 
findings, molecular genetic screens and histopathology if performed. Other investigations 
relevant to the patient were recorded. 
Based on these findings patients were divided into two groups – hereditary and acquired, 
using the diagnostic data in Tables 1.2 and 1.3 as a guide. Peripheral neuropathies were 
defined according to standard guidelines.(44,260,278) Particular attention was placed on the 
findings of two main areas: 
1. The sub-divisions of the hereditary group leading to possible or definitive diagnoses  
2. The frequency of children with human immunodeficiency type 1 (HIV-1) - related 
neuropathies, as this condition has such relevance in our context. 
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*"Mixed" ancestry includes people of predominantly Asian or indigenous Khoi-San descent, 
who have diverse but not necessarily mixed African / European ancestry 
 
RESULTS: 
From a database of 3581 children managed in the neurology service between 2000 
and 2009, 371 attended the neuromuscular service; of this group 123 carried a diagnosis of 
peripheral neuropathy. Forty-four children (36%) had hereditary causes for their peripheral 
neuropathy (Figure 5.1) and 79 were considered to have acquired disorders.  
HEREDITARY DISORDERS (n=44)  
(25 female: 19 male)  
Indigenous African n=10; European descent n=19; mixed n=15) 
Figure 5.1 


































































































No molecular genetic diagnosis molecular genetic diagnosis
 
Of the total group, thirty-six patients had axonal pathology; seven demyelinating and 
one could not be defined. This last patient was categorised in the axonal group based on his 
clinical presentation. Median age for symptoms to arise was three and a half years of age with 
a range from 0-10 years. Fifteen children underwent peripheral nerve biopsy – this was either 
specifically requested as part of their diagnostic screens or performed as an additional 
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tendon releases) (Table 5.1). Fourteen of the fifteen peripheral nerve biopsies identified 
pathology. Twenty-two children had molecular genetic screens sent for analysis with 
diagnostic results returned in eleven.  
 
Demyelinating CMT sub-groups n=6 
CMT1A (n=4) (3 female: 1 male). Median age at presentation with symptoms was 72 
months (range 36-120 months). Two were of European descent and the others were of mixed 
ancestry. There were no patients of indigenous African origin. Three had a positive family 
history. All had distal weakness, distal contractures and depressed or abnormal deep tendon 
reflexes (DTR) (Figure 5.2). One had scoliosis, two had pes cavus and three had sensory 
alteration. One patient had bilateral hip dysplasia. This complication was considered related 
to her underlying CMT1A and is described in other children with CMT1A.(403-405) Nerve 
conduction studies confirmed a demyelinating neuropathy in all based on the motor studies. 
The sensory nerves could not be stimulated. Median values for motor conduction were 
median 12.9 metres / second (range 10-18.6 metres / second), ulnar 13.1 metres / second 
(range 12.6-13.7 metres / second) and common peroneal 8 metres / second. One patient 
underwent sural nerve biopsy whilst undergoing an anaesthetic for lengthening of her achilles 
tendon – she had typical features with reduction in her MF density, onion bulb formations and 
thin myelin (Figure 5.3). Another girl had a nerve biopsy from her index finger digital nerve 
taken whilst undergoing hand surgery. Her biopsy confirmed reduced myelinated fibre 
density, thin myelin, a few tomaculous myelinated fibres and multiple onion bulb formations. 
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Figure 5.2: Patient with confirmed CMT1A. He has an affected father. Note the typically 
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Figure 5.3: Light microscopy toluidine blue stain of the sural nerve from a female patient with 
confirmed CMT1A (magnification x400). The sample confirmed reduced myelin fibre density, 
both thinly as well as excessively thick myelinated fibres and occasional onion bulb 
formations.  
 
CMT3: One female patient (mixed ancestry) presented from birth with profound distal 
weakness and hypotonia. She developed multiple complications from her disorder with 
recurrent chest infections, scoliosis and lost ambulation at a young age (Figure 5.4). She 
underwent several orthopaedic interventions. Despite multiple siblings there were no other 
affected family members. Her nerve conduction studies failed to stimulate any responses in 
her motor or sensory nerves. Light microscopy and electron microscopy of her sural nerve 
biopsy at the age of two years detected multiple onion bulb formations involving every 
myelinated fibre; her MF density was reduced and there was thinning of her myelin (Figure 
5.5). Her teased fibre analysis detected ovoid formations consistent with secondary axonal 
degeneration. Her electron microscopy examination confirmed multiple onion bulb formations 
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studies suggested CMT1A, but as this result was conflicting with her phenotype, she was 
categorised CMT3 based on her clinical, neurophysiological and histopathological findings. 
Figure 5.4. Affected patient with CMT3 phenotype at the age of eight years demonstrating her 
non-ambulant state and the severe distal involvement with ulnar deviation and clawed hands 
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Figure 5.5: Light microscopy toluidine blue stain of the sural nerve from the patient with 
clinical phenotype of CMT3 but molecular genetic diagnosis of CMT1A. The sample 
confirmed a moderate reduction in myelinated fibre density, many thinly myelinated fibres and 
multiple onion bulb formations.(Magnification x400)  
 
Figure 5.6. Electron microscopy appearance from the same patient with CMT3 demonstrating 
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Hereditary neuropathy with liability to pressure palsies (HNPP) (n=1) One female 
patient of indigenous African descent presented aged 2 years with frequent falls and proximal 
weakness. She had wasting of her thenar and hypothenar eminences, contractures of her 
achilles tendons, sensory loss, and depressed DTR. She did not have a history of intermittent 
palsies. She did not have any other affected family members. Due to her proximal weakness 
she was suspected to have a myopathy, although her creatine kinase was normal and her 
genetic screen for Spinal Muscular Atrophy was negative. She underwent a muscle biopsy 
which suggested neurogenic disease with evidence of denervation. Her nerve conduction 
studies confirmed absent sensory potentials and very delayed median distal latency and 
conduction velocity. Similarly, the common peroneal velocity was very slow with a reduced 
amplitude and her posterior tibial response was absent. Repeat study 5 years later detected a 
median conduction velocity of 13.9 metres / second. Her molecular genetic screens were 
negative for CMT1A but confirmed the deletion in the region consistent with HNPP. Her 
clinical phenotype is a little unusual but without a nerve biopsy, which might have shown 
tomaculous changes, confirmation of the genetic diagnosis could not be taken further. The 
family were hesitant to proceed to biopsy as it would not alter her direct management.  
 
Axonal CMT sub-types n=32 
CMT2: (n=10) (5 female: 5 male). Median age at onset of symptoms was 60 months 
(range 0-120 months). Five were of mixed ancestry and five of European descent. Family 
history was positive in six patients and correlated with an autosomal dominant pattern of 
inheritance. All presented with distal weakness, in addition to distal contractures (n=8), 
hypotonia (n=1), scoliosis (n=2), sensory loss (n=6), pes cavus (n=3) and depressed or 
absent DTR (n=5) (Figure 5.7). Unusual features included learning difficulties (n=2) and 
congenital equinus foot deformities (n=1). Nerve conduction studies were consistent with 
axonal pathology in all with reduced amplitudes and normal (n=6) or mildly slowed common 
peroneal conduction velocities (n=4 range 32.2-36.8 metres / second), sensory studies were 
abnormal in four patients. Two patients underwent sural nerve biopsy. One sural nerve biopsy 
was within normal limits in a patient with a clinical phenotype consistent with a peripheral 
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who was symptomatic from 5 years of age; his father was affected with the same condition. 
His sensory studies were abnormal. His motor studies confirmed reduced amplitudes and 
prolonged distal latencies with conduction velocities of 39.7m/s for the median nerve and 
36.8m/s for the common peroneal nerve. His sural nerve biopsy detected major axonal 
degeneration involving both myelinated fibres and unmyelinated fibres, with Bands of 
Büngner typical of an axonal degenerative and regenerative process; there were no onion 
bulb formations or abnormally thinned myelinated fibres (Figure 5.8). His molecular genetic 
screen detected CMT1A, and was duplicated on his repeat study in the same laboratory. In 
the light of his phenotype not concurring with this genetic diagnosis there remains some 
conflict as to his correct category.  
 
Figure 5.7: Appearance of hands from affected father and son with CMT2. Note the 
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Figure 5.8: Electron microscopy appearance from the patient with neurophysiological findings 
consistent with an axonal process but with a molecular genetic diagnosis of CMT1A. 
(Magnification x3000) The sample demonstrates reduced myelinated fibre density, adequate 
myelin thickness in the remaining fibres, axonal degeneration and numerous unmyelinated 
fibres, of which one group associated with a Schwann cell nucleus would be consistent with a 
Band of Büngner (B of B). 
 
Early onset neuronal hereditary motor sensory neuropathy (EOHMSN) (n=5). All 
children were female: two were of indigenous African descent, two were of mixed ancestry 
and one was of European ancestry. They presented between two and five and a half years of 
age (median three years) with severe progressive disability. One underwent ten orthopaedic 
surgical interventions (Figure 5.9). They required significant support at school as they were 
limited for independent functions and in their activities of daily living. Clinical features 
consisted of distal contractures (n=5), ataxia (n=1), hypotonia (n=3), scoliosis (n=2), distal 
weakness (n=5), additional proximal weakness (n=2), sensory loss (n=4), pes cavus (n=2) 
and absent DTR (n=3) (Figure 5.10 a and b). The child who presented from 2 years of age 
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had additional cognitive learning disabilities. She had a rapidly progressive course and aged 
13 years was wheel-chair dependent with marked limitations in her activities of daily living. 
Their nerve conduction studies revealed abnormal sensory studies (n=4) and markedly 
reduced amplitudes and distal latencies with conduction velocities in the demyelinating (n=2), 
axonal (n=1) and normal (n=1) range. One patient had absent responses. Sural nerve biopsy 
performed in four confirmed active axonal degeneration, reduction in the myelinated fibre 
density and one patient in addition had onion bulb formations detected (Figures 5.11, 5.12a 
and b). Abnormal mitochondrial aggregations were detected in one of the patients (Figure 
5.13). One family considered mitofusin analysis but the cost was too great for them and the 
child’s DNA remains stored. Another child was negative for CMT1A mutation. 
 
Figure 5.9: Clinical phenotype of patient with EOHMSN. Distal wasting is evident as well as 
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a b 
Figures 5.10 (a and b). Clinical phenotype of the other patient with EOHMSN with extreme 
distal wasting. 
 
Figure 5.11: Light microscopy appearance (toluidine blue stain, magnification x400) from the 
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Figure 5.12 (parts a and b): Light microscopy of appearance of the sural nerve from the 
second patient (Figure 5.10) demonstrating reduced myelinated fibre density, onion bulb 
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Figure 5.13: Electron microscopy from the patient in Figure 5.10 demonstrating abnormal 
mitochondrial aggregations at the periphery of the axon. (Magnification x30000) 
 
Congenital axonal neuropathy (n=1) This female child of mixed ancestry was born to 
well parents with extreme hypotonia evident from birth. She had some respiratory 
compromise but did not require ventilation and had no diaphragmatic involvement. She had 
dislocated hips at birth. She stabilised and gradually appeared to improve; she clearly had 
marked distal weakness in addition to her generalised condition. By 17 months of age she 
was standing and climbing, she remained of very small build, with her mouth open and 
drooling. Her nerve conduction studies aged one year revealed normal sensory ulnar studies 
and absent sural responses. Her common peroneal distal latency was delayed, with a 
reduced amplitude of 0.5mv, and normal conduction velocity, her posterior tibial conduction 
velocity was 24 metres / second, amplitude 4mV, distal latency mildly delayed at 2.88ms. Her 
ulnar responses were normal. These findings were considered consistent with an axonal 
process. Her phenotype is similar to the patients with arthrogryposis multiplex congenital 
(AMC) who improved with time, although those patients had hypomyelinating disorders.(406,407) 
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Axonal miscellaneous: One girl of European descent presented in her first decade with 
scoliosis (Figure 5.14 a and b). Her family had noted an altered gait since she was 13 months 
of age. Despite this she had functioned well participating in school sports and only became 
limited when she developed her scoliosis. This was aggressive and of rapid onset. The 
curvature became so marked that within 2 years she had developed a respiratory restrictive 
defect and was hypoventilating. Magnetic resonance imaging (MRI) of her spine identified a 
tethered cord. This was released but the scoliosis persisted. Spinal rods were inserted with 
excellent results allowing her to return to her previous level of functioning with limited and 
slow progression over the last 2 years. Her clinical phenotype has remained a challenge to 
categorise. She had distal contractures, distal weakness, sensory alteration, depressed DTR, 
pes cavus, and swallowing difficulties. She also had a tendency to bleed and bruise easily but 
an extended screen of her bleeding function was normal. Her nerve conduction studies 
detected normal sensory values. Her motor studies recorded delayed motor conduction (44.3 
metres / second common peroneal), reduced amplitudes and distal latencies suggestive of 
axonal disease. Muscle biopsy identified evidence of a neurogenic process on the muscle 
screen. Her sural nerve biopsy was normal. This girl appears to have an axonal process 
predominantly affecting her motor nerves. The combination with scoliosis and swallowing 
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Figure 5.14a  
 
 
Figure 5.14b  
 
 
Figure 5.14 parts a and b. Appearance of the girl with miscellaneous axonal disease. She had 
wasting of her thenar and hypothenar eminences (a) as well as high arches and wasted 
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SIANR (severe infantile axonal neuropathy with respiratory failure) / SMARD1 
(spinal muscular atrophy with respiratory distress type 1) (n=2) One male infant of 
European descent presented aged 3 months with a typical phenotype of SIANR (Figure 
5.15).(106) His genetic testing confirmed the IGHMBP2 mutation.(108) He had a paralysed 
diaphragm, no movement in his lower limbs and marked weakness distally in his upper limbs. 
He had features of autonomic dysfunction. He was discharged on a home ventilation 
programme. Aged 4 years he was cognitively intact and his family were planning his school 
placement. The second child was a female of mixed ancestry who presented aged 3 years 
with a paretic hemidiaphragm which was initially managed with a Nissen’s fundoplication 
intervention (Figure 5.16 and 5.17). When her respiratory dysfunction persisted, she was 
referred to a respiratory specialist who noted diaphragmatic dysfunction and in addition distal 
weakness and a myopathic facies. Her respiratory compromise increased such that she 
started nocturnal ventilation from 5 years of age. Her clinical state slowly deteriorated with 
ongoing distal weakness limiting (but not stopping) ambulation. She developed a marked 
scoliosis but did well following spinal surgery. Aged 13 years she continues to perform well at 
school and remains ambulant (except for long distances) and dependent on intermittent 
ventilation. Her nerve conduction studies recorded normal sensory potentials and delayed 
motor conduction velocities (common peroneal 43 metres / second) with reduced amplitudes 
(1.5mv). Her sural nerve biopsy detected axonal degeneration with preservation of the 
myelinated fibre density. Her phenotype is similar to that described in a juvenile form of 
SMARD1 (327) but her genetic screens did not detect the typical IGHMBP2 mutation. Extended 
screens from her and her family for possible point mutations are being analysed, courtesy of 
Professor Christof Hübner, in Germany. Other conditions with such diaphragmatic 
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Figure 5.15: Patient with SIANR genetically confirmed to have SMARD1 mutation aged 9 
months. He had limited head control and shoulder movements and no voluntary movements 
in his distal upper limbs or lower limbs. He was completely ventilator dependent. 
Figure 5.16: Patient with the juvenile form of SIANR demonstrating her distal wasting. She 
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Figure 5.17: Chest X-ray from the patient with juvenile SIANR demonstrating an elevated left 
hemidiaphragm. 
 
Distal SMA / Hereditary Motor Neuropathy (HMN) (n=2). Twin boys of Indigenous 
African ancestry presented aged four years with progressively abnormal gaits. They had distal 
weakness, contractures and reduced DTR. They had learning difficulties from the onset but 
appeared to have cognitive regression with time. Their greatest complaint was progressive 
deterioration in their vision associated with optic atrophy. They were both non-ambulant by 15 
years of age. Metabolic and mitochondrial screens were unremarkable, magnetic resonance 
imaging of one of their brains was normal. Nerve conduction studies detected normal sensory 
potentials, but the motor responses could not be stimulated, EMG detected fibrillations 
suggestive of denervation. A predominantly motor axonal process was suspected. Their VEP 
was abnormal, but ERG was within normal limits. Sural nerve biopsy detected axonal 
degeneration with no abnormal storage material. These boys had a neurodegenerative 
disorder but their major disability related to their peripheral neuropathy and optic atrophy. 
Conditions with these aspects and the cognitive involvement would include CMTX5 (deafness 
has not been excluded in them)(143,148,149), CMT2A / HMSN VI (this would not explain their 
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could be relevant)(75,77,252) and CMTX4 (but the lack of clinical sensory involvement limits 
this)(142). 
CMT5 (n=7) Four female and three male children had the clinical phenotype of 
CMT5, five were of European ancestry, one was of mixed descent and one was of indigenous 
African ancestry. Onset was from birth in two who had increased tone and abnormal foot 
posture. The remainder presented between nine months and seven years of age (median five 
years). The seven year old child had long standing “odd feet” noted by her parents before she 
started to complain of pain in her feet and was investigated. One of the children with 
symptoms from birth was labelled “spastic quadriplegic cerebral palsy”. She was non-
ambulant and attending a special school for children with motor and cognitive deficits. She 
was always considered cognitively intact in comparison to her motor disability. Her mother 
became concerned when she realised her daughter’s disability was progressive. Following 
confirmation of the diagnosis CMT5 her mother transferred her to mainstream education 
where she is doing well with some special support. All children had distal weakness, 
associated in some cases with distal contractures (n=5), brisk DTR (n=6), scoliosis (n=1), 
hypotonia (n=1), sensory alteration (n=3), pes cavus (n=2), and more generalised weakness 
(n=1). Six children were cognitively intact and one had mild learning diffculties. One had a 
positive family history of autosomal dominant inheritance pattern. Nerve conduction studies 
detected abnormal sensory conduction (n=2) and moderately delayed conduction velocities 
with a median common peroneal value of 36.9 metres / second (range 34.0-39.1 metres / 
second) with reduced CMAP amplitudes and delayed distal latencies. The picture was axonal 
though approaching the intermediate range suggestive of a possible mixed picture.(150) None 
of the children underwent sural nerve biopsy and molecular genetic testing was not available. 
CMTX: (n=3) Three male children presented with features compatible with forms of 
CMTX, two were of European descent and one was of mixed ancestry. They developed 
symptoms when aged 18 months, 5 years and 10 years. All had a positive family history with 
mildly affected mothers and clinically affected male relatives through the maternal side. 
Clinical features consisted of distal weakness (n=3), additional generalised weakness in one 
(n=1), distal contractures (n=2), hypotonia (n=2), scoliosis (n=1), sensory alteration (n=2), and 
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course with dysmorphic features and in addition some learning difficulties. He failed to attend 
for further investigations or follow up but may have complied with the CMTX2 sub-group.(146) 
The absence of neurophysiological and nerve biopsy data limited categorising him, however 
his clinical phenotype complied with an axonal or mixed disorder (CMTX). The oldest boy who 
presented at 10 years of age complained of gait disability. His maternal uncle was examined 
and had a typical phenotype of a peripheral neuropathy for which he had undergone multiple 
orthopaedic interventions. His nephew had mild distal weakness and abnormal nerve 
conduction studies compatible with an axonal process. However his predominant 
complication was dystonia which progressed and eventually rendered him non-ambulant. 
Molecular genetic screen confirmed a DYT1 mutation. The last boy who presented aged 5 
years had typical features of CMT, with an extensive affected family tree. His nerve 
conduction studies recorded conduction velocities of 28.9 metres / second from the common 
peroneal nerve and 32.1 metres / second from the median nerve with reduced CMAP 
amplitudes. His picture was compatible with intermediate conduction velocities and if he had 
undergone a biopsy a mixed picture may have been seen. He and his family underwent 
molecular genetic screening overseas and were found to be negative for MPZ, connexin 32 
mutation, PMP22 duplication and deletion as well as point mutations. 
Congenital insensitivity to pain (n=1). One male child of indigenous African 
descent presented with symptoms from birth of apparent lack of pain awareness. He was 
dysmorphic with mental retardation; he was not weak but did have multiple scars from old 
injuries. He was unaware of pain or temperature. He did not appear to have autonomic 
dysfunction with normal blood pressure, sweating, salivation and tear production. His mother 
could only discipline him through throwing water at him. His nerve conduction studies were 
normal. Genetic screening was negative for Smith Magenis syndrome. He defaulted before 
sural nerve biopsy could be taken – a small unmyelinated fibre disorder could not be excluded 
without biopsy material and his phenotype could be compatible with hereditary sensory 
neuropathy type 2.(213)  Another child, of mixed ancestry, presented with a similar phenotype 
of apparent insensitivity to pain at 2 years of age. His parents related his lack of response to 
numerous painful stimuli including being bitten by the family dog. He apparently felt no pain 
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normally. He had old injuries mainly from burns on his hands and a scar from the dog bite on 
his face. His nerve conduction studies were normal. His sural nerve biopsy was normal both 
on light microscopy examination of his small and large myelinated fibres and electron 
microscopy screening of his unmyelinated fibres. In addition his skin and muscle biopsies 
were unremarkable. He improved with time becoming conscious of noxious stimuli such as 
burns. By 10 years of age had mild learning difficulties and attention deficit hyperactivity 
disorder. 
 
Neurodegenerative disorders (n=6) 
One female patient of indigenous African descent was managed long term for liver 
cirrhosis of unknown origin (she was jaundiced from birth). She required a liver transplant but 
her social circumstances precluded this. Aged 6 years she developed altered vision 
(especially at night) and gait impairment (foot drop). She had progressive learning difficulties, 
external ophthalmoplegia, ptosis, depressed DTR and night blindness. She lost ambulation 
aged 10 years. Her vitamin E levels were extremely low at 0.17mg/l (normal range 4.22-16.8 
mg/l) but replacement therapy did not improve her clinical state. Her nerve conduction studies 
detected normal sural potentials and common peroneal values delayed at 41.9m/s suggestive 
of an axonal process. Her muscle biopsy detected atypical clustering of mitochondria, 
grouping of type 1 fibres, hypertrophy of type 2, with some degeneration and necrosis; these 
findings were consistent with vitamin e deficiency. Her mitochondrial screens were 
unremarkable. Her muscle biopsy was thought compatible with AVED (familial vitamin E 
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Figure 5.18. Muscle biopsy Gomori immunohistochemical stain from the patient with Vitamin 
E deficiency demonstrating atypical clustering of mitochondria.(Magnification x200)  
A male patient of indigenous African ancestry presented at six months of age with a 
slowly progressive degenerative disorder. He had mental retardation, was ataxic and had 
optic atrophy. His power was globally reduced and his DTRs were brisk. He evolved dystonic 
posturing and by 14 years of age was noted to have distal contractures and was weak in his 
distal regions. His nerve conduction studies were previously normal. They were repeated and 
revealed common peroneal conduction velocities of 49.5 metres / second, with his amplitude 
reduced at 1.8 mV and distal latencies of 2.6 ms and absent posterior tibial responses. His 
sensory studies remained normal. His findings were consistent with an axonal degenerative 
process. His CSF protein was normal, but his CSF lactate on two separate occasions was 
raised at 15.6 and 15.8 mmol/l. Magnetic resonance imaging of his brain detected a 
leucoencephalopathy. His mitochondrial screens were negative for MELAS (A8344G, 
A3243G and T3271C), Leigh (T8993G and T9176C) and NARP (T3993C). Despite these 
negative results he was considered most likely to have an underlying mitochondrial 
disorder.  
Another male patient of European descent was known to have hypotonia and 
developmental delay evident from birth. He was initially considered to have hypotonic cerebral 
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botulinum injections and surgical intervention. He had failure to thrive, short stature, ataxia, 
retinitis pigmentosa, scoliosis, depressed DTR, pes cavus, sensory alteration and wizened 
facies. He developed a corneal pannus. His BSAER, VEP and ERG were abnormal. His 
nerve conduction studies recorded normal sensory potentials, whilst his motor studies 
recorded common peroneal conduction velocities of 10m/s, with an amplitude of 1.5mV; 
median conduction velocity of 13m/s, amplitude 3.8mV and ulnar conduction velocity 19m/s 
and amplitude 1.3mV, consistent with a demyelinating process. His genetic studies confirmed 
Cockayne syndrome.(295) 
The next male patient of indigenous African descent had hypotonia from birth. His 
sibling died some years previously and was described as having an identical phenotype to 
him. Aged 2 years he was dysmorphic with tapered fingers, triangular facies, small build. He 
held his mouth open drooling, had intermittent strabismus, and woolly hair. He had distal 
weakness and depressed DTR. His nerve conduction studies detected borderline low sensory 
potentials, whilst his motor studies recorded common peroneal amplitude reduced at 1.83mV, 
distal latency delayed at 3.52ms, and delayed conduction velocities of 42.7m/s; his median 
amplitude was normal but his distal latency was delayed at 2.62ms with conduction velocity of 
46.4m/s. His EMG recorded occasional positive waves. He was thought to a have a 
neurodegenerative axonal disorder and his phenotype was similar to Giant Axonal 
Neuropathy (GAN).(224,225) 
A female patient of mixed ancestry presented at four years of age with a rapidly 
progressive ataxic disorder compromising her activities of daily living. She was hypotonic, 
with distal weakness, absent knee DTRs and extensor plantar responses. She developed a 
marked scoliosis requiring intervention with spinal rod surgery at 10 years of age. Magnetic 
resonance imaging of her brain was normal, as were her cardiac and ophthalomological 
examinations. Her sensory and motor neurophysiology studies were abnormal. Her common 
peroneal motor conduction velocity was 25.2 metres / second, the amplitude 4.83 mV and the 
distal latency 6.88 ms. Her posterior tibial conduction velocity was 36.6 metres / second, 
amplitude 7.83 mV and distal latency 6.3 ms, and her median conduction velocity was 49.2 
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investigations confirmed a large triplicate repeat consistent with a diagnosis of Friedreich 
ataxia (FA). She remains relatively stable on maintenance idebenone therapy. 
The last male patient of European descent (Portuguese parents) had a history of 
craniosynostosis which was corrected surgically in infancy. He re-presented aged 10 years 
complaining initially of having difficulties controlling his left foot whilst playing football. This 
seemed to stabilise but was followed by rapid asymmetrical upper limb weakness. He had 
extreme loss of power initially distally then with proximal progression and winging of his 
scapulae became evident. Five years into his illness his speech became nasal and he had 
evidence of tongue fibrillations. His DTR were initially depressed, became brisk in the lower 
limbs and then, seven years into his illness, became depressed again. His cognition was 
preserved throughout. Eight years into his illness he had more involvement of his lower limbs 
though his predominant site of weakness was in his upper limbs. MRI of his brain and spine 
detected hydromyelia from T5-9, and mild cerebral and cerebellar atrophy. The spinal 
pathology would not explain his marked upper limb involvement. His nerve conduction studies 
detected normal sensory potentials, whilst his motor studies revealed absent common 
peroneal responses. His posterior tibial conduction velocities were normal at 47m/s with 
amplitudes of 5.33 mV and distal latency of 3.72ms. His EMG recorded denervation. His sural 
nerve biopsy at 10 years of age confirmed axonal degeneration with relatively preservation of 
myelinated fibres. His muscle biopsy detected denervation. His diagnosis is not finalised, his 
molecular genetic screens were negative for MPZ mutation and SMN deletion, with his SOD1 
mutation outstanding but considered unlikely to be diagnostic. Testing for senataxin mutations 
was not available.(412,413) He clinically complies with a sub-type of amyotrophic lateral 
sclerosis – ALS4 (allelic to dHMN).(181-183,183,414) He was originally considered to have 
Hirayama’s syndrome but his lower limb involvement made this unlikely. However this 
condition does have overlap with motor neurone disease described.(415-419) . Other differential 
diagnoses considered were CMT2D which has predominantly upper limb involvement(92,93), 
CMT2H since it has pyramidal involvement described(71) and CMT2K which has vocal cord 
involvement with a severe early onset(99,100). These forms of CMT cannot be completely 
excluded but his combined features remain more consistent with ALS4.    
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ACQUIRED (n=79)  
(34 female: 45 male)  
(40 indigenous Africa; 6 European; 33 mixed ancestries) 
Figure 5.19 






















This group was dominated by patients with AIDP (n=54), axonal forms predominated 
and were often secondary to Mycoplasma or Campylobacter infections. Median age of 
presentation was 40 months (range 8 months – 12 years) and duration of admission was 30 
days (range 2 – 220 days).  A proportion of the children were admitted for several months 
with their monophasic illness requiring ventilation support and tracheostomy (n=18). All 
eventually weaned off their tracheostomies with full respiratory recovery but minimal foot drop 
was typically seen up to a year post presentation. One patient had a phenotype of Miller 
Fisher syndrome. In six patients the features were compatible with CIDP with relapsing 
pattern of illness. 
Nine patients had forms of arthrogryposis multiplex congenita, most were 
syndromic with multiple pathologies, three were described previously for their unusual focal 
amyoplasia in the context of normal intelligence, lack of progression and apparent perinatally 
acquired pathology.(420)  Peripheral nerve involvement was suspected in these patients based 
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pathologies with muscle and anterior horn cell involvement could not be excluded. Further 
since definitive diagnoses were lacking in these patients with congenital disorders, a 
hereditary cause could not be completely excluded. The lack of a positive family history was 
one of the supporting factors towards acquired causes.  
Seven children had toxin related neuropathies, five children related to HAART 
medication for HIV-1 infection, one related to dapsone therapy and one to vincristine therapy. 
The last child was a girl of European descent who was being treated for acute lymphocytic 
leukaemia. At 6 years of age she developed significant hypersensitivity symptoms affecting 
her palmar hand surfaces and the plantar surfaces of her feet. Her sensory 
neurophysiological studies were normal. Her median conduction velocities were 51.4 metres / 
second, amplitude 2.33 mV and distal latency 3.88ms; her common peroneal conduction 
velocity was 57 metres / second, amplitude reduced at 1.67 mV and distal latency delayed at 
5.52 ms. Her results were consistent with an axonal degenerative disorder. Her vincristine 
dosage was reduced and she clinically improved.  
Five children with HIV-1 infection developed peripheral neuropathies (3 female :2 
male, all were of indigenous African ancestry). Median age of presentation was 5 years 
(range 42-139 months). All children were receiving HAART (highly active antiretroviral 
therapy) medication which included stavudine (d4T) in their regimens. Conversion to 
zidovudine or abacavir resulted in clinical improvement (n=4). One patient spontaneously 
improved. Additional therapy with gabapentin was administered in three. Children presented 
with distal wasting (n=5), distal weakness (n=5), ataxia (n=1) and severe distal pain (n=3) 
(Figure 5.20a and b). All children were under weight for age with a globally wasted 
appearance. This tended to mask the degree to which the neuropathy was clinically evident. 
Two of the children also had evidence of lipodystrophy / lipoatrophy syndrome with transiently 
raised plasma lactate levels. One child had prior co-infection with tuberculous meningitis; she 
was treated with 9 months of standard therapy including isoniazid. She had not received 
pyridoxine prophylaxis. Another child was covered with isoniazid prophylaxis which included 
pyridoxine therapy. Nerve conduction studies were normal in one, could not be stimulated in 
another and revealed an axonal degenerative process in three whose common peroneal 
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Figure 5.20a. Image of the hands from the eleven year old girl with HIV-1 infection and 
previous tuberculous meningitis, demonstrating atrophy of her thenar and hypothenar 
eminences. She had severe hypersensitivity to pain in her distal palmar and plantar surfaces. 
She responded well after her stavudine was converted to abacavir and she received 
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Figure 5.20b. The lower limbs of the patient in Figure 5.20a demonstrating her tapered 
appearance with distal wasting.  
Two boys had focal signs of neuropathy related to isolated lesions in the common 
peroneal region. One had a biopsy-confirmed hamartoma in his left calf causing compression 
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Table 5.1: Summary of the patients who underwent peripheral nerve biopsy  
Pt Diagnosis Clinical NCS Genetics Biopsy Comment 
1 CMT1A Onset 8 years. Distal weakness, pes 





CMT1A Moderate reduction in 
MF density, onion 
bulb formations, thin 
myelin and 
tomaculous myelin 
fibres (Figure 5.3) 
This biopsy confirmed the 
suspected diagosis based on the 
clinical, NCS and molecular 
genetic results. The conduction 
velocities were very slow but the 
biopsy concurred with the 
diagnosis CMT1A   
2 CMT1A Onset 3 years. Distal weakness, 
scoliosis, pes cavus, absent DTR, 




















CMT1A Moderate reduction in 
MF density 
This biopsy confirmed the 
suspected diagnosis based on the 
clinical, NCS and molecular 
genetic results. The conduction 
velocities were very slow but the 
biopsy concurred with the 
diagnosis CMT1A. 
3 CMT3 Onset from birth, severe global 
hypotonia and weakness, scoliosis 
and distal contractures. Recurrent 
lower respiratory tract infections 
(Figure 5.4) 




CMT1A Multiple OB, MF 
density markedly 




(Figure 5.5 and 5.6) 
This biopsy was useful in that it 
reinforced the clinicians concern 
that the molecular genetic result 
did not correlate well with the 
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4 CMT 2 Onset 5 years of age with distal 
weakness, sensory alteration, pes 
cavus and absent DTRs. No family 


















- Normal myelinated 






The biopsy was performed on this 
child whilst she was undergoing 
corrective surgery for her foot 
deformity. It was useful to illustrate 
that she did not have marked 
disease involvement detected in 
her sensory nerve fibres.   
5 CMT2 Onset 5 years of age with distal 
weakness, scoliosis and mild 



















with Bands of 
Büngner (Figure 5.7) 
 
The clinical features could not 
differentiate the type of CMT, but 
the NCS suggested an axonal 
process. The molecular genetic 
diagnosis did not correlate with 
this. The biopsy findings were 
consistent with axonal disease 
supporting the neurophysiological 
data. 
6 EOHMSN Onset 3 years. Pes cavus, mild 
sensory impairment, generalised 
weakness (distal > proximal) and 












Extended reviews of these 
samples failed to identify the 
associated mitochondrial 
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7 EOHMSN Onset 4 years. Hypotonia, 
generalised weakness (distal > 
proximal), absent DTR and 

















normal. EMG  
denervation 
 
- Myelinated fibre 
density reduced, 
axonal degeneration.  
 
Extended reviews of these 
samples failed to identify the  
mitochondrial abnormalities 
described with MFN2 mutations 
8 EOHMSN Onset 6.5 years. Distal weakness, 
pes cavus, multiple surgical 
interventions, absent DTR, scoliosis 









- Severe axonal 
degeneration with 
reduced myelinated 




Extended reviews of these 
samples failed to identify the 
mitochondrial abnormalities 
described with MFN2 mutations 
9 EOHMSN Onset 3 years of age, initially lower 
limb distal weakness, by 5 years of 
age upper limb involvement and 
eventual clawing of the hands. 
Ataxia, hypotonia and severe distal 










- Severe axonal 
degeneration with 
reduced myelinated 
fibre density and 
regeneration with 
cluster formation. 
Also some fibres with 
features similar to 
onion bulb 
Confirming the appearances 
typical of the MFN2 mutation 
suggested a more definitive 
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formations. (Figures 






5.13)   
10 Axonal 
miscellaneous 
Onset 13 months of age with an 
abnormal gait. From 10 years of age 
rapid and severe scoliosis. Distal 
contractures, distal weakness, 
sensory alteration, depressed DTR, 
pes cavus and swallowing 










latencies.    
- Normal sural nerve 
biopsy 
This girl remains without a 
diagnosis. A motor axonal nerve 









Onset 3 months. Diaphragmatic 
paralysis, distal weakness and 
generalised hypotonia. Reduced 
sensory awareness. Scoliosis. 
Absent DTR. Home ventilation. 
Normal cognition. (Figure 5.15) 
Not performed IGMBP2 
mutation 
Moderate reduction in 
MF density. 
Predominance of 




Bands of Büngner.  
This biopsy result was obtained 
early in the infant’s course (prior to 
the genetic result). The result 
assisted in the early counselling 










Onset 3 years of age with a paretic 
hemidiaphragm, distal weakness 
and scoliosis. She required BIPAP 

















fibre density  
The combined information from 
this child has allowed collaboration 
with a centre overseas to 
undertake further extended 
molecular genetic screens of the 
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Twins. Onset 4 years of age with 
abnormal gait, distal weakness, 
contractures and reduced DTR. 
Learning difficulties and some 






could not be 
stimulated. 
- Axonal degeneration. 
No abnormal storage 
material  
A neurodegenerative disorder was 
suspected. The absence of 
abnormal storage material or 
neurofilaments reduced the 
likelihood of a number of 
differential diagnoses.  
14 ALS4 Onset 10 years of age. Portuguese 
ancestry. Upper and lower motor 
neurone signs, cognition preserved, 
















The biopsy confirmed the 
suspicion of a more global 
condition. This boy’s clinical 
course has also guided his 




Presented at 2 years of age with 
apparent insensitivity to pain. He 
was bitten by the family dog, he felt 
no pain but bit the dog back. Head 
banging. Hyperactive. Mild 
developmental delay. Normal 
sweating. Old burn marks on 
fingers. Did feel cold 
(shivers).Normal examination with 
retained DTR.    
Normal 
sensory and 
motor studies  
- Normal biopsy on 
light microscopy and 
electron microscopy 
examination. 
Additional skin and 
muscle biopsy were 
also normal. 
Finding no evidence of nerve 
disease directed the therapy 
towards behavioural interventions 
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DISCUSSION. 
Children with peripheral neuropathies represented a third of the patients seen in the 
neuromuscular service and 3% of the total group attending the service with neurological 
conditions. The neuromuscular service at Red Cross Children’s Hospital is a tertiary referral 
centre and as such children are referred nationally and from other countries bordering South 
Africa as well as from all sectors (government and private). This would have affected the 
ancestry groupings where typically government patients seen at Red Cross would be 
dominated by the Indigenous African and so-called “mixed” ancestries. This was evident in 
the “acquired” group where six children were of European descent.  
AIDP typically occurs after infections and many of our cohort had proven triggers 
(Campylobacter and Mycoplasma) – this has already been described as well as the more 
severe course.(421,422) Our centre has access to intensive care, high care support, intravenous 
immunoglobulin for relevant cases, and ancillary services so the management of these 
patients if they can access the tertiary setting is similar to that of international centres.  
The disparity of the larger size of the acquired group compared to the children with 
hereditary disorders could be explained by the increased number of trigger factors (poor 
nutrition, exposure to toxins and infections) but is more likely related to this study reviewing all 
patients with peripheral neuropathy whether sural nerve biopsy was performed or not. None 
the less both groups were of significant size and clinical impact. A review from Oman found 
similar results.(423) The authors identified 82 children with peripheral neuropathies of whom 45 
were related to acquired causes, mostly AIDP, and 37 related to hereditary causes. 
Seventeen patients (20%) from this group had forms of CMT. In another study of 74 children 
from Turkey 73% had acquired pathologies and 27% were considered hereditary.(424) A study 
from the Netherlands of 82 children with chronic peripheral neuropathies had the reverse 
evident with 68% of their cohort related to hereditary neuropathies and remaining 32% 
acquired.(425) The relevance of this study originating from a “resource equipped” country 
without the same levels of socioeconomic challenges cannot be ignored. Interestingly a three 
year audit of all children with peripheral neuropathies seen at a Sydney centre found that 40% 
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miscellaneous (personal communication Prof R Ouvrier). No cases of HIV-related neuropathy 
were identified in childhood. 
Five patients were managed with peripheral neuropathy symptoms related to HIV-1. 
These children became clinically symptomatic in relation to their antiretroviral medication and 
required adjustment of their treatment regimen. Peripheral neuropathy developing in relation 
to ARVs is a well described complication, commonly related to nucleoside reverse 
transcriptase inhibitors, especially stavudine (d4T).(426) Other described causes of peripheral 
neuropathy are distal symmetrical polyneuropathy (DSP), mononeuritis multiplex, 
inflammatory demyelinating polyneuropathy and progressive polyneuropathy.(427) Most of 
these conditions, especially DSP, are more recognised in adult patients with HIV-1 infection. 
In our centre the infectious diseases service routinely manages children with HIV-1 infection 
and discusses patients who may have neuropathy. Since this study related to patients 
managed within the neuromuscular services the number of children affected could have been 
underestimated. One patient was previously reported with AIDP at the time of seroconversion 
as part of a case series from our centre.(428) This patient was managed acutely but continued 
his long-term follow-up in the infectious diseases service at another centre. The signs of 
peripheral neuropathy in a chronically sick and malnourished child can be subtle and not be 
detected unless specifically looked for. In a prospective study of 80 children with HIV-1 
managed in the infectious disease service at Red Cross Children’s Hospital, five had 
evidence of unsuspected peripheral neuropathy (unpublished data R Govender, J Wilmshurst 
et al). Four were considered related to ARV toxicity and one secondary to Cytomegalovirus 
infection. The “layering” effect of HIV-1 infection results in multiple potential causes for a 
clinical phenotype. Children infected with HIV-1 are at increased risk of malnutrition, poor 
mobility, drug toxicity and additional infections. This was evident in the patient who had 
completed treatment for tuberculous meninigits. Her regimen included isoniazid and she did 
not receive prophylactic pyridoxine. Increased incidence of peripheral neuropathy is described 
with co-infection of HIV-1 and tuberculosis.(429) 
Acquired conditions seen in other parts of Africa but not seen in our cohort included 
sickle cell related sensory neuropathy (430), leprosy related neuropathy(431)  and an ataxic 
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Forty-four children had features of hereditary forms of peripheral neuropathy. CMT1A 
is described as the commonest sub-form even in childhood(29,30,33,35-37) – this was not the case 
in our group with only four patients confirmed genetically and no patients were of indigenous 
African descent. Our numbers were small but the trend would imply that this sub-form is not 
expressed in the same proportions in our population compared to other international centres. 
There is little data describing incidence of CMT1A in indigenous African populations. A study 
from Brazil reported that 13% of their cohort with CMT1A were of African descent (n=6).(433) 
This finding differed from a report from Nigeria where only 3 patients were identified with CMT 
from an extended audit of 2.1 million patients.(434) In the SA series the group was dominated 
by children with axonal forms of CMT. Genetic analysis of this group remains a challenge 
even for international centres and the group remains with the lowest molecular genetic 
mutation detection rate. Screening the cohort of patients with CMT2, the patients with 
EOHMSN and the twins with dHMN for mitofusin mutations would be of great interest as this 
molecular genetic error is described in all these forms.(77,81,105,164,252) CMT2A could not be 
excluded in the twins as they had optic atrophy. 
Sural nerve biopsy was performed in 14 of the 44 children; this proved a useful 
intervention in our setting (table 5.1). Samples either reinforced the diagnostic category for 
the patient or strengthened diagnostic concerns arising from conflicting molecular genetic and 
neurophysiological results. The histopathology laboratory at Red Cross Children’s Hospital is 
skilled in the preparation and analysis of muscle and nerve samples. Concentrating this 
service in the one centre, though not ideal for patients from further afield, has allowed a level 
of expertise to develop and the technical staff to perform high quality screens. Clinicians are 
encouraged to refer patients to the centre for counselling and for the studies to be performed 
on site to reduce artefact damage. A fifteenth biopsy was performed on the child with 
congenital insensitivity to pain, the normal result reinforced the belief that the child’s condition 
was of central origin and directed his interventions towards more behavioural therapy. 
Within South Africa the screening for hereditary forms of CMT is limited to testing for 
CMT1A and HNPP and no point mutations are analysed. The conflicting results in the study 
are of great concern. The infant whose molecular genetic screen detected a duplication of 
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occur in infancy (2), but the extreme severity of this patient’s disease and her marked 
involvement on sural nerve biopsy did not correlate with this result and she was recategorised 
CMT3.(435) Similarly the boy with a dominant family history who had axonal changes on his 
neurophysiology and histopathology studies had a positive result for CMT1A (twice). Some of 
the described mutations can present with either axonal or demyelinating pathology (MPZ, 
GDAP1) but this is not the case for PMP22 mutations. PMP22 duplications result in primarily 
demyelinating conditions only (CMT1A). The axonal disease in our patient appeared the 
primary process and he had no biopsy evidence of demyelination. When diagnostic 
challenges and conflicting results such as this arise sourcing other centres to perform repeat 
and extended screens is ideal. However the cost implications are beyond the government 
facilities’ and most parents’ finances. What is basically a clinical screen would be dubious to 
place in a research category – especially when so many of these screens are readily 
available overseas. There are huge implications from the lack of extensive genetic analysis in 
these patients as to drawing finite conclusions and reaching a level of diagnosis for the 
requirements of most peer reviewed journals would require the genetic screens to be 
equivalent to other studies. Resource-limited countries are falling behind with regard to this 
as, although large cohorts of patients are recruited in the small dedicated centres, genetic 
diagnostic closure is often not possible and accordingly these patients cannot be published. 
The genetic screens, beyond CMT1A and HNPP, performed from this group were all 
undertaken by individually sourced centres from the United Kingdom, Germany and Australia. 
Most provided the services at no cost. The DYT1 screen was performed at a research unit in 
Cape Town. 
A number of the patients were lost to follow-up. Unfortunately this is not an infrequent 
occurrence in SA. Families are driven by their daily living needs which often override the 
health needs of their children – especially where at the current time the investigations are 
unlikely to alter their child’s management. Children often move across different parts of South 
Africa according to who the main carer is or in pursuit of parental employment. It is not 
unusual for a child to be lost to follow-up for several years and then reappear when school 
placement must be arranged. Communication between primary health care centres is limited 
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usually good in most government centres but must be coordinated, otherwise the child is left 
without intervention and surgery becomes inevitable. 
The day to day care of children with peripheral neuropathies can and should be 
managed at the nearest centre to the child. The diagnostic “work-up” should occur at 
specialised centres with an interest in the pathology to allow comprehensive counselling and 
management plans to be drawn. Dedicated centres must be in place with the capacity to 
undertake and interpret accurately neurophysiological and histopathological screens in 
children. Molecular genetic services need to be drastically expanded to keep up with the 
international trends.  
Even with limited access to genetic facilities and not all the patients undergoing 
peripheral nerve biopsy, reasonable categorisation was possible for many of them based on 
combined data describing the clinical CMT sub-groups (Table 1.2). It was often necessary 
however to have at least two aspects of the investigations available (clinical, 
neurophysiological and ideally histopathological). For centres with limited resources children 
can be assessed with at least the first two in most tertiary facilities in South Africa. Complex 
patients can be and often are referred to Red Cross Children’s Hospital, Cape Town.  
Definitive diagnoses are likely to become of increasing import as studies progress looking at 
therapeutic interventions based on specific genetic mutations. A prime example would be the 
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 The preceding chapters have provided an overview of peripheral neuropathy 
occurring in children and infants. They have described the recognised categories (chapter 1, 
tables 1.2-1.4), the role of nerve biopsy (chapter 2), the spectrum of infantile and childhood 
peripheral neuropathies prevalent in a developed world setting (chapters 3 and 4) and in a 
resource-limited setting (chapter 5). 
The differences between adults with peripheral neuropathies and children are 
illustrated in chapter 3. Unlike adults, children have more hereditary aetiologies for their 
chronic neuropathy than acquired causes. More autosomal recessive conditions occur in 
children than adults. Despite this, CMT1 is prevalent in both groups – athough still more 
frequent in adults. Children are more likely to have undefined aetiologies than adults. Part of 
the explanation for this lies in the greater incidence of axonal degenerative peripheral 
neuropathies which occur in children (n=169 axonal versus n=107 demyelinating, chapter 3). 
Patients with axonal degenerative peripheral neuropathies are less likely to achieve a 
definitive molecular genetic diagnosis. As demonstrated in the Australian study (chapter 3), 
children with neurodegenerative disorders and infants with generalised hypotonia are more 
likely to undergo a peripheral nerve biopsy and have a normal result. This reflects some of the 
diagnostic challenges of investigating a hypotonic infant, as well as the screening undertaken 
when performing a neurodegenerative assessment or “work-up”. A normal result in this 
setting, for children, can be equally beneficial as it may exclude a number of serious 
differential diagnoses. The progress in molecular genetic and biochemical screens has 
resulted in this situation being less common in children analysed more recently. 
Children and infants suffer a similar spectrum of conditions (chapters 3 and 4), with a 
predominance of hereditary causes even more evident in the infantile group. A wide range of 
conditions is described in the group presenting in infancy (chapter 4), conditions which 
previously were more recognised in children and adults (e.g.CMT1).  Although the number of 
infants with axonal disease equalled those with demyelinating disease, those with axonal 
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peripheral neuropathy in the infantile period, apart from those with CMT3, a molecular genetic 
diagnosis was unusual.        
This study is of use for its large collection of affected patients enabling both a 
perspective of the groupings of the more “common” forms of chronic peripheral neuropathy in 
childhood and the identification of the rarer disorders. The disorders commonly under-
recognised in the adult-dominated literature would be EOHMSN and SMARD1 / 
SIANR.(103,106,108) Rarer disorders in this population would be conditions such as CMTX5 
(PRPSI mutation) and CMT4H (frabin mutation).(136,137,148,149,247) Although the data from the 
patients from Australia span 37 years (chapter 3) it remains, in part, a prospective study with 
on-going diagnoses emerging on many of the historical cases as each new mutation is 
identified. Important genetic screens which at the very least should be available to most 
populations include chromosome 17p duplications and deletions, MPZ, connexin 32, 
mitofusin2 and SMARD1. 
Despite the explosion in molecular genetics from the Sydney series, molecular 
genetic diagnoses were made in 34/50 (78%) of the demyelinating CMT group but in only 
13/31 (42%) of the axonal degenerative group of the patients who underwent genetic 
screening. A study from the Netherlands found that a causative gene was identified in 17% of 
their patients with axonal disease.(436) Most studies support the need however for extensive 
molecular genetic screens to fully delineate and understand large cohorts of patients with 
chronic peripheral neuropathy. This remains a great challenge in the resource-limited 
setting.(64)  
The groups which dominated the axonal cases were the patients with EOHSMN (22% 
of the axonal group) and the patients with SMARD1 mutations. Both conditions are severe 
disorders. Prenatal screening for SMARD1 mutations should be available as the implications 
for a family and child affected with this condition are devastating.(348) 
Comparing the Australian patients to the patients from South Africa (SA), there were 
several parallels but some interesting differences. The lack of patients with CMT1A cannot be 
assumed due to selective screening as the SA patients were included with or without nerve 
biopsy and as such the proportion of CMT1 cases should have been greater. The number of 
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CMT are not as prevalent as the axonal forms. This is supported by a study from Nigeria but 
there are few other studies to allow comparison.(434)  Adult SA data suggests that under 10% 
of the indigenous African neuropathy population seen in a government hospital have CMT1 
(personal communication J Heckman, Dissertation MMed (UCT) 1994; Inherited Neuropathies 
at Groote Schuur Hospital). 
In settings where access to molecular genetics is limited, screening using all possible 
tools is essential to attain a diagnostic label. Even when molecular genetic studies are 
available, the genetic confirmation alone may not correlate with a clinical diagnosis without 
supporting information from the combined findings of the clinical phenotype, neurophysiology 
and histopathology (“endotyping”). 
Based on this information the following specific diagnostic indicators could be used to 
focus the differential diagnoses of children presenting with peripheral neuropathy  
Clinical markers are summarised in table 6.1 with the relevant references. The table 
identifies recognised peripheral neuropathy sub-types linked to these clinical clues, namely 
those hereditary peripheral neuropathies with onset in early childhood, some of which have 
severe evolution. We have previously demonstrated that there is heterogeneity in the 
presentations of many of the hereditary neuropathies, as demonstrated by the patients with 
CMT1 who became symptomatic in infancy.(2) Additional clues are those conditions 
particularly associated with scoliosis, marked sensory involvement, respiratory involvement 
with diaphragmatic and or vocal cord impairment, predominantly upper limb involvement, 
additional proximal weakness, glaucoma, optic atrophy, deafness, pyramidal tract 
involvement, central involvement with white matter MRI abnormalities, and mental retardation. 
Useful neurophysiological markers other than the typical demyelinating and axonal 
ranges described in CMT1 and CMT2, are the extreme slowing evident in CMT3 (usually 
<10m/s motor conduction velocity) and most forms of CMT4, as well as the intermediate 
values seen in patients with DI-CMT and CMTX.(48,150) The patients with EOHMSN often have 
values in the borderline axonal / demyelinating range.(103) Patients with SMARD1 typically 
have no nerve responsive to stimulation.(2,106) 
Most guidelines discussing investigation of peripheral neuropathies recommend 
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underlying diagnosis.(256,322,424,437,438) Peripheral nerve biopsy is a safe investigation which if 
performed and analysed in an appropriate setting can enhance the diagnostic yield of 
complex patients.(323) Most guidelines, however, are adult based and few exist with paediatric 
emphasis.(2,424) 
Specific features on histology would include the giant axons of GAN and CMT2E,(78) 
the myelin-outfolding of CMT4B(116) the unusual Schwann cell cytoplasmic chains of CMT4C, 
the extreme paucity of fibres in some cases of lamin A mutations and the mixed ultrastructural 
demyelinating/ axonal degenerative picture of EOHMSN associated with abnormal 
mitochondria(105). 
Other tools yet to be explored include the role of neuroimaging – MRI has identified 
specific muscle groups affected in particular subgroups of CMT.(439,440) Additional studies have 
looked at the role of lumbosacral root and sciatic nerve imaging to assess disease severity 
and progression.(441-443) 
The combined data in Tables 1.2-4 should aid the clinician to try and subcategorise 
patients as specifically as possible using an “endotyping” approach.  
Confirming a diagnosis for patients is important for directing therapy towards specific 
complications (e.g. scoliosis, respiratory failure), for diagnostic closure for a family with 
information on subsequent risks for future pregnancies and potentially for therapies in the 
future (e.g. CMT1A and Vitamin C). 
An approach in a resource-limited setting. 
As stated, the main tool used consistently in most resource-limited centres is that of 
clinical assessment. As a result the majority of children, unless they demonstrate one or more 
of the key markers described above and in table 6.1, will lack a more definitive diagnosis 
beyond the label “peripheral neuropathy”. Clinical history should assist differentiating between 
acquired and hereditary neuropathies. 
In the context the author works in, the following management priorities are addressed 
and summarised in figure 6.1. Once clinical confirmation of a peripheral neuropathy is 
established, as described in the introduction of the text, basic interventions can be 
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Clues to support an acquired condition would include an acute onset, a monophasic 
illness in a previously well child, often with a prior history of infection or initiation of a 
potentially neurotoxic therapy (ARVs, isoniazid); also, the child with a chronic but relapsing 
course. The most prevalent peripheral neuropathy, as occurs internationally, remains AIDP. It 
may not be possible to perform nerve conduction studies but access to analysis of CSF, 
demonstrating an acellular response and a raised protein in the second week of clinical onset, 
should be available in most centres; also analysis of potential trigger factors – especially prior 
Campylobacter and Mycoplasma infections. Poliomyelitis remains a notifiable condition which 
is still prevalent in parts of Africa. Screening for enteroviruses in any child with flaccid 
paralysis remains essential.  
Few centres in South Africa, or other parts of Africa, have access to intensive care 
support and the management of the child with progressive weakness and airway compromise 
is challenging. Recommendations are that centres with access to intravenous immunoglobulin 
administer the agent to any child suspected of having AIDP, who has respiratory compromise 
or loss of ambulation.  
The other significant cause of peripheral neuropathy which is increasingly presenting 
is that related to HIV, either as part of direct disease involvement or secondary to the 
complications of ARVs. The neuropathy which arises has a similar clinical phenotype to distal 
symmetrical polyneuropathy (DSP) described more in adults with HIV.(427) Affected children 
may have severe sensory features of intense distal burning affecting the hands and the feet, 
as well as distal weakness.(427) This occurs as an adverse side effect of therapy with the 
nucleoside reverse-transcriptase inhibitors, stavudine and to a lesser extent didanosine.  
Stavudine remains part of the first line recommended regimen from the WHO guidelines. If 
peripheral neuropathy occurs conversion to zidovudine or abacavir is recommended.(426,444) 
Symptomatic relief is described with gabapentin, if it is available, otherwise amitriptyline can 
be used.(427) Adult based trials have assessed the role of acetyl-l-carnitine which may benefit 
some patients.(445) Peripheral neuropathy in children with HIV has not been extensively 
studied but is also described in the form of AIDP at the time of seroconversion or as an 
immune reconstitution phenomenon, and in relation to secondary infection with 
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author believes that the incidence of peripheral neuropathy in children with HIV-1 infection is 
underestimated. From the cohort of HIV-infected patients attending the infectious diseases 
service (n=80) prospectively reviewed at Red Cross Children’s Hospital 6% had peripheral 
neuropathies (R Govender, JM Wilmshurst unpublished data). Another study identified 
abnormal nerve conduction studies in 12 out of 50 children clinically suspected to have 
neuropathies.(287) A study from Rio de Janeiro quoted a 34% prevalence of peripheral 
neuropathy in their paediatric patients with HIV-1 infection.(449) The approach used specifically 
for patients with HIV-1 and peripheral neuropathy in the author’s centre is summarised in 
figure 6.2. 
The other toxic neuropathy seen infrequently is related to isoniazid therapy though 
with increased frequency when there is co-infection with HIV.(426) Prophylaxis with pyridoxine 
can reverse this.(450) Seen less frequently are the nutritional deficiency neuropathies, 
especially vitamin B12 deficiency, either in isolation or associated with the HIV infected 
patient.(451,452) These seem to be rare in South Africa but are described elsewhere in the 
continent.(453) 
A positive family history and a chronic progressive clinical course would support a 
hereditary nature in a child with peripheral neuropathy. Establishing if there is evidence of 
neuroregression would further direct the search for possible causes. Neuroregressive 
disorders with distinct clinical appearances include Friedreich ataxia, rare childhood forms of 
spinocerebellar ataxia, various metabolic disorders, mitochondrial disorders, 
leukodystrophies, giant axonal neuropathy, and Cockayne syndrome. Centres with the 
capacity should perform diagnostic neuroimaging and biochemical screens (e.g. CSF lactate, 
urinary organic and amino acids, mitochondrial screens). Frustratingly most suspected 
diagnoses require additional support from neurophysiology, molecular genetics and or 
histopathology. 
The management of both acquired and hereditary peripheral neuropathies should 
concentrate on the optimal outcome of the child. This requires supportive care, such as pain 
relief (gabapentin), therapeutic interventions where indicated (e.g. immunoglobulins) and 
ancillary input. Most children present to a primary health care centre and are managed by a 










Peripheral Neuropathies of Childhood Jo M Wilmshurst 
Thesis presented for the Degree of Doctor of Medicine 
 190 
training in the recognition of the clinical signs of peripheral neuropathy may result in some of 
these children being misdiagnosed. There is a need to train these service providers in the key 
clinical diagnostic features of peripheral neuropathy and to establish viable management 
guidelines for affected children. Commencing regular physiotherapy and occupational therapy 
early in the child’s illness is essential and should be available at most secondary and tertiary 
centres. As a result inevitably these children need to be referred on to a secondary or tertiary 
level facility. Across Africa there is significant limitation in paediatric specialist services, and 
paediatric neurologists are scarce in countries between South Africa and the Northern African 
countries. As a result the burden of care falls on the primary health care workers.  
Carers can be taught a home programme for avoidance of contracture formation. The 
child and carer should be educated of the increased need to avoid damage to the joints and 
distal regions due to sensory impairment. Many children in South Africa live in households 
where paraffin fires are the main heating and cooking devices. These are rarely protected and 
burns are frequent complications, all the more likely to occur to the child with altered sensory 
awareness. Orthotic devices are important and also should be available in most referral 
centres. Access to speech therapy and dieticians is also important. Support from other 
specialists, such as orthopaedic surgeons to undertake surgical interventions to promote 
mobility is ideal but often lacking. Regular assessments are necessary to avoid secondary 
complications such as contractures, scoliosis and respiratory tract infections occurring. Where 
available, prophylactic intervention with influenza and pneumococcal vaccinations should be 
given to those children who are considered to be at risk of chest infections.  
The centre where the author works has access to neurophysiology, histopathology 
and limited molecular genetics. Most other centres have only clinical assessment for 
diagnosis with the ancillary input often consisting of a community physiotherapist.  
 In summary the basic aims of care for a child with a peripheral neuropathy include:- 
1. Accurate diagnosis of a peripheral neuropathy, typically via clinical assessment. 
2. Where available referral to a specialist centre (there may be only one per country, or 
none, requiring referral to another country).  
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4. Counselling on the potential genetic implications (based on suspected aetiology).  
5. Involvement of any available ancillary services and access to orthotic and 
orthopaedic facilities.  
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Table 6.1. Summary of conditions commonly associated with specific clinical features 
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Figure 6.1 Approach to the child with suspected peripheral neuropathy in a Resource-Limited Setting 
Peripheral Neuropathy typical clinical phenotype:  
Key features: 
Distal Weakness, distal wasting, sensory alteration, reduced / absent DTR. 
'                                                                                                              ( 
    Acquired         Hereditary 
    '           $ 
   Clues:           Clinical Clues 
Usually - Acute Onset            $ 
Monophasic (Mostly)          Central Neuroregression 
Previously Well Child          '  ( 
Or - Chronic Relapsing Course         No   Yes 
$          '   ( 
Differentials:        Clinical Clues     Neurodegenerative 
'       (See Table 6.1 for associated conditions)  Conditions 
Inflammatory –       Early onset and severe course     Friedreich’s Ataxia 
Post-Infectious        Scoliosis      Spinocerebellat ataxia 
• AIDP        Marked sensory involvement    Metabolic 
(Mx – Supportive Care,       Respiratory involvement (Diaphragm)   Mitochondrial 
2g/kg IVIG over 2/7        Marked upper limb involvement    Leukodystrophies 
If airway or gait compromise)     Glaucoma      Giant Axonal Neuropathy 
• CIDP (Mx – Steroids / IVIG)     Central involvement     Cockayne Syndrome 
     Mononeuritis       Mental retardation 
     Autoimmune 
Toxins  
• HIV ARVs  
Mx:- Supportive care – gabapentin, 
Review ARV regimen, consider converting  
stavudine for zidovudine or abacavir) 
Structural (NF1, malignancy) 
Insult (AMC) 
Nutritional deficiencies (Vit B12, Vit E)  
Key:AIDP = acute inflammatory demyelinating polyradiculoneuropathy; AMC = arthrogryposis multiplex congenita; ARV= antiretoviral therapy; CIDP= chronic 
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Figure 6.2 Approach to the HIV infected child with distal weakness / sensory disturbances 
Neuropathy 
↓ 
         Clinical signs 
       Paini.  
Tingling numbness of the feet, less commonly with extension to the hands 
Distal sensory loss 




        ' ( 
    '   ( 
   '     ( 
Toxic response to ARVs:      Secondary to  
   (stavudine, didanosine)      '  ↓ ↓ (  
    ↓     HIV-1          Other Post-     Vasculitis / Infections 
   Symptoms persist     '          drugs infectious ( 
   switch to a different NRTI   ARV  (e.g. vincristine, (e.g. AIDP) e.g. CMV  
Eg zidovudine or abacavir    isoniazid) ↓  polyradiculopathy  
 ↓        IVIG 2g/kg ↓ 
Symptoms may resolve in several weeks         treat with ganciclovir 
but beware of “coasting” – paradoxical worsening 
which may occur for up to 8 weeks after art cessation. 
 
i. Consider using analgesics, amytriptyline, gabapentin; avoid carbamazepine 
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